Kazia Therapeutics Limited (KZIA) 20-F 15 Nov 24 2024 FY Annual report (foreign) Financial data

Cover

Cover - shares	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2022
Document Information [Line Items]
Document Type	20-F
Amendment Flag	false
Document Period End Date	Jun. 30, 2024
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	FY
Entity Registrant Name	Kazia Therapeutics Limited
Entity Central Index Key	0001075880
Current Fiscal Year End Date	--06-30
Entity Well-known Seasoned Issuer	No
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Entity Emerging Growth Company	false
Entity Voluntary Filers	No
Entity Shell Company	false
Entity Interactive Data Current	Yes
Document Transition Report	false
Document Annual Report	true
Document Shell Company Report	false
Entity Address, Address Line One	Three International Towers, Level 24, 300 Barangaroo Avenue
Entity Address, City or Town	Sydney
Entity Address, Postal Zip Code	2000
Entity Address Country	AU
Document Registration Statement	false
Document Accounting Standard	International Financial Reporting Standards
Entity Common Stock, Shares Outstanding	332,850,784
Entity Incorporation, State or Country Code	C3
Entity File Number	0-29962
Title of 12(b) Security	American Depositary Shares, each representing one-hundredOrdinary Shares*
Trading Symbol	KZIA
Security Exchange Name	NASDAQ
ICFR Auditor Attestation Flag	false
Auditor Name	BDO Audit Pty Ltd	GRANT THORNTON AUDIT PTY LTD
Auditor Firm ID	2256	2233
Auditor Location	Sydney, Australia	Sydney, Australia
Document Financial Statement Error Correction [Flag]	false
Business Contact [Member]
Document Information [Line Items]
Contact Personnel Name	John Friend, M.D
Contact Personnel Email Address	John.Friend@kaziatherapeutics.com
Entity Address, Address Line One	Three International Towers, Level 24, 300 Barangaroo Avenue
Entity Address, City or Town	Sydney
Entity Address, Postal Zip Code	2000
Entity Address Country	AU
Country Region	61
City Area Code	2
Local Phone Number	9472-4101

Consolidated statements of prof

Consolidated statements of profit or loss and other comprehensive income - AUD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2022
Revenue and other income
Licensing revenue	$ 2,308	$ 0	$ 0
Other income	173	1	25
Finance income	12	22	2
Expenses
Research and development expense	(17,380)	(15,564)	(20,169)
General and administrative expense	(13,563)	(8,583)	(5,113)
Gain/(loss) on remeasurement of other financial liabilities	1,257	0	0
Gain/(loss) on remeasurement of promissory note	25	0	0
Gain/(loss) on remeasurement of contingent consideration	119	3,388	0
Commercialisation	0	0	(127)
Loss before income tax benefit	(27,049)	(20,736)	(25,382)
Income tax benefit	271	271	368
Loss after income tax benefit	(26,778)	(20,465)	(25,014)
Items that may be reclassified subsequently to profit or loss
Net exchange difference on translation of financial statements of foreign controlled entities, net of tax	(8)	110	35
Other comprehensive loss, net of tax	(8)	110	35
Total comprehensive loss	$ (26,786)	$ (20,355)	$ (24,979)
Earnings per share for loss attributable to the owners of Kazia Therapeutics Limited
Basic earnings per share	$ (0.1016)	$ (0.1123)	$ (0.1888)
Diluted earnings per share	$ (0.1016)	$ (0.1123)	$ (0.1888)

Consolidated statements of fina

Consolidated statements of financial position - AUD ($) $ in Thousands	Jun. 30, 2024	Jun. 30, 2023
Current assets:
Cash and cash equivalents	$ 1,657	$ 5,241
Trade and other receivables	3,897	3,899
Other assets	591	1,632
Total current assets	6,145	10,772
Non-current assets:
Other receivables	40	43
Intangibles	15,400	17,269
Total non-current assets	15,440	17,312
Total assets	21,585	28,084
Current liabilities
Trade and other payables	15,067	4,329
Other financial liabilities	6,478	8,599
Borrowings	634	1,796
Employee benefits	365	690
Contingent consideration	3,253	750
Total current liabilities	25,797	7,565
Non-Current liabilities
Deferred tax	2,018	2,289
Employee benefits	35	59
Contingent consideration	3,752	6,121
Total non-current liabilities	5,805	8,469
Total liabilities	31,602	16,034
Equity:
Contributed equity	101,638	97,452
Reserves	3,475	3,681
Accumulated losses	(115,130)	(89,083)
Total equity	(10,017)	12,050
Total liabilities and shareholders' (deficit) / equity	$ 21,585	$ 28,084

Consolidated statements of chan

Consolidated statements of changes in equity - AUD ($)	Total	Contributed equity [member]	Other Contributed equity [member]	Reserves [member]	Accumulated Losses [member]	Non-controlling interests [member]
Beginning Balance at Jun. 30, 2021		$ 80,290,062	$ 464,000	$ 1,301,000	$ (44,202,000)	$ 37,853,000
Loss after income tax benefit	$ (25,014,000)			0	(25,014,000)	(25,014,000)
Other comprehensive income, (loss) net of tax	35,000			35,000	0	35,000
Total comprehensive income (loss) for the year	(24,979,000)			35,000	(25,014,000)	(24,979,000)
Transactions with owners in their capacity as owners
Shares issued		4,202,000				4,202,000
Share issue cost		(493,000)				(493,000)
Immaterial reclassification				(434,000)	434,000	0
Share based payment				1,674,000		1,674,000
Issue of shares on exercise of options		17,000		(6,000)	6,000	17,000
Shares issued upon conversion of convertible note	0	464,000	(464,000)	0
Expired options				(159,000)	159,000
Ending balance at Jun. 30, 2022		84,480,249		2,412,000	(68,617,000)	18,275,000
Loss after income tax benefit	(20,465,000)	0		0	(20,465,000)	(20,465,000)
Other comprehensive income, (loss) net of tax	110,000	0		110,000		110,000
Total comprehensive income (loss) for the year	(20,355,000)			110,000	(20,465,000)	(20,355,000)
Transactions with owners in their capacity as owners
Shares issued		13,373,000				13,373,000
Share issue cost		(401,000)				(401,000)
Share based payment				1,159,000		1,159,000
Shares issued upon conversion of convertible note	0
Ending balance at Jun. 30, 2023		97,452,246		3,681,000	(89,083,000)	12,050,000
Loss after income tax benefit	(26,778,000)				(26,778,000)	(26,778,000)
Other comprehensive income, (loss) net of tax	(8,000)			(8,000)		(8,000)
Total comprehensive income (loss) for the year	(26,786,000)			(8,000)	(26,778,000)	(26,786,000)
Transactions with owners in their capacity as owners
Shares issued		4,182,000				4,182,000
Share issue cost		(376,000)				(376,000)
Share based payment				533,000		533,000
Shares issued upon conversion of convertible note	$ 380,000	380,000	0	0	0	380,000
Expired options		0	0	(731,000)	731,000
Ending balance at Jun. 30, 2024		$ 101,637,758		$ 3,475,000	$ (115,130,000)	$ (10,017,000)

Consolidated statements of cash

Consolidated statements of cash flows $ in Thousands		12 Months Ended
		Jun. 30, 2024 AUD ($)	Jun. 30, 2023 AUD ($)	Jun. 30, 2022 AUD ($)
CASH FLOWS FROM OPERATING ACTIVITIES:
Loss after income tax expense for the year		$ (26,778)	$ (20,465)	$ (25,014)
Adjustments for:
Amortisation		1,869	1,869	1,869
Issuance of liability classified warrants for services		5,961	0	0
Share-based payments	[1]	533	1,159	1,675
Foreign currency (gain) / loss		(20)	46	(2,154)
Loss/(gain) on remeasurement of contingent consideration		134	(2,097)	0
Gain on remeasurement of promissory note		(25)	0	0
Gain on remeasurement of financial assets		(1,257)	0	0
Cash flows from used in operations before changes in working capital		(19,583)	(19,488)	(23,624)
Change in operating assets and liabilities:
Increase/(decrease) in trade and other receivables		5	3,450	(7)
Increase/(decrease) in other assets		1,041	365	(277)
Increase/(decrease) in trade and other payables		10,738	569	(528)
(Decrease)/increase in other provisions		(349)	264	201
Decrease in deferred tax liability		(271)	(271)	(368)
(Decrease)/increase in borrowings		(1,162)	(45)	1,841
Net cash used in operating activities		(9,581)	(15,156)	(22,762)
CASH FLOWS FROM INVESTING ACTIVITIES:
Payment of milestone related to contingent consideration		0	0	(2,365)
Net cash used in investing activities		0	0	(2,365)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of shares, net of transaction costs		2,914	12,972	3,726
Proceeds from issuance of equity and pre-funded warrants		2,666	0	0
Proceeds from promissory note		776	0	0
Repayment of promissory note		(371)	0	0
Net cash provided by financing activities		5,985	12,972	3,726
Net (decrease)/increase in cash and cash equivalents		(3,596)	(2,184)	(21,401)
Cash and cash equivalents at the beginning of the financial year		5,241	7,361	27,587
Effects of exchange rate changes on cash		12	64	1,175
Cash and cash equivalents at the end of the financial year		1,657	5,241	7,361
NON-CASH INVESTING AND FINANCING ACTIVITIES
Conversion of convertible promissory note		380	0	0
Exercise of pre-funded warrants		$ 864	$ 0	$ 0
[1]1,674 per statement of changes in equity

General information

General information	12 Months Ended
	Jun. 30, 2024
Text block [abstract]
General information	Note 1. General information The consolidated financial statements cover Kazia Therapeutics Limited (the “Consolidated Entity”, the “Company” or “Kazia”) as a consolidated entity which consists of Kazia Therapeutics Limited and its subsidiaries. The consolidated financial statements are presented in Australian dollars, which is Kazia Therapeutics Limited’s functional and reporting currency. Kazia Therapeutics Limited is a listed public company limited by shares, incorporated and domiciled in Australia. Its registered office and principal place of business is: Three International Towers Level 24, 300 Barangaroo Avenue Sydney NSW 2000 The consolidated financial statements were authorized for issue, in accordance with a resolution of Directors, on 15 November

Material accounting policies

Material accounting policies	12 Months Ended
	Jun. 30, 2024
Text block [abstract]
Material accounting policies	Note 2. Material accounting policies The material accounting policies adopted in the preparation of the consolidated financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated. New or amended Accounting Standards and Interpretations adopted The Consolidated Entity has adopted all of the new, revised or amending Accounting Standards and Interpretations issued by the International Accounting Standards Board (‘IASB’) that are mandatory for the current reporting period. The adoption of these standards has not had any material impact on the disclosures or amounts reported in these consolidated financial statements. New Accounting Standards and Interpretations not yet mandatory or early adopted In April 2024, IFRS 18, “Presentation and Disclosure in Financial Statements” was issued to achieve comparability of the financial performance of similar entities. The standard, which replaces IAS 1 “Presentation of Financial Statements”, impacts the presentation of primary financial statements and notes, including the statement of earnings where companies will be required to present separate categories of income and expense for operating, investing, and financing activities with prescribed subtotals for each new category. The standard will also require management-defined performance measure to be explained and included in a separate note within the consolidated financial statements. The standard is effective for annual reporting periods beginning on or after January 1, 2027, including interim financial statements, and require retroactive application. The Consolidated Entity is currently assessing the impact of the new standard. The Consolidated Entity is currently analyzing the potential impact of the amendments to IFRS 9 “Financial Instruments”, IFRS 7 “Financial Instruments: Disclosures”, and small changes to various standards or interpretations as part of the annual improvements to IFRS project. The amendments are effective for reporting periods beginning on or after 1 January 2026. There were no other new accounting standards and interpretations not yet adopted by the Consolidated Entity for the 30 June 2024 reporting period that are expected to materially impact the Consolidated Entity. Going concern The Consolidated Entity incurred a loss after income tax of A$26.8 million was in a net current liability position of A$19.7 million and had net cash outflows from operating activities of A$9.6 million as at and for the year ended 30 June 2024. As at 30 June 2024 the Consolidated Entity had cash and cash equivalents . The consolidated financial statements have been prepared on a going concern basis, which contemplates continuity of normal activities and realization of assets and settlement of liabilities in the normal course of business. As is often the case with drug development companies, the Company has not generated significant revenues nor does the Company anticipate generating significant revenues in the near future. The ability of the Consolidated Entity to continue its development activities as a going concern is dependent upon it deriving sufficient cash from investors, from licensing and partnering activities, and from other sources of revenue such as grant funding. The directors have considered the cash flow forecasts and the funding requirements of the business and continue to explore grant funding, licensing opportunities and equity investment opportunities in the Company. The at-the-market’ “ ”), From July through September 2024, the Consolidated Entity raised total proceeds of US$3,609,757 using the ATM facility and continues to seek additional funding sources both in Australia and overseas. For the same period , Accordingly , consolidated consolidated Basis of preparation These general purpose consolidated financial statements have been prepared in accordance with Australian Accounting Standards and Interpretations issued by the Australian Accounting Standards Board (‘AASB’) and the Corporations Act, as appropriate for for-profit Critical accounting estimates The preparation of the consolidated financial statements requires the use of certain critical accounting estimates. It also requires management to exercise its judgement in the process of applying the Consolidated Entity’s accounting policies. The areas involving a higher degree of judgement or complexity, or areas where assumptions and estimates are significant to the consolidated financial statements, are disclosed in note 3. Parent entity information In accordance with the Corporations Act, these consolidated financial statements present the results of the Consolidated Entity only. Supplementary information about the parent entity is disclosed in note 29. Principles of consolidation The consolidated financial statements incorporate the assets and liabilities of all subsidiaries of Kazia Therapeutics Limited. Kazia Therapeutics Limited and its subsidiaries together are referred to in these consolidated financial statements as the ‘Consolidated Entity’. Subsidiaries are all those entities over which the Consolidated Entity has control. The Consolidated Entity controls an entity when the Consolidated Entity is exposed to, or has rights to, variable returns from its involvement with the entity and has the ability to affect those returns through its power to direct the activities of the entity. Subsidiaries are fully consolidated from the date on which control is transferred to the Consolidated Entity. They are de-consolidated Intercompany transactions, balances and unrealized gains on transactions between entities in the Consolidated Entity are eliminated. Unrealized losses are also eliminated unless the transaction provides evidence of the impairment of the asset transferred. Accounting policies of subsidiaries have been changed where necessary to ensure consistency with the policies adopted by the Consolidated Entity. The acquisition of subsidiaries is accounted for using the acquisition method of accounting. A change in ownership interest, without the loss of control, is accounted for as an equity transaction, where the difference is between the consideration transferred and the book value. Where the Consolidated Entity loses control over a subsidiary, it derecognize the assets including goodwill, liabilities and non-controlling Operating segments Operating segments are presented using the ‘management approach’ where the information presented is on the same basis as the internal reports provided to the Chief Operating Decision Makers (‘CODM’). The CODM is responsible for the allocation of resources to operating segments and assessing their performance. The CODM is considered to be the Board of Directors. Foreign currency translation The consolidated financial statements are presented in Australian dollars. Foreign currency transactions Foreign currency transactions are translated into Australian dollars using the exchange rates prevailing at the dates of the transactions. Foreign exchange gains and losses resulting from the settlement of such transactions and from the translation at reporting date exchange rates of monetary assets and liabilities denominated in foreign currencies are recognized in profit or loss. Foreign operations The assets and liabilities of foreign operations are translated into Australian dollars using the exchange rates at the reporting date. The revenues and expenses of foreign operations are translated into Australian dollars using the average exchange rates, which approximate the rate at the date of the transaction, for the period. All resulting foreign exchange differences are recognized in other comprehensive income through the foreign currency reserve in equity. The foreign currency reserve is recognized in profit or loss when the foreign operation is disposed of. Exchange differences arising on a monetary item that forms part of a reporting entity’s net investment in a foreign operation shall be recognized initially in other comprehensive income and reclassified from equity to profit or loss on disposal of the net investment. Financial Instruments Subsequent measurement of financial assets For the purpose of subsequent measurement, financial assets are classified into the following categories upon initial recognition: • financial assets at amortized cost • financial assets at fair value through profit or loss (FVPL) Classifications are determined by both: • the entity’s business model for managing the financial asset • the contractual cash flow characteristics of the financial assets All income and expenses relating to financial assets that are recognized in profit or loss are presented within finance costs, finance income or other financial items, except for impairment of trade receivables which is presented within other expenses. Financial assets at amortised cost Financial assets are measured at amortised cost if the assets meet the following conditions (and are not designated as FVPL): • they are held within a business model whose objective is to hold the financial assets and collect its contractual cash flows; and • the contractual terms of the financial assets give rise to cash flows that are solely payments of principal and interest on the principal amount outstanding. After initial recognition, these are measured at amortised cost using the effective interest method. Discounting is omitted where the effect of discounting is immaterial. The Consolidated Entity’s cash and cash equivalents, trade and most other receivables fall into this category of financial instruments. Classification and measurement of financial liabilities The Consolidated Entity’s financial liabilities comprise trade and other payables. Financial liabilities, borrowings and contingent consideration for business combination and licensing agreement acquisitions are initially measured at fair value, and, where applicable, adjusted for transaction costs unless the Consolidated Entity designated a financial liability at fair value through profit or loss. Subsequently, financial liabilities are measured at amortised cost using the effective interest method, except for contingent consideration in a business combination and liability classified warrants, which are measured at fair value. All interest-related charges and, if applicable, changes in an instrument’s fair value that are reported in profit or loss are included within finance costs or finance income. Revenue from contracts with customers Revenue is measured at the fair value of the consideration received or receivable. Revenue is recognized using a five step approach in accordance with IFRS 15, “Revenue from Contracts with Customers” to depict the transfer of promised services to customers in an amount that reflects the consideration to which the Group expects to be entitled in exchange for those services. Distinct promises within the contract are identified as performance obligations. The transaction price of the contract is measured based on the amount of consideration the Consolidated Entity expects to be entitled to from the customer in exchange for services. Factors such as requirements around variable consideration, significant financing components, noncash consideration, or amounts payable to customers also determine the transaction price. The transaction price is then allocated to separate performance obligations in the contract based on relative standalone selling prices. Revenue is recognized when, or as, performance obligations are satisfied, which is when control of the promised service is transferred to the customer. Amounts received prior to satisfying the revenue recognition criteria are recorded as deferred revenue. Amounts expected to be recognized as revenue within the 12 months following the balance sheet date are classified within current liabilities. Amounts not expected to be recognized as revenue within the 12 months following the balance sheet date are classified within non-current The Consolidated Entity recognizes contract liabilities for consideration received in respect of unsatisfied performance obligations and reports these amounts as other liabilities in its consolidated statement of financial position. Similarly, if the Consolidated Entity satisfies a performance obligation before it receives the consideration, the Consolidated Entity recognizes either a contract asset or a receivable in its statement of financial position, depending on whether something other than the passage of time is required before the consideration is due. Licensing revenues, including milestone revenue Revenue from licensees of the Consolidated Entity’s intellectual property reflects the transfer of a right to use the intellectual property as it exists at the point in time in which the license is transferred to the customer. Licensing agreements are examined to determine whether they contain additional performance obligations, over and above the right to use the intellectual property. To the extent that additional performance obligations exist, the transaction price the Consolidated Entity expects to receive for the contract is allocated to the separate performance obligations. The receipt of milestone payments is often contingent on meeting certain clinical, regulatory or commercial targets, and is therefore considered variable consideration. The transaction price of the contingent milestone is estimated using the most likely amount method. Within the transaction price, the price associated with a contingent milestone is included only to the extent that it is highly probable that a significant reversal in the amount of cumulative revenue recognized will not occur. Milestone payments that are not within the control of the Group, such as regulatory approvals, are not considered highly probable of being achieved until those approvals are achieved. Finance income Interest revenue is recognized as interest accrues using the effective interest method. This is a method of calculating the amortised cost of a financial asset and allocating the interest income over the relevant period using the effective interest rate, which is the rate that exactly discounts estimated future cash receipts through the expected life of the financial asset to the net carrying amount of the financial asset. Grant income Grants from governments are recognized at their fair value when there is a reasonable assurance that the grant will be received and the Company will comply with all attached conditions. Government grants relating to operating costs are recognized in the Statements of Comprehensive Income as other income. A New South Wales Export Development Grant was received in the year ended 30 June 2022. Other income Other income is recognized when it is received or when the right to receive payment is established. Income tax Income tax expense or benefit for the period is the tax payable on that period’s taxable income based on the applicable income tax rate for each jurisdiction, adjusted by changes in deferred tax assets and liabilities attributable to temporary differences, unused tax losses and the adjustment recognized for prior periods, where applicable. Deferred tax assets and liabilities are recognized for temporary differences at the tax rates expected to apply when the assets are recovered or liabilities are settled, based on those tax rates that are enacted or substantively enacted, except for: • When the deferred income tax asset or liability arises from the initial recognition of goodwill or an asset or liability in a transaction that is not a business combination and that, at the time of the transaction, affects neither the accounting nor taxable profits; or • When the taxable temporary difference is associated with interests in subsidiaries, associates or joint ventures, and the timing of the reversal can be controlled and it is probable that the temporary difference will not reverse in the foreseeable future. Deferred tax assets are recognized for deductible temporary differences and unused tax losses only if it is probable that future taxable amounts will be available to utilize those temporary differences and losses. The carrying amount of recognized and unrecognized deferred tax assets are reviewed each reporting date. Deferred tax assets recognized are reduced to the extent that it is no longer probable that future taxable profits will be available for the carrying amount to be recovered. Previously unrecognized deferred tax assets are recognized to the extent that it is probable that there are future taxable profits available to recover the asset. Deferred tax assets and liabilities are offset only where there is a legally enforceable right to offset current tax assets against current tax liabilities and deferred tax assets against deferred tax liabilities; and they relate to the same taxable authority on either the same taxable entity or different taxable entities which intend to settle simultaneously. Kazia Therapeutics Limited and its wholly-owned Australian controlled entities have formed an income tax consolidated group under the tax consolidation regime. Kazia Therapeutics Limited as the parent entity discloses all of the deferred tax assets of the tax consolidated group in relation to tax losses carried forward (after elimination of inter-group transactions). The tax consolidated group has applied the ‘separate taxpayer in the group’ allocation approach in determining the appropriate amount of taxes to allocate to members of the tax consolidated group. As the tax consolidation group continues to generate tax losses there has been no reason for the Company to enter a tax funding agreement with members of the tax consolidation group. Uncertain tax positions IFRIC 23 clarified the application of the recognition and measurement criteria of IAS 12, “Income Taxes,” where there is uncertainty over income tax treatments and requires an assessment of each uncertain tax position as to whether it is probable that a taxation authority will accept the position. Where it is not probable, the effect of the uncertainty is reflected in determining the relevant taxable profit or loss, tax bases, unused tax losses and unused tax credits or tax rates. The amount is determined as either the single most likely amount or the sum of the probability weighted amounts in a range of possible outcomes, whichever better predicts the resolution of the uncertainty. Management believes that historical tax losses are not expected to be available for offset against the deferred tax liability at 30 June 2024 and 2023. Current and non-current Assets and liabilities are presented in the statement of financial position based on current and non-current An asset is current when: it is expected to be realized or intended to be sold or consumed in normal operating cycle; it is held primarily for the purpose of trading; it is expected to be realized within 12 months after the reporting period; or the asset is cash or cash equivalent unless restricted from being exchanged or used to settle a liability for at least 12 months after the reporting period. All other assets are classified as non-current. A liability is current when: it is expected to be settled in normal operating cycle; it is held primarily for the purpose of trading; it is due to be settled within 12 months after the reporting period; or there is no unconditional right to defer the settlement of the liability for at least 12 months after the reporting period. All other liabilities are classified as non-current. Deferred tax assets and liabilities are always classified as non-current. Cash and cash equivalents Cash and cash equivalents includes cash on hand, deposits held at call with financial institutions, other short-term, highly liquid investments with original maturities of three months or less that are readily convertible to known amounts of cash and which are subject to an insignificant risk of changes in value. Research and development Expenditure during the research phase of a project is recognized as an expense when incurred. Development costs are capitalized only when technical feasibility studies identify that the project will deliver future economic benefits and these benefits can be measured reliably. Intangible assets Separately acquired intangible assets are shown at historical cost. The cost of intangible assets acquired as part of a business combination is their fair value at the acquisition date. They have a finite useful life and are subsequently carried at cost less accumulated amortization and impairment losses. The method and useful lives of finite life intangible assets are reviewed annually. Changes in the expected pattern of consumption or useful life are accounted for prospectively by changing the amortization method or period. Amortization expense is included in research and development expenditure. Licensing agreement for paxalisib The paxalisib licensing agreement asset was acquired as part of a business combination and is being amortised on a straight-line basis over the period of its expected benefit, being the remaining life of the patent which was 15 years from the date of acquisition. Licensing agreement for EVT801 The EVT801 licensing agreement asset was acquired via an asset acquisition and is being amortised on a straight-line basis over the period of its expected benefit, being the remaining life of the patent which was 12.5 years from the date of acquisition. Impairment of non-financial Non-financial Recoverable amount is the higher of an asset’s fair value less costs of disposal and value-in-use. value-in-use pre-tax Provisions Provisions are recognized when the Consolidated Entity has a present (legal or constructive) obligation as a result of a past event, it is probable the Consolidated Entity will be required to settle the obligation, and a reliable estimate can be made of the amount of the obligation. The amount recognized as a provision is the best estimate of the consideration required to settle the present obligation at the reporting date, taking into account the risks and uncertainties surrounding the obligation. If the time value of money is material, provisions are discounted using a current pre-tax Employee benefits Short-term employee benefits Liabilities for wages and salaries, including non-monetary Other long-term employee benefits The liability for annual leave and long service leave not expected to be settled within 12 months of the reporting date is measured as the present value of expected future payments to be made in respect of services provided by employees up to the reporting date using the projected unit credit method. Consideration is given to expected future wage and salary levels, experience of employee departures and periods of service. Expected future payments are discounted using market yields at the reporting date on high quality corporate bonds with terms to maturity and currency that match, as closely as possible, the estimated future cash outflows. Share-based payments Equity-settled share-based compensation benefits are provided to employees under the terms of the Employee Share Option Plan (‘ESOP’) and consultants as compensation for services performed. Equity-settled transactions are awards of shares, or options over shares that are provided to employees in exchange for the rendering of services. The value of the instruments is measured by reference to the fair value of the underlying instruments on grant date, as required by IFRS2, “Share-Based Payments.” Fair value is estimated using an appropriate option pricing model that takes into account the exercise price, the term of the option, the impact of dilution, the share price at grant date and expected price volatility of the underlying share, the expected dividend yield and the risk free interest rate for the term of the option, together with non-vesting The cost of equity-settled transactions are recognized as an expense with a corresponding increase in equity over the vesting period. The cumulative charge to profit or loss is calculated based on the grant date fair value of the award, the best estimate of the number of awards that are likely to vest and the expired portion of the vesting period. The amount recognized in profit or loss for the period is the cumulative amount calculated at each reporting date less amounts already recognized in previous periods. The cumulative charge to profit or loss until settlement of the options is calculated as follows: • during the options vesting period, the liability at each reporting date is the fair value of the award at that date multiplied by the expired portion of the vesting period. • from the end of the option vesting period until settlement of the award, the liability is the full fair value of the option at the reporting date. Market conditions are taken into consideration in determining fair value. Therefore, any awards subject to market conditions are considered to vest irrespective of whether or not that market condition has been met, provided all other conditions are satisfied. If equity-settled awards are modified, as a minimum an expense is recognized as if the modification has not been made. An additional expense is recognized, over the remaining vesting period, for any modification that increases the total fair value of the share-based compensation benefit as at the date of modification. If the non-vesting If equity-settled awards are cancelled, it is treated as if it has vested on the date of cancellation, and any remaining expense is recognized immediately. If a new replacement award is substituted for the cancelled award, the cancelled and new award is treated as if they were a modification. Finance costs Finance costs attributable to qualifying assets are capitalized as part of the asset. All other finance costs are expensed in the period in which they are incurred, including interest on short-term and long-term borrowings. Fair value measurement When an asset or liability, financial or non-financial, Fair value is measured using the assumptions that market participants would use when pricing the asset or liability, assuming they act in their economic best interest. For non-financial Assets and liabilities measured at fair value are classified, into three levels, using a fair value hierarchy that reflects the significance of the inputs used in making the measurements. Classifications are reviewed each reporting date and transfers between levels are determined based on a reassessment of the lowest level input that is significant to the fair value measurement. For recurring and non-recurring Issued capital Ordinary shares are classified as equity. Incremental costs directly attributable to the issue of new shares or options, including share-based payments relating to the issue of shares, are shown in equity as a deduction, from the proceeds. Earnings per share Basic earnings per share Basic earnings per share is calculated by dividing the profit attributable to the owners of Kazia Therapeutics Limited, excluding any costs of servicing equity other than ordinary shares, by the weighted average number of ordinary shares outstanding during the financial year, adjusted for bonus elements in ordinary shares issued during the financial year. Diluted earnings per share Diluted earnings per share adjusts the figures used in the determination of basic earnings per share to take into account the after income tax effect of interest and other financing costs associated with dilutive potential ordinary shares and the weighted average number of shares assumed to have been issued for no consideration in relation to dilutive potential ordinary shares. Goods and Services Tax (‘GST’) and other similar taxes Revenues, expenses and assets are recognized net of the amount of associated GST, unless the GST incurred is not recoverable from the tax authority. In this case it is recognized as part of the cost of the acquisition of the asset or as part of the expense. Receivables and payables are stated inclusive of the amount of GST receivable or payable. The net amount of GST recoverable from, or payable to, the tax authority is included in other receivables or other payables in the statement of financial position. Cash flows are presented on a gross basis. The GST components of cash flows arising from investing or financing activities which are recoverable from, or payable to the tax authority, are presented as operating cash flows. Commitments and contingencies are disclosed net of the amount of GST recoverable from, or payable to, the tax authority.

Critical accounting judgements,

Critical accounting judgements, estimates and assumptions	12 Months Ended
	Jun. 30, 2024
Text block [abstract]
Critical accounting judgements, estimates and assumptions	Note 3. Critical accounting judgements, estimates and assumptions The preparation of the consolidated financial statements requires management to make judgements, estimates and assumptions that affect the reported amounts in the consolidated financial statements. Management continually evaluates its judgements and estimates in relation to assets, liabilities, contingent liabilities, revenue and expenses. Management bases its judgements, estimates and assumptions on historical experience and on other various factors, including expectations of future events, management believes to be reasonable under the circumstances. The resulting accounting judgements and estimates will seldom equal the related actual results. The judgements, estimates and assumptions that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities (refer to the respective notes) within the next financial year are discussed as follows: Research and development expenses The Directors do not consider the development programs to be sufficiently advanced to reliably determine the economic benefits and technical feasibility to justify capitalization of development costs. These costs have been recognized as an expense when incurred. Research and development expenses relate primarily to the cost of conducting human clinical and pre-clinical Clinical trial expenses The timing of payment for work conducted under clinical trials often bears little relation to the timing of the work effort. Detailed estimates are made to determine the amount of work effort expended during a reporting period in order to determine the appropriate expense to be recognized, with the resulting prepayments or un-invoiced Share-based payment transactions The Consolidated Entity measures the cost of equity-settled transactions with employees by reference to the fair value of the equity instruments at the date at which they are granted. The fair value is estimated using an appropriate option pricing model taking into account the terms and conditions upon which the instruments were granted. The accounting estimates and assumptions relating to equity-settled share-based payments would have no impact on the carrying amounts of assets and liabilities within the next annual reporting period but may impact profit or loss and equity. Acquisition of intangible assets During the 2017 financial year, the Consolidated Entity acquired the rights to develop and commercialize paxalisib, as part of a business combination from Genentech. Significant judgement was required in determining that the transaction was a business combination and in relation to the identification and valuation of assets and liabilities acquired. The Consolidated Entity has applied judgement in determining the accounting treatment for the acquisition of the License agreement for EVT801. The License agreement has been determined to be a standalone transaction, independent from any other agreements which have been or may be entered into with Evotec (France) SAS. Management has also made the decision to account for the cost of the asset conferred by the License agreement on the basis of the milestones that are probable of being payable, that is, those for which there is judged to be a probability of greater than 50% that the milestone will be triggered. Contingent consideration Contingent consideration relates to the intangible assets acquired, and the fair value of contingent consideration is dependent on the key assumptions used in accounting for the acquisition of those intangible assets. These assumptions include the probability of milestones occurring, and can also include the anticipated timing of settlement and discount rates used. In the case where contingent consideration is recognized on the basis that the liability is probable of occurring, judgement is used in determining which milestones are considered probable of being triggered and the timing thereof. Intangible assets available for use The Consolidated Entity has exercised judgement in determining that its intangible assets, being license agreements, have a finite life and are available for use once acquired. As the business model is to acquire such assets and then develop them to generate returns from future license transactions or other means, management have determined that the assets are available for use from the time that they are acquired. In each case the prima facie useful life is the remaining life of the patent over the asset, unless other factors over-ride this assessment. Impairment of licensing agreements and other indefinite life intangible assets The Consolidated Entity assesses impairment of licensing agreements at each reporting date by evaluating conditions specific to the Consolidated Entity and to the particular asset that may lead to impairment. Judgement is used to determine whether any indicators of impairment exist, and reference is made to the considerations included in IAS 36, Impairment of Assets, in this assessment. If an impairment trigger is found to exist, the recoverable amount of the asset is determined.

Restatement of comparatives

Restatement of comparatives	12 Months Ended
	Jun. 30, 2024
Text block [abstract]
Restatement of comparatives	Note 4. Restatement of comparatives During the year ended 30 June 2023, management determined the calculation of the EVT-801 specifically EVT-801 30 June 2022 Reported Increase/ (decrease) 30 June 2022 Restated A$’000 A$’000 A$’000 Consolidated statement of financial position Intangibles - licensing agreement 27,266 (1,045 ) 26,221 Less Accumulated amortisation (7,216 ) 134 (7,082 ) 20,050 (911 ) 19,139 Current contingent consideration (759 ) —  (759 ) Non-Current (8,756 ) 547 (8,209 ) (9,515 ) 547 (8,968 ) Accumulated losses (68,253 ) (364 ) (68,617 ) Total equity 18,638 (363 ) 18,275 30 June 2022 Increase/ (decrease) 30 June 2022 Restated Consolidated statement of profit and loss Research and development expense (20,252 ) 83 (20,169 ) General and administrative expense (4,511 ) (602 ) (5,113 ) Loss on revaluation of contingent consideration (152 ) 152 —  Commercialisation expense (127 ) —  (127 ) Loss before income tax benefit (25,016 ) (366 ) (25,382 ) Income tax benefit 368 —  368 Loss after income tax benefit (24,648 ) (366 ) (25,014 ) Impact on basic and diluted earnings per share increase/ (decrease) in earning per share Cents Cents Cents Basic and diluted loss for the year attributable to equity holders $ (18.61 ) $ (0.27 ) $ (18.88 )

Reclassification of comparative

Reclassification of comparatives	12 Months Ended
	Jun. 30, 2024
Text block [abstract]
Reclassification of comparatives	Note 5. Reclassification of comparatives During the preparation of the consolidated financial statements for the year ended 30 June 2023, a reclassification between borrowings and other assets was performed to better reflect the insurance funding premium utilized by the Company, a reclassification of non-current 30 June 2022 Restated Reclassification 30 June 2022 Reclassified Other assets 156 1,841 1,997 Borrowings —  (1,841 ) (1,841 ) Current employee benefits 166 203 369 Non-current 319 (202 ) 117 Loss on remeasurement of contingent consideration 152 (152 ) —  General and administrative expense (4,961 ) (152 ) (5,113 )

Revenue

Revenue	12 Months Ended
	Jun. 30, 2024
Text block [abstract]
Revenue	Note 6. Revenue 2024 A$’000 2023 A$’000 2022 A$’000 Licensing revenue 2,301 —  —  Sale of paxalisib 7 —  —  2,308 —  —  Disaggregation of revenue The disaggregation of revenue from contracts with customers is as follows: 2024 A$’000 2023 A$’000 2022 A$’000 Geographical regions South Korea 2,308 —  —  2,308 —  —  Timing of revenue recognition Licensing revenue at a point in time 2,301 —  —  Sale of paxalisib at a point in time 7 —  —  License Agreement with Oasmia Pharmaceutical AB In March 2021, the C Cantrixil (TRX-E-002 - 1), a clinical stage drug candidate for the treatment of ovarian cancer. During fiscal , Oasmia made an upfront payment of US$ million with contingent milestones of up to US$ million and double-digit royalties License Agreement with Simcere Pharmaceutical Group Ltd. In March 2021, the C C paxalisib C C mid-teen License Agreement with Sovargen Co Ltd. In March 2024, the Company entered into a licensing agreement with Sovargen Co Ltd. (“Sovargen”) to develop and commercialize the Company’s C C sub-licensing During fiscal year 2024, the C note 2.

Operating segments

Operating segments	12 Months Ended
	Jun. 30, 2024
Text block [abstract]
Operating segments	Note 7. Operating segments Identification of reportable operating segments The Consolidated Entity’s operating segment is based on the internal reports that are reviewed and used by the Board of Directors (being the Chief Operating Decision Makers (‘CODM’) in assessing performance and in determining the allocation of resources. The Consolidated Entity operates in the pharmaceutical research and development business. There are no operating segments for which discrete financial information exists. The information reported to the CODM, on at least a quarterly basis, is the consolidated results as shown in the statement of profit or loss and other comprehensive income and statement of financial position.

Other income

Other income	12 Months Ended
	Jun. 30, 2024
Text block [abstract]
Other income	Note 8. Other income 2024 A$’000 2023 A$’000 2022 A$’000 Research and development rebate 173 —  —  Subsidies and grants —  —  10 Bad debt recovery —  —  15 Other sundry income —  1 —  173 1 25

Expenses

Expenses	12 Months Ended
	Jun. 30, 2024
Text block [abstract]
Expenses	Note 9. Expenses 2024 A$’000 2023 A$’000 2022 restated A$’000 Research and development EVT-801 5,277 5,060 2,520 Cantrixil program costs 1 5 12 Paxalisib program costs 7,551 5,618 13,713 Scientific Advisory Board costs —  31 —  Employee benefits expense - salaries & wages and staff benefits 2,161 2,250 1,665 - superannuation 36 29 25 - share based payments 485 702 365 Total research & development (excluding amortisation) 15,511 13,695 18,300 Amortisation Paxalisib licensing agreement 1,084 1,084 1,084 Evotech licensing agreement 785 785 785 Total amortisation 1,869 1,869 1,869 Total research & development 17,380 15,564 20,169 Net foreign exchange loss Net foreign exchange (gain) / loss (20 ) 46 (2,154 ) Rental expense relating to operating leases Minimum lease payments 124 152 73 Superannuation expense Defined contribution superannuation expense 88 131 138 Employee benefits expense G&A - salaries & wages and staff benefits 486 1,467 1,674 - superannuation 52 102 129 - share based payments 48 457 1,310 Total employee benefits expense G&A 586 2,026 3,113

Income taxes

Income taxes	12 Months Ended
	Jun. 30, 2024
Text block [abstract]
Income taxes	Note 10. Income taxes 2024 2023 2022 A$’000 A$’000 A$’000 Numerical reconciliation of income tax benefit and tax at the statutory rate Loss before income tax benefit (27,049 ) (20,736 ) (25,382 ) Tax at the statutory tax rate of 25 % (6,762 ) (5,184 ) (6,345 ) Tax effect amounts which are not deductible/(taxable) in calculating taxable income: Research and d —  —  —  Amortisation of intangibles 467 467 467 Employee option plan 133 289 419 Gain/loss on revaluation of contingent consideration (22 ) (847 ) 38 (6,184) (5,275) (5,421) Adjustment recognised —  —  16 Adjustment to deferred tax balances as a result of change in statutory tax rate —  —  (113 ) Tax losses and timing differences not recognised 5,913 5,004 5,150 Income tax benefit (271 ) (271 ) (368 ) 2024 A$’000 2023 A$’000 2022 restated A$’000 Tax losses not recognised Unused tax losses for which no deferred tax asset has been recogni s 139,430 120,412 96,519 Potential tax benefit 25.0 % - Australia 34,858 30,103 24,130 Unused tax losses for which no deferred tax asset has been recogni s 7,836 4,305 2,380 Potential tax benefit 1,646 904 500

Current assets - cash and cash

Current assets - cash and cash equivalents	12 Months Ended
	Jun. 30, 2024
Text block [abstract]
Current assets - cash and cash equivalents	Note 11. Current assets - cash and cash equivalents 2024 2023 A$’000 A$’000 Cash at bank and on hand 1,657 5,241 1,657 5,241

Trade and other receivables

Trade and other receivables	12 Months Ended
	Jun. 30, 2024
Text block [abstract]
Trade and other receivables	Note 12. Trade and other receivables 2024 2023 A$’000 A$’000 Current assets Trade receivables —  1 GBM Agile deposit 3,756 3,753 BAS receivables 133 104 Deposits held 8 41 3,897 3,899 The GBM Agile deposit was advanced to GCAR at the start of the GBM Agile trial, and is refundable if not utilized against trial expenses. The amount will be allocated against expenditure towards the latter end of the trial. Completion of the final analysis is expected in second half of 2024. The Business Activity Statement (“BAS”) receivable consist of GST that is recoverable and refundable from the tax authority.

Trade and other receivables - n

Trade and other receivables - non-current	12 Months Ended
	Jun. 30, 2024
Text block [abstract]
Trade and other receivables - non-current	Note 13. Trade and other receivables - non-current 2024 2023 A$’000 A$’000 Non-current Corporate credit card deposit 40 43 40 43

Other assets

Other assets	12 Months Ended
	Jun. 30, 2024
Text block [abstract]
Current assets - other	Note 14. Other assets 2024 2023 A$’000 A$’000 Prepayments 591 1,632 Other assets is comprised of this contains the prepayment of invoices in relation to the annual insurance renewal program and an offsetting borrowing for the funding of this prepayment in included in Borrowings - See Note 17 Borrowings.

Intangibles

Intangibles	12 Months Ended
	Jun. 30, 2024
Text block [abstract]
Intangibles	Note 15. Intangibles Consolidated 2024 A$’000 2023 A$’000 Licensing agreement - Paxalisib 16,408 16,408 Less: Accumulated amortisation (8,335 ) (7,251 ) 8,073 9,157 Licensing agreement - EVT-801 9,813 9,813 Less: Accumulated amortisation (2,486 ) (1,701 ) 7,327 8,112 15,400 17,269 Reconciliations Reconciliations of the carrying values at the beginning and end of the current and previous financial year are set out below: EVT801 licensing agreement A$’000 Paxalisib licensing agreement A$’000 Total A$’000 Balance at 30 June 2022 restated 8,897 10,242 19,139 Amortisation expense (785 ) (1,085 ) (1,870 ) Balance at 30 June 2023 8,112 9,157 17,269 Amortisation expense (785 ) (1,084 ) (1,869 ) Balance at 30 June 2024 7,327 8,073 15,400

Trade and other payables

Trade and other payables	12 Months Ended
	Jun. 30, 2024
1 year or less [member]
Statement [line items]
Trade and other payables	Note 16. Trade and other payables 2024 2023 A$’000 A$’000 Trade payables 4,548 857 Accrued payables 10,519 3,472 15,067 4,329 Refer to Note 25 for further information on financial instruments.

Borrowings

Borrowings	12 Months Ended
	Jun. 30, 2024
Borrowings [abstract]
Borrowings	Note 17. Borrowings Current liabilities 2024 2023 A$’000 A$’000 Insurance premium funding 634 1,796 Borrowings related to the annual insurance renewal program. An offsetting prepayment of insurance invoices is included in Prepayments - See Note 14 Other Assets. On 23 October 2023, the Company entered into a securities purchase agreement with an accredited investor, pursuant to which the Company issued a six month unsecured convertible promissory note (the “Note”) in the principal amount of A$ (US$ ). The Note bears interest at a rate of % per annum. The investor called upon % of the Note and cash of US$253,014 was paid, which represented US$ of principal and US$3,014 of interest (total payment of A$ ). The investor exercised their option to receive the remaining 50% in ADSs on 20 December 2023, which resulted in 591,697 ADS to be issued. On 19 June 2024, ADSs representing ordinary shares were issued at a price of A$ per ordinary share, which resulted in recognizing gain of A$25,174 through the fair value movement in liability between the exercise date and date the ADSs were issued.

Employee benefits

Employee benefits	12 Months Ended
	Jun. 30, 2024
1 year or less [member]
Statement [line items]
Employee benefits	Note 18. Employee benefits 2024 A$’000 2023 A$’000 Current Liabilities Employee benefits —  201 Annual leave 365 489 365 690 Non-Current Long service leave 35 59 400 749

Contingent consideration

Contingent consideration	12 Months Ended
	Jun. 30, 2024
Statement [line items]
Contingent consideration	Note 19. Contingent consideration 2024 A$’000 2023 A$’000 Current Contingent consideration - Paxalisib —  750 Contingent consideration - EVT801 3,253 —  3,253 750 Non-current Contingent consideration - paxalisib 1,266 654 Contingent consideration - EVT801 2,486 5,467 3,752 6,121 7,005 6,871 Reconciliations Reconciliation of the balance at the beginning and end of the reporting period is set out below: Consolidated 2024 2023 $ $ Contingent consideration at start of period (current and non-current) 6,871 8,968 Payment of EVT801 milestone —  —  Interest accretion 339 594 Effect of exchange rates on contingent consideration (86 ) 697 Gain on remeasurement of contingent consideration (119 ) (3,388 ) 7,005 6,871 Contingent consideration - paxalisib During the 2017 financial year, the Consolidated Entity acquired the rights to develop and commercialize paxalisib, as part of a business combination. The acquisition contained four development contingent milestone payments, the first two milestone payment settlements being Kazia shares, and the third and fourth development milestone payment settlements either cash or Kazia shares at the discretion of Kazia. Milestones 1 and 4 have now been paid out, and Milestone 3 has lapsed. Milestone 2 comprises shares to the value of $1,250,000. Each milestone payment is probability weighted for valuation purposes. Milestone 2 is contingent on the completion of a Phase II clinical trial of the molecule where such trial demonstrates a statistically significant improvement in progression-free survival or other approval endpoint indicated by the US Food and Drug Administration and was classified as a current liability as at 30 June 2023. Based on data received during June 2024, the Directors do not believe that this milestone payment will ultimately be due and payable and as such the probability weighting assigned in the current year has been reduced to nil (2023:60%). Milestone 5 is a revenue based milestone contingent on net sales, which the Directors expect to ultimately be achieved and has an assigned probability of 100% (2023:57%). Milestone 5 is discounted to present value, using a discount rate of % (2023: 20%) per annum. The discount rate was considered at 30 June 2024 and revised to reflect an incremental borrowing rate at the date of acquisition revised to reflect recent market changes as the milestone payments are already probability weighted for valuation purposes. Kazia is also required to pay royalties to Genentech in relation to net sales. These payments are related to future financial performance and are not considered as part of the consideration in relation to the Genentech agreement. Contingent consideration - EVT801 The acquisition of EVT801 has been accounted for at cost, with milestones where the payment is considered probable being recognised non-current based on are current periods utilised is i changes recognised totals A

Deferred tax

Deferred tax	12 Months Ended
	Jun. 30, 2024
Text block [abstract]
Deferred tax	Note 20. Deferred tax 2024 2023 A$’000 A$’000 Non-current Deferred tax liability associated with Licensing Agreement 2,018 2,289 The Company completed an analysis of the availability of historical tax losses to offset the deferred tax liability concluding the historical tax losses are not expected to be available for offset against the deferred tax liability.

Other financial liabilities

Other financial liabilities	12 Months Ended
	Jun. 30, 2024
Other Financial Liabilities Current [Abstract]
Other financial liabilities	Note 21. Other financial liabilities Consolidated June 2024 June 2023 A$’000 A$’000 Prefunded and ordinary warrants at initial recognition $ 8,599 $ —  Prefunded warrants exercised (864 ) —  Gain on remeasurement of financial liabilities (1,257 ) —  Prefunded and ordinary warrants at period end 6,478 —  On 3 pre-funded t The Ordinary Warrants were determined to be classified as a financial liability and a derivative under IAS 32 because they are denominated in a foreign currency, causing the value to vary with the USD/AUD exchange rate and the Consolidated Entity’s share price, requires a smaller net investment, and is settled at a future date. The initial fair value of the Ordinary Warrants was A$3,020,316. Additionally, as a part of the Securities Purchase Agreement, warrants were issued to the broker with an initial fair value of A$132,763. Transaction costs of A$382,463 were incurred. 21 pre-funded In connection with the Purchase Agreement with Alumni Capital described in Note 22, the Consolidated Entity issued warrants to purchase ADSs (“Warrant ADS”) that are accounted for at fair value through profit and loss. The Warrant ADS were determined to be classified as a financial liability and a derivative under IAS 32 because they are denominated in a foreign currency, causing the value to vary with the USD/AUD exchange rate and the Consolidated Entity’s share price, requires a smaller net investment, and is settled at a future date.

Equity - contributed equity

Equity - contributed equity	12 Months Ended
	Jun. 30, 2024
Text block [abstract]
Equity - contributed equity	Note 22. Equity - contributed equity 2024 2023 2022 2024 2023 2022 Shares Shares Shares A$‘000 A$‘000 A$‘000 Ordinary shares - fully paid 332,850,784 228,029,114 138,755,376 101,638 97,452 84,480 Movements in ordinary share capital Details Date Shares Issue price A$ Balance 1 July 2021 132,012,209 80,290,062 Issued on conversion of options 15 December 2021 25,000 $ 0.668 16,700 Conversion of Triaxial Convertible Note 5 May 2022 1,855,357 $ 0.25 464,000 ATM issue of shares No. 1 24 May 2022 10,000 $ 0.826 8,256 ATM issue of shares No. 2 2 June 2022 10,000 $ 0.802 8,025 ATM issue of shares No. 3 6 June 2022 88,710 $ 0.837 74,258 ATM issue of shares No. 4 9 June 2022 603,500 $ 0.84 507,035 ATM issue of shares No. 5 14 June 2022 75,940 $ 0.824 62,583 ATM issue of shares No. 6 15 June 2022 2,000 $ 0.83 1,661 ATM issue of shares No. 7 20 June 2022 4,072,660 $ 0.869 3,540,403 Less: share issue transaction costs —  $ —  ( 492,735 ) Balance 30 June 2022 138,755,376 84,480,249 Balance 1 July 2022 138,755,376 84,480,249 ATM issue of shares No. 8 7 July 2022 573,370 $ 0.7102 407,201 ATM issue of shares No. 9 8 August 2022 8,561,490 $ 0.3316 2,839,346 ATM issue of shares No. 10 9 August 2022 10,000 $ 0.2723 2,723 ATM issue of shares No. 11 10 August 2022 158,020 $ 0.2465 38,949 ATM issue of shares No. 12 11 August 2022 330,960 $ 0.2413 79,868 ATM issue of shares No. 13 12 August 2022 1,247,440 $ 0.2469 308,050 ATM issue of shares No. 14 12 September 2022 651,030 $ 0.2211 143,964 ATM issue of shares No. 15 13 September 2022 28,350 $ 0.2187 6,200 Shares issued to Scientific Advisory Board 14 September 2022 60,000 $ 0.21 12,600 ATM issue of shares No. 16 7 October 2022 736,760 $ 0.1789 131,797 ATM issue of shares No. 17 28 October 2022 12,296,180 $ 0.1865 2,293,288 ATM issue of shares No. 18 11 January 2023 20,000 $ 0.138 2,761 Professional and sophisticated investors placement - 1st tranche 16 January 2023 25,387,018 $ 0.11 2,792,572 Professional and sophisticated investors placement - 2nd tranche 28 February 2023 15,522,075 $ 0.11 1,707,428 Share Placement Plan 3 March 2023 23,691,045 $ 0.11 2,606,000 Less: share issue transaction costs (400,750 ) Balance 30 June 2023 228,029,114 97,452,246 Balance 01 July 2023 228,029,114 97,452,246 ATM issue of shares No. 19 06 July 2023 8,148,140 $ 0.19 1,512,523 ATM issue of shares No. 20 07 July 2023 157,120 $ 0.16 25,877 ATM issue of shares No. 21 03 August 2023 15,000 $ 0.17 2,519 ATM issue of shares No. 22 29 November 2023 1,066,070 $ 0.10 107,268 Registered Direct Offering 05 December 2023 26,200,000 $ —  —  ATM issue of shares No. 23 13 February 2024 25,910 $ 0.0466 1,207 ATM issue of shares No. 24 14 February 2024 319,650 $ 0.0464 14,834 ATM issue of shares No. 25 15 February 2024 2,195,980 $ 0.0468 102,825 ATM issue of shares No. 26 16 205,260 $ 0.0614 12,597 Armistice warrants 21 February 2024 18,244,450 $ 0.0450 892,655 ATM issue of shares No. 27 21 February 2024 8,626,580 $ 0.0595 513,584 ATM issue of shares No. 28 22 February 2024 316,540 $ 0.0461 14,584 ATM issue of shares No. 29 2 3 304,860 $ 0.0464 14,147 ATM issue of shares No. 30 26 February 2024 250,000 $ 0.0460 11,502 ATM issue of shares No. 31 01 May 2024 2,112,560 $ 0.0478 100,961 ATM issue of shares No. 32 02 May 2024 375,410 $ 0.0457 17,147 ATM issue of shares No. 33 03 May 2024 288,900 $ 0.0469 13,544 ATM issue of shares No. 34 07 May 2024 790,100 $ 0.0456 36,024 ATM issue of shares No. 35 10 May 2024 20,000 $ 0.0455 910 ATM issue of shares No. 36 16 May 242,170 $ 0.0450 10,891 Repayment of promissory note 19 June 2024 5,916,970 $ 0.0643 380,223 Equity line of credit 24 June 2024 29,000,000 $ 0.0268 776,264 Less: share issue transaction costs (376,573 ) Balance 30 June 2024 332,850,784 101,637,758 For , pre-funded ) before transaction costs of A$382,463. In February 2024, Armistice Capital exercised 1,824,445 prefunded warrants for a cash price of US$18,244 (translated into A$27,901) On 17 May 2024, the terms of the Securities Purchase Agreement were amended. in which the exercise price for the previously issued warrants was reduced to US$0.27 per ADS, and new warrants were issued to purchase up to 1,100,000 ADSs, with an exercise price of $0.27 per ADS. The original transaction resulted in the entire consideration being allocated to the derivative liability and all transaction fees associated with the transaction were expensed immediately. As such, the modification was directly adjusted through profit and loss along with any movement in the fair value of the derivative. The initial fair value of the newly issued warrants was A$232,488 and recorded as a derivative liability. On 19 April 2024, Kazia entered into a purchase agreement (the “Purchase Agreement”) with Alumni Capital LP (“Alumni Capital”). Pursuant to the Purchase Agreement, the Company may sell to Alumni Capital up to an aggregate of $15,000,000, of ADSs from time to time during Ordinary shares Ordinary shares entitle the holder to participate in dividends and the proceeds on the winding up of the C C On a show of hands every member present at a meeting in person or by proxy shall have one vote and upon a poll each share shall have one vote. Share buy-back There is no current on-market buy-back. Capital risk management The Consolidated Entity’s objectives when managing capital are to safeguard its ability to continue as a going concern, so that it can provide returns for shareholders and benefits for other stakeholders and to maintain an optimum capital structure to reduce the cost of capital. Capital is regarded as total equity, as recognized in the statement of financial position, plus net debt. Net debt is calculated as total borrowings less cash and cash equivalents. The capital structure of the Consolidated Entity consists of cash and cash equivalents and equity attributable to equity holders. The overall strategy of the Consolidated Entity is to continue its drug development programs, which depends on raising sufficient funds, through a variety of sources including issuing of additional share capital, as may be required from time to time. The capital risk management policy remains unchanged from the prior year.

Equity - reserves

Equity - reserves	12 Months Ended
	Jun. 30, 2024
Text block [abstract]
Equity - reserves	Note 23. Equity - reserves 2024 2023 2022 A$’000 A$’000 A$’000 Foreign currency reserve (750 ) (742 ) (852 ) Share-based payments reserve for Employee Share Option Plan 4,225 4,423 3,264 3,475 3,681 2,412 Foreign currency translation reserve The reserve is used to recognize exchange differences arising from translation of the consolidated financial statements of foreign operations to Australian dollars. Share based payments reserve for Employee Share Option Plan The reserve is used to recognize the value of equity benefits provided to employees and executive directors as part of their remuneration, and other parties as part of their compensation for services. For the year ended 30 June 2024, there were A$0.5 million issuances from the share-based payment reserve for Employee Share Option plan and A$

Equity - dividends

Equity - dividends	12 Months Ended
	Jun. 30, 2024
Text block [abstract]
Equity - dividends	Note 24. Equity - dividends Dividends There were dividends paid, recommended or declared during the current or previous financial year.

Financial instruments

Financial instruments	12 Months Ended
	Jun. 30, 2024
Text block [abstract]
Financial instruments	Note 25. Financial instruments Financial risk management objectives The Consolidated Entity’s activities expose it to a variety of financial risks: market risk, credit risk and liquidity risk. The Consolidated Entity uses different methods to measure and manage the different types of risks to which it is exposed. These methods include monitoring the levels of exposure to interest rates and foreign exchange, aging analysis and monitoring of specific credit allowances to manage credit risk, and, rolling cash flow forecasts to manage liquidity risk. Market risk Foreign currency risk The Consolidated Entity operates internationally and is exposed to foreign exchange risk arising from various currency exposures, primarily with respect to the US dollars (‘USD’). Foreign exchange risk arises from future transactions and recognized assets and liabilities denominated in a currency that is not the entity’s functional currency and net investments in foreign operations. Foreign currency risk is the risk that the fair value of future cash flows of a financial instrument will fluctuate because they are denominated in currencies that differ from the Company’s functional currency. The Company is exposed to foreign currency risk on fluctuations related to cash and cash equivalents, trade and other receivables, trade and other payables, and derivative financial liabilities on warrants that are denominated in foreign currencies. The Company has not used derivative instruments to reduce its exposure to foreign currency risk nor has it entered into foreign exchange contracts to hedge against gains or losses from foreign exchange fluctuations. Foreign subsidiaries with a functional currency of Australian Dollars (‘AUD’) have exposure to the local currency of these subsidiaries and any other currency these subsidiaries trade in. The carrying amount of the Consolidated Entity’s foreign currency denominated financial assets and financial liabilities at the reporting date was as follows: 2024 2023 US Dollar A$’000 Euro A$’000 Pound Sterling A$’000 Singapore A$’000 US Dollar A$’000 Euro A$’000 Pound Sterling A$’000 Singapore A$’000 Cash and cash equivalents - current 1,421 —  —  —  2,326 —  —  —  Trade and other receivables - current 1,908 —  —  —  —  —  —  —  Trade and other payables - current 942 7,320 18 —  1,135 2,710 —  1 Other financial liabilities 6,478 —  —  —  —  —  —  —  10,749 7,320 18 —  3,461 2,710 —  1 The Consolidated Entity had net liabilities If all currencies had AUD strengthened AUD weakened Consolidated - 2024 % change Effect on profit before tax A$’000 Effect on equity A$’000 % change Effect on profit before tax A$’000 Effect on equity A$’000 US dollars 10 % 142 142 (10 )% (142 ) (142 ) Euros 10 % —  —  (10 )% —  —  Pound Sterling 10 % (2 ) (2 ) (10 )% 2 2 140 140 (140 ) (140 ) AUD strengthened AUD weakened Consolidated - 2023 % change Effect on profit before tax A$’000 Effect on equity A$’000 % change Effect on profit before tax A$’000 Effect on equity A$’000 US dollars 10 % (494 ) (494 ) (10 )% 494 494 Euros 10 % 271 271 (10 )% (271 ) (271 ) (223 ) (223 ) 223 223 Price risk The Consolidated Entity is not exposed to any significant price risk. Interest rate risk The Consolidated Entity’s exposure to market interest rates relate primarily to the investments of cash balances. The Consolidated Entity has cash reserves held primarily in Australian dollars and United States dollars and places funds on deposit with financial institutions for periods generally not exceeding three months. As at the reporting date, the Consolidated Entity had the following variable interest rate balances: 2024 2023 Weighted average interest rate % Balance A$’000 Weighted average interest rate % Balance A$’000 Cash and cash equivalents 0.39 1,657 0.40 5,241 Net exposure to cash flow interest rate risk 1,657 5,241 The Consolidated Entity has cash and cash equivalents totaling A$1.7 million (2023: A $5.2 100 100 Credit risk Credit risk refers to the risk that a counterparty will default on its contractual obligations resulting in financial loss to the Consolidated Entity. The Consolidated Entity is not exposed to significant credit risk on receivables. The Consolidated Entity has adopted a lifetime expected loss allowance in estimating expected credit losses to trade receivables through the use of a provisions matrix using fixed rates of credit loss provisioning. These provisions are considered representative across all customers of the Consolidated Entity based on recent sales experience, historical collection rates and forward-looking information that is available. The Consolidated Entity places its cash deposits with high credit quality financial institutions and by policy, limits the amount of credit exposure to any single counterparty. The Consolidated Entity is averse to principal loss and ensures the safety and preservation of its invested funds by limiting default risk, market risk, and reinvestment risk. The Consolidated Entity mitigates default risk by constantly positioning its portfolio to respond appropriately to a significant reduction in a credit rating of any financial institution. Generally, trade receivables are written off when there is no reasonable expectation of recovery. Indicators of this include the failure of a debtor to engage in a repayment plan, no active enforcement activity and a failure to make contractual payments for a period greater than one There are no significant concentrations of credit risk within the Consolidated Entity. The credit risk on liquid funds is limited as the counter parties are banks with high credit ratings. Credit risk is managed by limiting the amount of credit exposure to any single counter-party for cash deposits. Liquidity risk The Consolidated Entity manages liquidity risk by maintaining adequate cash reserves and by continuously monitoring actual and forecast cash flows and matching the maturity profiles of financial assets and liabilities. In particular, contingent consideration may be satisfied either by payment of cash or by issue of shares, at the discretion of the entity. Remaining contractual maturities The following tables detail the Consolidated Entity’s remaining contractual maturity for its financial instrument liabilities. The tables have been drawn up based on the undiscounted cash flows of financial liabilities based on the earliest date on which the financial liabilities are required to be paid. The tables include both interest and principal cash flows disclosed as remaining contractual maturities and therefore these totals may differ from their carrying amount in the statement of financial position. 2024 Weighted average interest rate % 1 year or less A$’000 Between 1 and 2 years A$’000 Between 2 and 5 years A$’000 Over 5 years A$’000 Remaining contractual maturities A$’000 Carrying Non-derivatives Trade payables —  4,548 —  —  —  4,548 4,548 Accrued payables —  10,519 —  —  —  10,519 10,519 Contingent consideration —  3,389 —  4,549 —  7,938 7,005 Derivatives Other financial liabilities —  —  —  6,478 —  6,478 6,478 Total undiscounted financial liabilities 18,456 —  11,027 —  29,483 28,550 2023 Weighted average interest rate % 1 year or less A$’000 Between 1 and 2 years A$’000 Between 2 and 5 years A$’000 Over 5 years A$’000 Remaining contractual maturities A$’000 Carrying Amount A$’000 Non-derivatives Trade payables —  857 —  —  —  857 857 Accrued payables —  3,472 —  —  —  3,472 3,472 Contingent consideration —  750 4,303 3,099 —  8,152 6,871 Total undiscounted financial liabilities 5,079 4,303 3,099 —  12,481 11,200 The cash flows in the maturity analysis above are not expected to occur significantly earlier than contractually disclosed above.

Fair value measurement

Fair value measurement	12 Months Ended
	Jun. 30, 2024
Text block [abstract]
Fair value measurement	Note 26. Fair value measurement Fair value hierarchy The following tables detail the Consolidated Entity’s assets and liabilities, measured or disclosed at fair value, using a three level hierarchy, based on the lowest level of input that is significant to the entire fair value Level 1: Quoted prices (unadjusted) in active markets for identical assets or liabilities that the entity can access at the measurement date Level 2: Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly Level 3: Unobservable inputs for the asset or liability Consolidated - 2024 Level 1 Level 2 Level 3 Total Liabilities Contingent Consideration —  —  7,005 7,005 Warrant liability —  —  6,478 6,478 Total liabilities —  —  13,483 13,483 Consolidated - 2023 Liabilities Contingent Consideration —  —  6,871 6,871 Total liabilities —  —  6,871 6,871 There were no transfers between levels during the financial year. The fair value of contingent consideration related to the acquisition of Glioblast Pty Ltd and the license agreement is estimated by probability-weighting the expected future cash outflows, adjusting for risk and discounting. The effects on the fair value of risk and uncertainty in the future cash flows are dealt with by adjusting the estimated cash flows rather than adjusting the discount rate. The estimated cashflows were adjusted based on the directors’ assessment of achieving contracted milestones as disclosed in Note 19. The probabilities used fell in the range of 0% to 100% and were informed by generally accepted industry probabilities of drugs achieving certain milestones in their progression towards registration. The fair value of the warrant liability is determined using a Black-Scholes Model. Please refer to Note 21 for additional information regarding the private placement warrants. Level 3 assets and liabilities Movements in level 3 assets and liabilities during the current and previous financial year are set out below: Level 3 A$’000 Total A$’000 Consolidated Balance at 30 June 2022 8,968 8,968 Losses recognized in profit or loss (2,097 ) (2,097 ) Balance at 30 June 2023 6,871 6,871 Issuance of warrants 8,599 8,599 Exercise of warrants (864 ) (864 ) Gain recognized in profit or loss (1,123 ) (1,123 ) Balance at 30 June 2024 13,483 13,483

Key management personnel disclo

Key management personnel disclosures	12 Months Ended
	Jun. 30, 2024
Text block [abstract]
Key management personnel disclosures	Note 27. Key management personnel disclosures Compensation The aggregate compensation made to directors and other members of key management personnel (‘KMP’) of the Consolidated Entity is set out below: 2024 A$ 2023 A$ 2022 A$ Short-term employee benefits 1,962,563 3,148,514 2,589,088 Post-employment benefits 72,784 149,626 115,950 Share-based payments 353,437 1,045,860 1,559,930 2,388,784 4,344,000 4,264,968 Please refer to Note 28 for other transactions with key management personnel and their related parties.

Related party transactions

Related party transactions	12 Months Ended
	Jun. 30, 2024
Text block [abstract]
Related party transactions	Note 28. Related party transactions Parent entity Kazia Therapeutics Limited is the parent entity. Subsidiaries Interests in subsidiaries are set out in note 30. Key management personnel Disclosures relating to key management personnel are set out in note 27. Transactions with related parties There were no other transactions with KMP and their related parties. Receivable from and payable to related parties There were no trade receivables from or trade payables to related parties at the current and previous reporting date. Loans to/from related parties There were no loans to or from related parties at the current and previous reporting date. Terms and conditions All transactions were made on normal commercial terms and conditions and at market rates.

Parent entity information

Parent entity information	12 Months Ended
	Jun. 30, 2024
Text block [abstract]
Parent entity information	Note 29. Parent entity information Set out below is the supplementary information about the parent entity. Parent 2024 A$’000 2023 A$’000 Statement of profit or loss and other comprehensive income Loss after income tax (24,008 ) (20,863 ) Total comprehensive loss (24,008 ) (20,863 ) 2024 A$’000 2023 A$’000 Statement of financial position Total current assets 3,048 4,645 Total assets 18,488 21,915 Total current liabilities 25,529 7,003 Total liabilities 31,335 15,472 Equity Contributed equity 101,638 97,452 Reserves 4,225 4,423 Accumulated losses (118,710 ) (95,432 ) Total equity (12,847 ) 6,443 Reserves comprise Share Based Payments Reserve. Contingent liabilities The parent entity contingent liabilities as at 30 June 2024 and 30 June 2023 are as set out in note 19. Capital commitments - Property, plant and equipment The parent entity had no capital commitments for property, plant and equipment at as 30 June 2024 and 30 June 2023. Significant accounting policies The accounting policies of the parent entity are consistent with those of the Consolidated Entity, as disclosed in note 2, except for the following: • Investments in subsidiaries are accounted for at cost, less any impairment, in the parent entity. • Dividends received from subsidiaries are recognized as other income by the parent entity and its receipt may be an indicator of an impairment of the investment.

Interests in subsidiaries

Interests in subsidiaries	12 Months Ended
	Jun. 30, 2024
Investments accounted for using equity method [abstract]
Interests in subsidiaries	Note 30. Interests in subsidiaries The consolidated financial statements incorporate the assets, liabilities and results of the following subsidiaries in accordance with the accounting policy described in note 2: Ownership interest Name Principal place of business / Country of incorporation 2024 % 2023 % Kazia Laboratories Pty Ltd Australia 100 % 100 % Kazia Research Pty Ltd Australia 100 % 100 % Kazia Therapeutics Inc. United States of America 100 % 100 % Glioblast Pty Ltd Australia 100 % 100 %

Earnings per share

Earnings per share	12 Months Ended
	Jun. 30, 2024
Text block [abstract]
Earnings per share	Note 31. Earnings per share 2024 A$‘000 2023 A$‘000 2022 A$‘000 Earnings per share for losses from continuing operations Loss after income tax attributable to the owners of Kazia Therapeutics Limited (26,778 ) (20,465 ) (25,014 ) Loss after income tax attributable to the owners of Kazia Therapeutics Limited (26,778 ) (20,465 ) (25,014 ) Number Number Number Weighted average number of ordinary shares used in calculating basic and diluted earnings per share 263,676,313 184,284,350 132,467,686 Cents Cents Cents Basic and diluted earnings per share (10.16 ) (11.23 ) (18.88 ) The number of unissued shares under option that have been excluded from the diluted EPS are 36,180,000 (2024), 14,780,000 (2023), and 8,655,500 (2022).

Share-based payments

Share-based payments	12 Months Ended
	Jun. 30, 2024
Text block [abstract]
Share-based payments	Note 32. Share-based payments All of the options set out below have been issued to employees and directors under the ESOP. During the financial year an expense of $532,597 (30 June 2023: $1,159,125) ( 3 Number of 2024 - Ordinary Weighted Number of 2023 - Ordinary Weighted Outstanding at the beginning of the financial year 14,780,000 A$ 0.63 8,655,500 A$ 1.28 Granted —  A$ —  7,930,000 A$ 0.18 Forfeited (3,400,000 ) A$ 0.42 (1,550,000 ) A$ 1.90 Exercised —  A$ —  —  A$ —  Expired (1,200,000 ) A$ 0.49 (255,500 ) A$ 1.90 Outstanding at the end of the financial year 10,180,000 A$ 0.72 14,780,000 A$ 0.63 Exercisable at the end of the financial year 7,290,000 A$ 0.84 6,483,333 A$ 0.96 Number of 2024 - ADS Weighted Number of 2023 - ADS Weighted Outstanding at the beginning of the financial year —  A$ —  —  A$ —  Granted 2,850,000 A$ 0.5600 —  A$ —  Forfeited (250,000 ) A$ 0.5760 —  A$ —  Exercised —  A$ —  —  A$ —  Expired —  A$ —  —  A$ —  Outstanding at the end of the financial year 2,600,000 A$ 0.5580 —  A$ —  Exercisable at the end of the financial year —  A$ —  —  A$ —  2024 Tranche Grant date Expiry date Exercise price Balance at the start of the year - Granted Exercised Expired / lapsed on termination of employment Balance at the end of the year - 3 13/11/2019 04/01/2024 A$ 0.4925 1,200,000 —  —  (1,200,000 ) —  4 13/01/2020 13/01/2025 A$ 0.8812 187,500 —  —  (50,000 ) 137,500 5 09/11/2020 09/11/2024 A$ 1.1320 1,200,000 —  —  —  1,200,000 6 09/11/2020 13/01/2025 A$ 0.8812 600,000 —  —  —  600,000 7 04/01/2021 04/01/2025 A$ 1.6900 187,500 —  —  (50,000 ) 137,500 8 09/09/2021 26/06/2026 A$ 1.3650 100,000 —  —  —  100,000 9 16/11/2021 16/11/2025 A$ 1.6900 750,000 —  —  —  750,000 10 16/11/2021 16/11/2025 A$ 2.2400 500,000 —  —  —  500,000 11 16/11/2021 16/11/2025 A$ 1.5600 800,000 —  —  —  800,000 12 01/02/2022 01/02/2027 A$ 0.9400 800,000 —  —  (800,000 ) —  13 01/02/2022 01/02/2027 A$ 0.9400 425,000 —  —  (100,000 ) 325,000 14 24/05/2022 24/05/2027 A$ 0.7800 100,000 —  —  —  100,000 15 03/03/2023 03/03/2027 A$ 0.1500 3,930,000 —  —  (1,400,000 ) 2,530,000 16 03/05/2023 03/05/2027 A$ 0.1870 4,000,000 —  —  (1,000,000 ) 3,000,000 14,780,000 —  —  (4,600,000 ) 10,180,000 Weighted average exercise price $ 0.6292 $ —  $ —  $ 0.4349 $ 0.7207 At the end of the period the following outstanding options were vested and exerc isab - Options in tranches 3 & 12 expired during the year - Options in tranches 6 were vested and exercisable - Options in tranches 4, 7, 8, & 9 were vested and exercisable to 69%, apart from those in the above table which have expired - Options in tranche 5 were vested and exercisable to 75%, apart from those in the above table which have expired - Options in tranches 10 & 15 were vested and exercisable as to 33%, apart from those in the above table which have expired - Options in tranches 11, 14, & 16 were vested and exercisable as to 50%, apart from those in the above table which have expired - Options in tranches 13 were vested and exercisable as to 35%, apart from those in the above table which have expired The weighted average remaining contractual life of ordinary share options outstanding at 2024 is 2.00 years. Tranche Grant date Expiry date Exercise price Balance at the start of the year - Granted Exercised Expired / lapsed on termination of employment Balance at the end of the year - 17 22/04/2024 22/04/2029 A$ 0.5860 —  1,500,000 —  —  1,500,000 18 17/06/2024 17/06/2029 A$ 0.5130 —  1,100,000 —  (250,000 ) 850,000 19 27/06/2024 27/06/2030 A$ 0.2970 —  250,000 —  —  250,000 —  2,850,000 —  (250,000 ) 2,600,000 Weighted average exercise price $ 0.560 $ 0.576 $ 0.558 At the end of the period the following outstanding options were vested and exercisable: - Options in tranche 17, 18, & 19 were unvested The weighted average remaining contractual life of ADS share options outstanding at 30 June 2024 is years. 2023 Tranche Grant date Expiry date Exercise price Balance at the start of the year - Granted Exercised Expired / lapsed on of Balance at the end of the year - 1 07/08/2017 07/08/2022 A$ 0.6700 15,500 —  —  (15,500 ) —  2 05/02/2018 05/02/2023 A$ 0.7802 240,000 —  —  (240,000 ) —  3 13/11/2019 04/01/2024 A$ 0.4925 1,200,000 —  —  —  1,200,000 4 13/01/2020 13/01/2025 A$ 0.8812 200,000 —  —  (12,500 ) 187,500 5 09/11/2020 09/11/2024 A$ 1.1320 1,200,000 —  —  —  1,200,000 6 09/11/2020 13/01/2025 A$ 0.8812 800,000 —  —  (200,000 ) 600,000 7 04/01/2021 04/01/2025 A$ 1.6900 200,000 —  —  (12,500 ) 187,500 8 09/09/2021 26/06/2026 A$ 1.3650 100,000 —  —  —  100,000 9 16/11/2021 16/11/2025 A$ 1.6900 1,000,000 —  —  (250,000 ) 750,000 10 16/11/2021 16/11/2025 A$ 2.2400 1,500,000 —  —  (1,000,000 ) 500,000 11 16/11/2021 16/11/2025 A$ 1.5600 800,000 —  —  —  800,000 12 01/02/2022 01/02/2027 A$ 0.9400 800,000 —  —  —  800,000 13 01/02/2022 01/02/2027 A$ 0.9400 500,000 —  —  (75,000 ) 425,000 14 24/05/2022 24/05/2027 A$ 0.7800 100,000 —  —  —  100,000 15 03/03/2023 03/03/2027 A$ 0.1500 —  3,930,000 —  —  3,930,000 16 05/03/2023 03/05/2027 A$ 0.1870 —  4,000,000 —  —  4,000,000 8,655,500 7,930,000 —  (1,805,500 ) 14,780,000 Weighted average exercise price $ 1.2826 $ 0.1785 $ —  $ 1.8977 $ 0.6292 At the end of the period the following outstanding options were vested and ex erc - Options in tranches 1 - 2 expired during the year - Options in tranches 3 & 6 were vested and exercisable - Options in tranches 4, 5, 7 & 9 were vested and exercisable to 75%, apart from those in the above table which have expired - Options in tranche 8 were vested and exercisable to 50%, apart from those in the above table which have expired - Options in tranches 10 & 16 were vested and exercisable as to 33%, apart from those in the above table which have expired - Options in tranches 11, 12, 13 & 14 were vested and exercisable as to 25%, apart from those in the above table which have expired - Options in tranche 15 were unvested - Options in tranche 16 were 33% vested The weighted average remaining contractual life of options outstanding at 30 June 2023 is years. Employee share options During the year ended 30 June 2024, 2,850,000 options have been issued to directors and employees by the Consolidated Entity pursuant to the Company’s Employee Share Option Plan. • Tranches 12 & 13 vests 25% 6 months from issue date and then in 3 amounts at 6 monthly intervals from the date of issue. • Tranches 14 vests 33% immediately then in two equal amounts annually from the date of grant. • Tranches 15 vests 6 months from issue date then in two equal amounts annually from the date of grant. • Tranches 16 vests 33% immediately then in two equal amounts annually from the date of grant. • Tranches 17 vests quarterly over 3 years from the date of the grant. • Tranches 18 vests quarterly over 3 years from the date of the grant. • Tranches 19 vests yearly over 4 years from the date of the grant Vesting conditions for options within all tranches, is based on service period only; i.e. options will only vest if the option holder continues to be a full-time employee with the Company or an Associated Company during the vesting period relating to the option. Conditions for an option to be exercised: • The options must have vested; • Option holder must have provided the Company with an Exercise Notice and have paid the Exercise Price for the option; • The Exercise Notice must be for the exercise of at least the Minimum Number of Options; and • The Exercise Notice must have been provided to the Company and Exercise Price paid before the expiry of 4 years from the date the Option is issued. Options Valuation In order to obtain a fair valuation of these options, the following assumptions have been made: The Black Scholes option valuation methodology has been used with the expectation that the majority of these options would be exercised towards the end of the option term. Inputs into the Black Scholes model includes the share price at grant date, exercise price, volatility, and the risk free rate of a five year Australian Government Bond on grant date. Risk-free rate and grant date For all tranches, the risk-free rate of a five-year Australian Government bond on grant date was used. Please refer to the table below for details. The above mentioned options have various vesting periods and exercising conditions. These options are unlisted as of 30 June 2024. No dividends are expected to be declared or paid by the Consolidated Entity during the terms of the options. The underlying expected volatility was determined by reference to historical data of the Company’s shares over a period of time. No special features inherent to the options granted were incorporated into measurement of fair value. Based on the above assumptions, the table below sets out the valuation for each tranche of options: Grant date Expiry date Share price Grant Date Exercise price Volatility (%) Dividend yield (%) Risk Rate Fair value per option 13/11/2019 04/01/2024 A A 74.50% —  1.95% A$ 0.1800 13/01/2020 13/01/2025 A A 74.50% —  1.95% A$ 0.3400 09/11/2020 09/11/2024 A A 90.00% —  0.10% A$ 0.4130 09/11/2020 13/01/2025 A A 90.00% —  0.10% A$ 0.5030 04/01/2021 04/01/2025 A A 90.00% —  0.19% A$ 0.6000 09/09/2021 26/06/2026 A A 76.00% —  1.50% A$ 0.8800 16/11/2021 16/11/2025 A A 76.00% —  1.50% A$ 0.8500 16/11/2021 16/11/2025 A A 76.00% —  1.50% A$ 0.7500 16/11/2021 16/11/2025 A A 76.00% —  1.50% A$ 0.9700 01/02/2022 01/02/2027 A A 79.00% —  1.50% A$ 0.5900 01/02/2022 01/02/2027 A A 44.00% —  2.95% A$ 0.6300 24/05/2022 24/05/2027 A A 80.00% —  3.64% A$ 0.1014 03/03/2023 03/03/2027 A A 80.00% —  3.64% A$ 0.1014 03/05/2023 03/05/2027 A A 80.00% —  3.22% A$ 0.1111 22/04/2024 22/04/2029 A A 95.00% —  3.96% A$ 0.4300 17/06/2024 17/06/2029 A A 95.00% —  3.84% A$ 0.2300 27/06/2024 27/06/2030 A A 95.00% —  4.17% A$ 0.2700

Subsequent events

Subsequent events	12 Months Ended
	Jun. 30, 2024
Text block [abstract]
Subsequent events	Note 33. Subsequent events Fundraising Activities From July 2024 through September 2024, the Consolidated E ntity Change in ADS Ratio The Company announced on October 15, 2024, that it had modified the provisions of its ADR program. The previous conversion ratio of 10 Kazia Therapeutic Limited ordinary shares for each ADR share has become 100 Kazia Therapeutic Limited ordinary shares for each ADR share. The change was effective from October 28, 2024. The change in the ADR ratio had no effect on the number of outstanding ordinary shares. Phase II/III Clinical Trial Results for Paxalisib in Glioblastoma The Company announced on July 10, 2024, promising results for paxalisib in treating newly diagnosed unmethylated glioblastoma (GBM) patients. The drug showed a 3.8-month In a study involving 313 patients, those treated with paxalisib had a median OS of 14.77 months, compared to 13.84 months for SOC. A secondary analysis showed even better results, with paxalisib patients having a median OS of 15.54 months versus 11.89 months for SOC. Paxalisib was well tolerated, with no new safety concerns. However, it did not show efficacy in recurrent GBM patients. Kazia plans to discuss these findings with the FDA to explore an accelerated approval pathway for paxalisib, which already has orphan drug and fast track designations. No other matter or circumstance has arisen since 30 June 2024 that has significantly affected, or may significantly affect the Consolidated Entity’s operations, the results of those operations, or the Consolidated Entity’s state of affairs in future financial years.

Material accounting policies (P

Material accounting policies (Policies)	12 Months Ended
	Jun. 30, 2024
Text block [abstract]
New or amended Accounting Standards and Interpretations adopted	New or amended Accounting Standards and Interpretations adopted The Consolidated Entity has adopted all of the new, revised or amending Accounting Standards and Interpretations issued by the International Accounting Standards Board (‘IASB’) that are mandatory for the current reporting period. The adoption of these standards has not had any material impact on the disclosures or amounts reported in these consolidated financial statements.
New Accounting Standards and Interpretations not yet mandatory or early adopted	New Accounting Standards and Interpretations not yet mandatory or early adopted In April 2024, IFRS 18, “Presentation and Disclosure in Financial Statements” was issued to achieve comparability of the financial performance of similar entities. The standard, which replaces IAS 1 “Presentation of Financial Statements”, impacts the presentation of primary financial statements and notes, including the statement of earnings where companies will be required to present separate categories of income and expense for operating, investing, and financing activities with prescribed subtotals for each new category. The standard will also require management-defined performance measure to be explained and included in a separate note within the consolidated financial statements. The standard is effective for annual reporting periods beginning on or after January 1, 2027, including interim financial statements, and require retroactive application. The Consolidated Entity is currently assessing the impact of the new standard. The Consolidated Entity is currently analyzing the potential impact of the amendments to IFRS 9 “Financial Instruments”, IFRS 7 “Financial Instruments: Disclosures”, and small changes to various standards or interpretations as part of the annual improvements to IFRS project. The amendments are effective for reporting periods beginning on or after 1 January 2026. There were no other new accounting standards and interpretations not yet adopted by the Consolidated Entity for the 30 June 2024 reporting period that are expected to materially impact the Consolidated Entity.
Going concern	Going concern The Consolidated Entity incurred a loss after income tax of A$26.8 million was in a net current liability position of A$19.7 million and had net cash outflows from operating activities of A$9.6 million as at and for the year ended 30 June 2024. As at 30 June 2024 the Consolidated Entity had cash and cash equivalents . The consolidated financial statements have been prepared on a going concern basis, which contemplates continuity of normal activities and realization of assets and settlement of liabilities in the normal course of business. As is often the case with drug development companies, the Company has not generated significant revenues nor does the Company anticipate generating significant revenues in the near future. The ability of the Consolidated Entity to continue its development activities as a going concern is dependent upon it deriving sufficient cash from investors, from licensing and partnering activities, and from other sources of revenue such as grant funding. The directors have considered the cash flow forecasts and the funding requirements of the business and continue to explore grant funding, licensing opportunities and equity investment opportunities in the Company. The at-the-market’ “ ”), From July through September 2024, the Consolidated Entity raised total proceeds of US$3,609,757 using the ATM facility and continues to seek additional funding sources both in Australia and overseas. For the same period , Accordingly , consolidated consolidated
Basis of preparation	Basis of preparation These general purpose consolidated financial statements have been prepared in accordance with Australian Accounting Standards and Interpretations issued by the Australian Accounting Standards Board (‘AASB’) and the Corporations Act, as appropriate for for-profit Critical accounting estimates The preparation of the consolidated financial statements requires the use of certain critical accounting estimates. It also requires management to exercise its judgement in the process of applying the Consolidated Entity’s accounting policies. The areas involving a higher degree of judgement or complexity, or areas where assumptions and estimates are significant to the consolidated financial statements, are disclosed in note 3.
Parent entity information	Parent entity information In accordance with the Corporations Act, these consolidated financial statements present the results of the Consolidated Entity only. Supplementary information about the parent entity is disclosed in note 29.
Principles of consolidation	Principles of consolidation The consolidated financial statements incorporate the assets and liabilities of all subsidiaries of Kazia Therapeutics Limited. Kazia Therapeutics Limited and its subsidiaries together are referred to in these consolidated financial statements as the ‘Consolidated Entity’. Subsidiaries are all those entities over which the Consolidated Entity has control. The Consolidated Entity controls an entity when the Consolidated Entity is exposed to, or has rights to, variable returns from its involvement with the entity and has the ability to affect those returns through its power to direct the activities of the entity. Subsidiaries are fully consolidated from the date on which control is transferred to the Consolidated Entity. They are de-consolidated Intercompany transactions, balances and unrealized gains on transactions between entities in the Consolidated Entity are eliminated. Unrealized losses are also eliminated unless the transaction provides evidence of the impairment of the asset transferred. Accounting policies of subsidiaries have been changed where necessary to ensure consistency with the policies adopted by the Consolidated Entity. The acquisition of subsidiaries is accounted for using the acquisition method of accounting. A change in ownership interest, without the loss of control, is accounted for as an equity transaction, where the difference is between the consideration transferred and the book value. Where the Consolidated Entity loses control over a subsidiary, it derecognize the assets including goodwill, liabilities and non-controlling
Operating segments	Operating segments Operating segments are presented using the ‘management approach’ where the information presented is on the same basis as the internal reports provided to the Chief Operating Decision Makers (‘CODM’). The CODM is responsible for the allocation of resources to operating segments and assessing their performance. The CODM is considered to be the Board of Directors.
Foreign currency translation	Foreign currency translation The consolidated financial statements are presented in Australian dollars. Foreign currency transactions Foreign currency transactions are translated into Australian dollars using the exchange rates prevailing at the dates of the transactions. Foreign exchange gains and losses resulting from the settlement of such transactions and from the translation at reporting date exchange rates of monetary assets and liabilities denominated in foreign currencies are recognized in profit or loss. Foreign operations The assets and liabilities of foreign operations are translated into Australian dollars using the exchange rates at the reporting date. The revenues and expenses of foreign operations are translated into Australian dollars using the average exchange rates, which approximate the rate at the date of the transaction, for the period. All resulting foreign exchange differences are recognized in other comprehensive income through the foreign currency reserve in equity. The foreign currency reserve is recognized in profit or loss when the foreign operation is disposed of. Exchange differences arising on a monetary item that forms part of a reporting entity’s net investment in a foreign operation shall be recognized initially in other comprehensive income and reclassified from equity to profit or loss on disposal of the net investment.
Financial instruments	Financial Instruments Subsequent measurement of financial assets For the purpose of subsequent measurement, financial assets are classified into the following categories upon initial recognition: • financial assets at amortized cost • financial assets at fair value through profit or loss (FVPL) Classifications are determined by both: • the entity’s business model for managing the financial asset • the contractual cash flow characteristics of the financial assets All income and expenses relating to financial assets that are recognized in profit or loss are presented within finance costs, finance income or other financial items, except for impairment of trade receivables which is presented within other expenses. Financial assets at amortised cost Financial assets are measured at amortised cost if the assets meet the following conditions (and are not designated as FVPL): • they are held within a business model whose objective is to hold the financial assets and collect its contractual cash flows; and • the contractual terms of the financial assets give rise to cash flows that are solely payments of principal and interest on the principal amount outstanding. After initial recognition, these are measured at amortised cost using the effective interest method. Discounting is omitted where the effect of discounting is immaterial. The Consolidated Entity’s cash and cash equivalents, trade and most other receivables fall into this category of financial instruments. Classification and measurement of financial liabilities The Consolidated Entity’s financial liabilities comprise trade and other payables. Financial liabilities, borrowings and contingent consideration for business combination and licensing agreement acquisitions are initially measured at fair value, and, where applicable, adjusted for transaction costs unless the Consolidated Entity designated a financial liability at fair value through profit or loss. Subsequently, financial liabilities are measured at amortised cost using the effective interest method, except for contingent consideration in a business combination and liability classified warrants, which are measured at fair value. All interest-related charges and, if applicable, changes in an instrument’s fair value that are reported in profit or loss are included within finance costs or finance income. Revenue from contracts with customers Revenue is measured at the fair value of the consideration received or receivable. Revenue is recognized using a five step approach in accordance with IFRS 15, “Revenue from Contracts with Customers” to depict the transfer of promised services to customers in an amount that reflects the consideration to which the Group expects to be entitled in exchange for those services. Distinct promises within the contract are identified as performance obligations. The transaction price of the contract is measured based on the amount of consideration the Consolidated Entity expects to be entitled to from the customer in exchange for services. Factors such as requirements around variable consideration, significant financing components, noncash consideration, or amounts payable to customers also determine the transaction price. The transaction price is then allocated to separate performance obligations in the contract based on relative standalone selling prices. Revenue is recognized when, or as, performance obligations are satisfied, which is when control of the promised service is transferred to the customer. Amounts received prior to satisfying the revenue recognition criteria are recorded as deferred revenue. Amounts expected to be recognized as revenue within the 12 months following the balance sheet date are classified within current liabilities. Amounts not expected to be recognized as revenue within the 12 months following the balance sheet date are classified within non-current The Consolidated Entity recognizes contract liabilities for consideration received in respect of unsatisfied performance obligations and reports these amounts as other liabilities in its consolidated statement of financial position. Similarly, if the Consolidated Entity satisfies a performance obligation before it receives the consideration, the Consolidated Entity recognizes either a contract asset or a receivable in its statement of financial position, depending on whether something other than the passage of time is required before the consideration is due. Licensing revenues, including milestone revenue Revenue from licensees of the Consolidated Entity’s intellectual property reflects the transfer of a right to use the intellectual property as it exists at the point in time in which the license is transferred to the customer. Licensing agreements are examined to determine whether they contain additional performance obligations, over and above the right to use the intellectual property. To the extent that additional performance obligations exist, the transaction price the Consolidated Entity expects to receive for the contract is allocated to the separate performance obligations. The receipt of milestone payments is often contingent on meeting certain clinical, regulatory or commercial targets, and is therefore considered variable consideration. The transaction price of the contingent milestone is estimated using the most likely amount method. Within the transaction price, the price associated with a contingent milestone is included only to the extent that it is highly probable that a significant reversal in the amount of cumulative revenue recognized will not occur. Milestone payments that are not within the control of the Group, such as regulatory approvals, are not considered highly probable of being achieved until those approvals are achieved. Finance income Interest revenue is recognized as interest accrues using the effective interest method. This is a method of calculating the amortised cost of a financial asset and allocating the interest income over the relevant period using the effective interest rate, which is the rate that exactly discounts estimated future cash receipts through the expected life of the financial asset to the net carrying amount of the financial asset. Grant income Grants from governments are recognized at their fair value when there is a reasonable assurance that the grant will be received and the Company will comply with all attached conditions. Government grants relating to operating costs are recognized in the Statements of Comprehensive Income as other income. A New South Wales Export Development Grant was received in the year ended 30 June 2022. Other income Other income is recognized when it is received or when the right to receive payment is established.
Income tax	Income tax Income tax expense or benefit for the period is the tax payable on that period’s taxable income based on the applicable income tax rate for each jurisdiction, adjusted by changes in deferred tax assets and liabilities attributable to temporary differences, unused tax losses and the adjustment recognized for prior periods, where applicable. Deferred tax assets and liabilities are recognized for temporary differences at the tax rates expected to apply when the assets are recovered or liabilities are settled, based on those tax rates that are enacted or substantively enacted, except for: • When the deferred income tax asset or liability arises from the initial recognition of goodwill or an asset or liability in a transaction that is not a business combination and that, at the time of the transaction, affects neither the accounting nor taxable profits; or • When the taxable temporary difference is associated with interests in subsidiaries, associates or joint ventures, and the timing of the reversal can be controlled and it is probable that the temporary difference will not reverse in the foreseeable future. Deferred tax assets are recognized for deductible temporary differences and unused tax losses only if it is probable that future taxable amounts will be available to utilize those temporary differences and losses. The carrying amount of recognized and unrecognized deferred tax assets are reviewed each reporting date. Deferred tax assets recognized are reduced to the extent that it is no longer probable that future taxable profits will be available for the carrying amount to be recovered. Previously unrecognized deferred tax assets are recognized to the extent that it is probable that there are future taxable profits available to recover the asset. Deferred tax assets and liabilities are offset only where there is a legally enforceable right to offset current tax assets against current tax liabilities and deferred tax assets against deferred tax liabilities; and they relate to the same taxable authority on either the same taxable entity or different taxable entities which intend to settle simultaneously. Kazia Therapeutics Limited and its wholly-owned Australian controlled entities have formed an income tax consolidated group under the tax consolidation regime. Kazia Therapeutics Limited as the parent entity discloses all of the deferred tax assets of the tax consolidated group in relation to tax losses carried forward (after elimination of inter-group transactions). The tax consolidated group has applied the ‘separate taxpayer in the group’ allocation approach in determining the appropriate amount of taxes to allocate to members of the tax consolidated group. As the tax consolidation group continues to generate tax losses there has been no reason for the Company to enter a tax funding agreement with members of the tax consolidation group. Uncertain tax positions IFRIC 23 clarified the application of the recognition and measurement criteria of IAS 12, “Income Taxes,” where there is uncertainty over income tax treatments and requires an assessment of each uncertain tax position as to whether it is probable that a taxation authority will accept the position. Where it is not probable, the effect of the uncertainty is reflected in determining the relevant taxable profit or loss, tax bases, unused tax losses and unused tax credits or tax rates. The amount is determined as either the single most likely amount or the sum of the probability weighted amounts in a range of possible outcomes, whichever better predicts the resolution of the uncertainty. Management believes that historical tax losses are not expected to be available for offset against the deferred tax liability at 30 June 2024 and 2023.
Current and non-current classification	Current and non-current Assets and liabilities are presented in the statement of financial position based on current and non-current An asset is current when: it is expected to be realized or intended to be sold or consumed in normal operating cycle; it is held primarily for the purpose of trading; it is expected to be realized within 12 months after the reporting period; or the asset is cash or cash equivalent unless restricted from being exchanged or used to settle a liability for at least 12 months after the reporting period. All other assets are classified as non-current. A liability is current when: it is expected to be settled in normal operating cycle; it is held primarily for the purpose of trading; it is due to be settled within 12 months after the reporting period; or there is no unconditional right to defer the settlement of the liability for at least 12 months after the reporting period. All other liabilities are classified as non-current. Deferred tax assets and liabilities are always classified as non-current.
Cash and cash equivalents	Cash and cash equivalents Cash and cash equivalents includes cash on hand, deposits held at call with financial institutions, other short-term, highly liquid investments with original maturities of three months or less that are readily convertible to known amounts of cash and which are subject to an insignificant risk of changes in value.
Research and development	Research and development Expenditure during the research phase of a project is recognized as an expense when incurred. Development costs are capitalized only when technical feasibility studies identify that the project will deliver future economic benefits and these benefits can be measured reliably.
Intangible assets	Intangible assets Separately acquired intangible assets are shown at historical cost. The cost of intangible assets acquired as part of a business combination is their fair value at the acquisition date. They have a finite useful life and are subsequently carried at cost less accumulated amortization and impairment losses. The method and useful lives of finite life intangible assets are reviewed annually. Changes in the expected pattern of consumption or useful life are accounted for prospectively by changing the amortization method or period. Amortization expense is included in research and development expenditure. Licensing agreement for paxalisib The paxalisib licensing agreement asset was acquired as part of a business combination and is being amortised on a straight-line basis over the period of its expected benefit, being the remaining life of the patent which was 15 years from the date of acquisition. Licensing agreement for EVT801 The EVT801 licensing agreement asset was acquired via an asset acquisition and is being amortised on a straight-line basis over the period of its expected benefit, being the remaining life of the patent which was 12.5 years from the date of acquisition.
Impairment of non-financial assets	Impairment of non-financial Non-financial Recoverable amount is the higher of an asset’s fair value less costs of disposal and value-in-use. value-in-use pre-tax
Provisions	Provisions Provisions are recognized when the Consolidated Entity has a present (legal or constructive) obligation as a result of a past event, it is probable the Consolidated Entity will be required to settle the obligation, and a reliable estimate can be made of the amount of the obligation. The amount recognized as a provision is the best estimate of the consideration required to settle the present obligation at the reporting date, taking into account the risks and uncertainties surrounding the obligation. If the time value of money is material, provisions are discounted using a current pre-tax
Employee benefits	Employee benefits Short-term employee benefits Liabilities for wages and salaries, including non-monetary Other long-term employee benefits The liability for annual leave and long service leave not expected to be settled within 12 months of the reporting date is measured as the present value of expected future payments to be made in respect of services provided by employees up to the reporting date using the projected unit credit method. Consideration is given to expected future wage and salary levels, experience of employee departures and periods of service. Expected future payments are discounted using market yields at the reporting date on high quality corporate bonds with terms to maturity and currency that match, as closely as possible, the estimated future cash outflows.
Share-based payments	Share-based payments Equity-settled share-based compensation benefits are provided to employees under the terms of the Employee Share Option Plan (‘ESOP’) and consultants as compensation for services performed. Equity-settled transactions are awards of shares, or options over shares that are provided to employees in exchange for the rendering of services. The value of the instruments is measured by reference to the fair value of the underlying instruments on grant date, as required by IFRS2, “Share-Based Payments.” Fair value is estimated using an appropriate option pricing model that takes into account the exercise price, the term of the option, the impact of dilution, the share price at grant date and expected price volatility of the underlying share, the expected dividend yield and the risk free interest rate for the term of the option, together with non-vesting The cost of equity-settled transactions are recognized as an expense with a corresponding increase in equity over the vesting period. The cumulative charge to profit or loss is calculated based on the grant date fair value of the award, the best estimate of the number of awards that are likely to vest and the expired portion of the vesting period. The amount recognized in profit or loss for the period is the cumulative amount calculated at each reporting date less amounts already recognized in previous periods. The cumulative charge to profit or loss until settlement of the options is calculated as follows: • during the options vesting period, the liability at each reporting date is the fair value of the award at that date multiplied by the expired portion of the vesting period. • from the end of the option vesting period until settlement of the award, the liability is the full fair value of the option at the reporting date. Market conditions are taken into consideration in determining fair value. Therefore, any awards subject to market conditions are considered to vest irrespective of whether or not that market condition has been met, provided all other conditions are satisfied. If equity-settled awards are modified, as a minimum an expense is recognized as if the modification has not been made. An additional expense is recognized, over the remaining vesting period, for any modification that increases the total fair value of the share-based compensation benefit as at the date of modification. If the non-vesting If equity-settled awards are cancelled, it is treated as if it has vested on the date of cancellation, and any remaining expense is recognized immediately. If a new replacement award is substituted for the cancelled award, the cancelled and new award is treated as if they were a modification.
Finance costs	Finance costs Finance costs attributable to qualifying assets are capitalized as part of the asset. All other finance costs are expensed in the period in which they are incurred, including interest on short-term and long-term borrowings.
Fair value measurement	Fair value measurement When an asset or liability, financial or non-financial, Fair value is measured using the assumptions that market participants would use when pricing the asset or liability, assuming they act in their economic best interest. For non-financial Assets and liabilities measured at fair value are classified, into three levels, using a fair value hierarchy that reflects the significance of the inputs used in making the measurements. Classifications are reviewed each reporting date and transfers between levels are determined based on a reassessment of the lowest level input that is significant to the fair value measurement. For recurring and non-recurring
Issued capital	Issued capital Ordinary shares are classified as equity. Incremental costs directly attributable to the issue of new shares or options, including share-based payments relating to the issue of shares, are shown in equity as a deduction, from the proceeds.
Earnings per share	Earnings per share Basic earnings per share Basic earnings per share is calculated by dividing the profit attributable to the owners of Kazia Therapeutics Limited, excluding any costs of servicing equity other than ordinary shares, by the weighted average number of ordinary shares outstanding during the financial year, adjusted for bonus elements in ordinary shares issued during the financial year. Diluted earnings per share Diluted earnings per share adjusts the figures used in the determination of basic earnings per share to take into account the after income tax effect of interest and other financing costs associated with dilutive potential ordinary shares and the weighted average number of shares assumed to have been issued for no consideration in relation to dilutive potential ordinary shares.
Goods and Services Tax ('GST') and other similar taxes	Goods and Services Tax (‘GST’) and other similar taxes Revenues, expenses and assets are recognized net of the amount of associated GST, unless the GST incurred is not recoverable from the tax authority. In this case it is recognized as part of the cost of the acquisition of the asset or as part of the expense. Receivables and payables are stated inclusive of the amount of GST receivable or payable. The net amount of GST recoverable from, or payable to, the tax authority is included in other receivables or other payables in the statement of financial position. Cash flows are presented on a gross basis. The GST components of cash flows arising from investing or financing activities which are recoverable from, or payable to the tax authority, are presented as operating cash flows. Commitments and contingencies are disclosed net of the amount of GST recoverable from, or payable to, the tax authority.

Restatement of comparatives (Ta

Restatement of comparatives (Tables)	12 Months Ended
	Jun. 30, 2024
Text block [abstract]
Schedule Of Material Restatement Of EVT 801 Asset	EVT-801 30 June 2022 Reported Increase/ (decrease) 30 June 2022 Restated A$’000 A$’000 A$’000 Consolidated statement of financial position Intangibles - licensing agreement 27,266 (1,045 ) 26,221 Less Accumulated amortisation (7,216 ) 134 (7,082 ) 20,050 (911 ) 19,139 Current contingent consideration (759 ) —  (759 ) Non-Current (8,756 ) 547 (8,209 ) (9,515 ) 547 (8,968 ) Accumulated losses (68,253 ) (364 ) (68,617 ) Total equity 18,638 (363 ) 18,275
Schedule Of Material Restatement Of Income Statement	30 June 2022 Increase/ (decrease) 30 June 2022 Restated Consolidated statement of profit and loss Research and development expense (20,252 ) 83 (20,169 ) General and administrative expense (4,511 ) (602 ) (5,113 ) Loss on revaluation of contingent consideration (152 ) 152 —  Commercialisation expense (127 ) —  (127 ) Loss before income tax benefit (25,016 ) (366 ) (25,382 ) Income tax benefit 368 —  368 Loss after income tax benefit (24,648 ) (366 ) (25,014 ) Impact on basic and diluted earnings per share increase/ (decrease) in earning per share Cents Cents Cents Basic and diluted loss for the year attributable to equity holders $ (18.61 ) $ (0.27 ) $ (18.88 )

Reclassification of comparati_2

Reclassification of comparatives (Tables)	12 Months Ended
	Jun. 30, 2024
Reclassification Of Comparatives [Abstract]
Disclosure in tabular form of reclassification of comparatives	30 June 2022 Restated Reclassification 30 June 2022 Reclassified Other assets 156 1,841 1,997 Borrowings —  (1,841 ) (1,841 ) Current employee benefits 166 203 369 Non-current 319 (202 ) 117 Loss on remeasurement of contingent consideration 152 (152 ) —  General and administrative expense (4,961 ) (152 ) (5,113 )

Revenue (Tables)

Revenue (Tables)	12 Months Ended
	Jun. 30, 2024
Text block [abstract]
Summary of licensing revenue	2024 A$’000 2023 A$’000 2022 A$’000 Licensing revenue 2,301 —  —  Sale of paxalisib 7 —  —  2,308 —  —
Summary of disaggregation of revenue from contracts with customers	The disaggregation of revenue from contracts with customers is as follows: 2024 A$’000 2023 A$’000 2022 A$’000 Geographical regions South Korea 2,308 —  —  2,308 —  —  Timing of revenue recognition Licensing revenue at a point in time 2,301 —  —  Sale of paxalisib at a point in time 7 —  —

Other income (Tables)

Other income (Tables)	12 Months Ended
	Jun. 30, 2024
Text block [abstract]
Summary of other income	2024 A$’000 2023 A$’000 2022 A$’000 Research and development rebate 173 —  —  Subsidies and grants —  —  10 Bad debt recovery —  —  15 Other sundry income —  1 —  173 1 25

Expenses (Tables)

Expenses (Tables)	12 Months Ended
	Jun. 30, 2024
Text block [abstract]
Summary of expenses	2024 A$’000 2023 A$’000 2022 restated A$’000 Research and development EVT-801 5,277 5,060 2,520 Cantrixil program costs 1 5 12 Paxalisib program costs 7,551 5,618 13,713 Scientific Advisory Board costs —  31 —  Employee benefits expense - salaries & wages and staff benefits 2,161 2,250 1,665 - superannuation 36 29 25 - share based payments 485 702 365 Total research & development (excluding amortisation) 15,511 13,695 18,300 Amortisation Paxalisib licensing agreement 1,084 1,084 1,084 Evotech licensing agreement 785 785 785 Total amortisation 1,869 1,869 1,869 Total research & development 17,380 15,564 20,169 Net foreign exchange loss Net foreign exchange (gain) / loss (20 ) 46 (2,154 ) Rental expense relating to operating leases Minimum lease payments 124 152 73 Superannuation expense Defined contribution superannuation expense 88 131 138 Employee benefits expense G&A - salaries & wages and staff benefits 486 1,467 1,674 - superannuation 52 102 129 - share based payments 48 457 1,310 Total employee benefits expense G&A 586 2,026 3,113

Income taxes (Tables)

Income taxes (Tables)	12 Months Ended
	Jun. 30, 2024
Text block [abstract]
Summary of Income taxes	2024 2023 2022 A$’000 A$’000 A$’000 Numerical reconciliation of income tax benefit and tax at the statutory rate Loss before income tax benefit (27,049 ) (20,736 ) (25,382 ) Tax at the statutory tax rate of 25 % (6,762 ) (5,184 ) (6,345 ) Tax effect amounts which are not deductible/(taxable) in calculating taxable income: Research and d —  —  —  Amortisation of intangibles 467 467 467 Employee option plan 133 289 419 Gain/loss on revaluation of contingent consideration (22 ) (847 ) 38 (6,184) (5,275) (5,421) Adjustment recognised —  —  16 Adjustment to deferred tax balances as a result of change in statutory tax rate —  —  (113 ) Tax losses and timing differences not recognised 5,913 5,004 5,150 Income tax benefit (271 ) (271 ) (368 ) 2024 A$’000 2023 A$’000 2022 restated A$’000 Tax losses not recognised Unused tax losses for which no deferred tax asset has been recogni s 139,430 120,412 96,519 Potential tax benefit 25.0 % - Australia 34,858 30,103 24,130 Unused tax losses for which no deferred tax asset has been recogni s 7,836 4,305 2,380 Potential tax benefit 1,646 904 500

Current assets - cash and cas_2

Current assets - cash and cash equivalents (Tables)	12 Months Ended
	Jun. 30, 2024
Text block [abstract]
Summary of cash and cash equivalents	2024 2023 A$’000 A$’000 Cash at bank and on hand 1,657 5,241 1,657 5,241

Trade and other receivables (Ta

Trade and other receivables (Tables)	12 Months Ended
	Jun. 30, 2024
Statement [line items]
Summary of current assets - trade and other receivables	2024 2023 A$’000 A$’000 Current assets Trade receivables —  1 GBM Agile deposit 3,756 3,753 BAS receivables 133 104 Deposits held 8 41 3,897 3,899

Trade and other receivables -_2

Trade and other receivables - non-current (Tables)	12 Months Ended
	Jun. 30, 2024
Text block [abstract]
Summary of non-current assets - trade and other receivables non-current	2024 2023 A$’000 A$’000 Non-current Corporate credit card deposit 40 43 40 43

Other assets (Tables)

Other assets (Tables)	12 Months Ended
	Jun. 30, 2024
Text block [abstract]
Summary of current assets - other	2024 2023 A$’000 A$’000 Prepayments 591 1,632

Intangibles (Tables)

Intangibles (Tables)	12 Months Ended
	Jun. 30, 2024
Text block [abstract]
Summary of non-current assets - intangibles	Consolidated 2024 A$’000 2023 A$’000 Licensing agreement - Paxalisib 16,408 16,408 Less: Accumulated amortisation (8,335 ) (7,251 ) 8,073 9,157 Licensing agreement - EVT-801 9,813 9,813 Less: Accumulated amortisation (2,486 ) (1,701 ) 7,327 8,112 15,400 17,269
Summary of reconciliations of intangibles	EVT801 licensing agreement A$’000 Paxalisib licensing agreement A$’000 Total A$’000 Balance at 30 June 2022 restated 8,897 10,242 19,139 Amortisation expense (785 ) (1,085 ) (1,870 ) Balance at 30 June 2023 8,112 9,157 17,269 Amortisation expense (785 ) (1,084 ) (1,869 ) Balance at 30 June 2024 7,327 8,073 15,400

Trade and other payables (Table

Trade and other payables (Tables)	12 Months Ended
	Jun. 30, 2024
1 year or less [member]
Statement [line items]
Summary of trade and other payables	2024 2023 A$’000 A$’000 Trade payables 4,548 857 Accrued payables 10,519 3,472 15,067 4,329

Borrowings (Tables)

Borrowings (Tables)	12 Months Ended
	Jun. 30, 2024
Borrowings [abstract]
Schedule of borrowings	Current liabilities 2024 2023 A$’000 A$’000 Insurance premium funding 634 1,796

Employee benefits (Tables)

Employee benefits (Tables)	12 Months Ended
	Jun. 30, 2024
1 year or less [member]
Statement [line items]
Summary of provisions	2024 A$’000 2023 A$’000 Current Liabilities Employee benefits —  201 Annual leave 365 489 365 690 Non-Current Long service leave 35 59 400 749

Contingent consideration (Table

Contingent consideration (Tables)	12 Months Ended
	Jun. 30, 2024
Statement [line items]
Summary of liabilities - contingent consideration	2024 A$’000 2023 A$’000 Current Contingent consideration - Paxalisib —  750 Contingent consideration - EVT801 3,253 —  3,253 750 Non-current Contingent consideration - paxalisib 1,266 654 Contingent consideration - EVT801 2,486 5,467 3,752 6,121 7,005 6,871
Summary of reconciliation of contingent consideration	Consolidated 2024 2023 $ $ Contingent consideration at start of period (current and non-current) 6,871 8,968 Payment of EVT801 milestone —  —  Interest accretion 339 594 Effect of exchange rates on contingent consideration (86 ) 697 Gain on remeasurement of contingent consideration (119 ) (3,388 ) 7,005 6,871

Deferred tax (Tables)

Deferred tax (Tables)	12 Months Ended
	Jun. 30, 2024
Text block [abstract]
Summary of non-current liabilities - deferred tax	2024 2023 A$’000 A$’000 Non-current Deferred tax liability associated with Licensing Agreement 2,018 2,289

Other financial liabilities (Ta

Other financial liabilities (Tables)	12 Months Ended
	Jun. 30, 2024
Other Financial Liabilities Current [Abstract]
Summary of other financial liabilities	Consolidated June 2024 June 2023 A$’000 A$’000 Prefunded and ordinary warrants at initial recognition $ 8,599 $ —  Prefunded warrants exercised (864 ) —  Gain on remeasurement of financial liabilities (1,257 ) —  Prefunded and ordinary warrants at period end 6,478 —

Equity - contributed equity (Ta

Equity - contributed equity (Tables)	12 Months Ended
	Jun. 30, 2024
Text block [abstract]
Summary of equity - contributed equity	2024 2023 2022 2024 2023 2022 Shares Shares Shares A$‘000 A$‘000 A$‘000 Ordinary shares - fully paid 332,850,784 228,029,114 138,755,376 101,638 97,452 84,480
Summary of movements in ordinary share capital	Movements in ordinary share capital Details Date Shares Issue price A$ Balance 1 July 2021 132,012,209 80,290,062 Issued on conversion of options 15 December 2021 25,000 $ 0.668 16,700 Conversion of Triaxial Convertible Note 5 May 2022 1,855,357 $ 0.25 464,000 ATM issue of shares No. 1 24 May 2022 10,000 $ 0.826 8,256 ATM issue of shares No. 2 2 June 2022 10,000 $ 0.802 8,025 ATM issue of shares No. 3 6 June 2022 88,710 $ 0.837 74,258 ATM issue of shares No. 4 9 June 2022 603,500 $ 0.84 507,035 ATM issue of shares No. 5 14 June 2022 75,940 $ 0.824 62,583 ATM issue of shares No. 6 15 June 2022 2,000 $ 0.83 1,661 ATM issue of shares No. 7 20 June 2022 4,072,660 $ 0.869 3,540,403 Less: share issue transaction costs —  $ —  ( 492,735 ) Balance 30 June 2022 138,755,376 84,480,249 Balance 1 July 2022 138,755,376 84,480,249 ATM issue of shares No. 8 7 July 2022 573,370 $ 0.7102 407,201 ATM issue of shares No. 9 8 August 2022 8,561,490 $ 0.3316 2,839,346 ATM issue of shares No. 10 9 August 2022 10,000 $ 0.2723 2,723 ATM issue of shares No. 11 10 August 2022 158,020 $ 0.2465 38,949 ATM issue of shares No. 12 11 August 2022 330,960 $ 0.2413 79,868 ATM issue of shares No. 13 12 August 2022 1,247,440 $ 0.2469 308,050 ATM issue of shares No. 14 12 September 2022 651,030 $ 0.2211 143,964 ATM issue of shares No. 15 13 September 2022 28,350 $ 0.2187 6,200 Shares issued to Scientific Advisory Board 14 September 2022 60,000 $ 0.21 12,600 ATM issue of shares No. 16 7 October 2022 736,760 $ 0.1789 131,797 ATM issue of shares No. 17 28 October 2022 12,296,180 $ 0.1865 2,293,288 ATM issue of shares No. 18 11 January 2023 20,000 $ 0.138 2,761 Professional and sophisticated investors placement - 1st tranche 16 January 2023 25,387,018 $ 0.11 2,792,572 Professional and sophisticated investors placement - 2nd tranche 28 February 2023 15,522,075 $ 0.11 1,707,428 Share Placement Plan 3 March 2023 23,691,045 $ 0.11 2,606,000 Less: share issue transaction costs (400,750 ) Balance 30 June 2023 228,029,114 97,452,246 Balance 01 July 2023 228,029,114 97,452,246 ATM issue of shares No. 19 06 July 2023 8,148,140 $ 0.19 1,512,523 ATM issue of shares No. 20 07 July 2023 157,120 $ 0.16 25,877 ATM issue of shares No. 21 03 August 2023 15,000 $ 0.17 2,519 ATM issue of shares No. 22 29 November 2023 1,066,070 $ 0.10 107,268 Registered Direct Offering 05 December 2023 26,200,000 $ —  —  ATM issue of shares No. 23 13 February 2024 25,910 $ 0.0466 1,207 ATM issue of shares No. 24 14 February 2024 319,650 $ 0.0464 14,834 ATM issue of shares No. 25 15 February 2024 2,195,980 $ 0.0468 102,825 ATM issue of shares No. 26 16 205,260 $ 0.0614 12,597 Armistice warrants 21 February 2024 18,244,450 $ 0.0450 892,655 ATM issue of shares No. 27 21 February 2024 8,626,580 $ 0.0595 513,584 ATM issue of shares No. 28 22 February 2024 316,540 $ 0.0461 14,584 ATM issue of shares No. 29 2 3 304,860 $ 0.0464 14,147 ATM issue of shares No. 30 26 February 2024 250,000 $ 0.0460 11,502 ATM issue of shares No. 31 01 May 2024 2,112,560 $ 0.0478 100,961 ATM issue of shares No. 32 02 May 2024 375,410 $ 0.0457 17,147 ATM issue of shares No. 33 03 May 2024 288,900 $ 0.0469 13,544 ATM issue of shares No. 34 07 May 2024 790,100 $ 0.0456 36,024 ATM issue of shares No. 35 10 May 2024 20,000 $ 0.0455 910 ATM issue of shares No. 36 16 May 242,170 $ 0.0450 10,891 Repayment of promissory note 19 June 2024 5,916,970 $ 0.0643 380,223 Equity line of credit 24 June 2024 29,000,000 $ 0.0268 776,264 Less: share issue transaction costs (376,573 ) Balance 30 June 2024 332,850,784 101,637,758

Equity - reserves (Tables)

Equity - reserves (Tables)	12 Months Ended
	Jun. 30, 2024
Disclosure of reserves within equity [abstract]
Summary of tabular form of other reserves	2024 2023 2022 A$’000 A$’000 A$’000 Foreign currency reserve (750 ) (742 ) (852 ) Share-based payments reserve for Employee Share Option Plan 4,225 4,423 3,264 3,475 3,681 2,412

Financial instruments (Tables)

Financial instruments (Tables)	12 Months Ended
	Jun. 30, 2024
Statement [line items]
Summary of foreign currency denominated financial assets and financial liabilities	The carrying amount of the Consolidated Entity’s foreign currency denominated financial assets and financial liabilities at the reporting date was as follows: 2024 2023 US Dollar A$’000 Euro A$’000 Pound Sterling A$’000 Singapore A$’000 US Dollar A$’000 Euro A$’000 Pound Sterling A$’000 Singapore A$’000 Cash and cash equivalents - current 1,421 —  —  —  2,326 —  —  —  Trade and other receivables - current 1,908 —  —  —  —  —  —  —  Trade and other payables - current 942 7,320 18 —  1,135 2,710 —  1 Other financial liabilities 6,478 —  —  —  —  —  —  —  10,749 7,320 18 —  3,461 2,710 —  1
Summary of foreign currency risk sensitivity	If all currencies had AUD strengthened AUD weakened Consolidated - 2024 % change Effect on profit before tax A$’000 Effect on equity A$’000 % change Effect on profit before tax A$’000 Effect on equity A$’000 US dollars 10 % 142 142 (10 )% (142 ) (142 ) Euros 10 % —  —  (10 )% —  —  Pound Sterling 10 % (2 ) (2 ) (10 )% 2 2 140 140 (140 ) (140 ) AUD strengthened AUD weakened Consolidated - 2023 % change Effect on profit before tax A$’000 Effect on equity A$’000 % change Effect on profit before tax A$’000 Effect on equity A$’000 US dollars 10 % (494 ) (494 ) (10 )% 494 494 Euros 10 % 271 271 (10 )% (271 ) (271 ) (223 ) (223 ) 223 223
Summary of variable interest rate balances	As at the reporting date, the Consolidated Entity had the following variable interest rate balances: 2024 2023 Weighted average interest rate % Balance A$’000 Weighted average interest rate % Balance A$’000 Cash and cash equivalents 0.39 1,657 0.40 5,241 Net exposure to cash flow interest rate risk 1,657 5,241
Summary of remaining contractual maturities of financial instrument liabilities	2024 Weighted average interest rate % 1 year or less A$’000 Between 1 and 2 years A$’000 Between 2 and 5 years A$’000 Over 5 years A$’000 Remaining contractual maturities A$’000 Carrying Non-derivatives Trade payables —  4,548 —  —  —  4,548 4,548 Accrued payables —  10,519 —  —  —  10,519 10,519 Contingent consideration —  3,389 —  4,549 —  7,938 7,005 Derivatives Other financial liabilities —  —  —  6,478 —  6,478 6,478 Total undiscounted financial liabilities 18,456 —  11,027 —  29,483 28,550 2023 Weighted average interest rate % 1 year or less A$’000 Between 1 and 2 years A$’000 Between 2 and 5 years A$’000 Over 5 years A$’000 Remaining contractual maturities A$’000 Carrying Amount A$’000 Non-derivatives Trade payables —  857 —  —  —  857 857 Accrued payables —  3,472 —  —  —  3,472 3,472 Contingent consideration —  750 4,303 3,099 —  8,152 6,871 Total undiscounted financial liabilities 5,079 4,303 3,099 —  12,481 11,200

Fair value measurement (Tables)

Fair value measurement (Tables)	12 Months Ended
	Jun. 30, 2024
Text block [abstract]
Summary of assets and liabilities, measured or disclosed at fair value	The following tables detail the Consolidated Entity’s assets and liabilities, measured or disclosed at fair value, using a three level hierarchy, based on the lowest level of input that is significant to the entire fair value Level 1: Quoted prices (unadjusted) in active markets for identical assets or liabilities that the entity can access at the measurement date Level 2: Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly Level 3: Unobservable inputs for the asset or liability Consolidated - 2024 Level 1 Level 2 Level 3 Total Liabilities Contingent Consideration —  —  7,005 7,005 Warrant liability —  —  6,478 6,478 Total liabilities —  —  13,483 13,483 Consolidated - 2023 Liabilities Contingent Consideration —  —  6,871 6,871 Total liabilities —  —  6,871 6,871
Summary of movements in level 3 assets and liabilities	Movements in level 3 assets and liabilities during the current and previous financial year are set out below: Level 3 A$’000 Total A$’000 Consolidated Balance at 30 June 2022 8,968 8,968 Losses recognized in profit or loss (2,097 ) (2,097 ) Balance at 30 June 2023 6,871 6,871 Issuance of warrants 8,599 8,599 Exercise of warrants (864 ) (864 ) Gain recognized in profit or loss (1,123 ) (1,123 ) Balance at 30 June 2024 13,483 13,483

Key management personnel disc_2

Key management personnel disclosures (Tables)	12 Months Ended
	Jun. 30, 2024
Text block [abstract]
Summary of compensation made to directors and other members of key management personnel	The aggregate compensation made to directors and other members of key management personnel (‘KMP’) of the Consolidated Entity is set out below: 2024 A$ 2023 A$ 2022 A$ Short-term employee benefits 1,962,563 3,148,514 2,589,088 Post-employment benefits 72,784 149,626 115,950 Share-based payments 353,437 1,045,860 1,559,930 2,388,784 4,344,000 4,264,968

Parent entity information (Tabl

Parent entity information (Tables)	12 Months Ended
	Jun. 30, 2024
Text block [abstract]
Parent entity financial information	Set out below is the supplementary information about the parent entity. Parent 2024 A$’000 2023 A$’000 Statement of profit or loss and other comprehensive income Loss after income tax (24,008 ) (20,863 ) Total comprehensive loss (24,008 ) (20,863 ) 2024 A$’000 2023 A$’000 Statement of financial position Total current assets 3,048 4,645 Total assets 18,488 21,915 Total current liabilities 25,529 7,003 Total liabilities 31,335 15,472 Equity Contributed equity 101,638 97,452 Reserves 4,225 4,423 Accumulated losses (118,710 ) (95,432 ) Total equity (12,847 ) 6,443

Interests in subsidiaries (Tabl

Interests in subsidiaries (Tables)	12 Months Ended
	Jun. 30, 2024
Investments accounted for using equity method [abstract]
Summary of interest in subsidiaries	The consolidated financial statements incorporate the assets, liabilities and results of the following subsidiaries in accordance with the accounting policy described in note 2: Ownership interest Name Principal place of business / Country of incorporation 2024 % 2023 % Kazia Laboratories Pty Ltd Australia 100 % 100 % Kazia Research Pty Ltd Australia 100 % 100 % Kazia Therapeutics Inc. United States of America 100 % 100 % Glioblast Pty Ltd Australia 100 % 100 %

Earnings per share (Tables)

Earnings per share (Tables)	12 Months Ended
	Jun. 30, 2024
Text block [abstract]
Summary of earnings per share	2024 A$‘000 2023 A$‘000 2022 A$‘000 Earnings per share for losses from continuing operations Loss after income tax attributable to the owners of Kazia Therapeutics Limited (26,778 ) (20,465 ) (25,014 ) Loss after income tax attributable to the owners of Kazia Therapeutics Limited (26,778 ) (20,465 ) (25,014 ) Number Number Number Weighted average number of ordinary shares used in calculating basic and diluted earnings per share 263,676,313 184,284,350 132,467,686 Cents Cents Cents Basic and diluted earnings per share (10.16 ) (11.23 ) (18.88 )

Share-based payments (Tables)

Share-based payments (Tables)	12 Months Ended
	Jun. 30, 2024
Text block [abstract]
Summary of share-based payments	All of the options set out below have been issued to employees and directors under the ESOP. During the financial year an expense of $532,597 (30 June 2023: $1,159,125) ( 3 Number of 2024 - Ordinary Weighted Number of 2023 - Ordinary Weighted Outstanding at the beginning of the financial year 14,780,000 A$ 0.63 8,655,500 A$ 1.28 Granted —  A$ —  7,930,000 A$ 0.18 Forfeited (3,400,000 ) A$ 0.42 (1,550,000 ) A$ 1.90 Exercised —  A$ —  —  A$ —  Expired (1,200,000 ) A$ 0.49 (255,500 ) A$ 1.90 Outstanding at the end of the financial year 10,180,000 A$ 0.72 14,780,000 A$ 0.63 Exercisable at the end of the financial year 7,290,000 A$ 0.84 6,483,333 A$ 0.96 Number of 2024 - ADS Weighted Number of 2023 - ADS Weighted Outstanding at the beginning of the financial year —  A$ —  —  A$ —  Granted 2,850,000 A$ 0.5600 —  A$ —  Forfeited (250,000 ) A$ 0.5760 —  A$ —  Exercised —  A$ —  —  A$ —  Expired —  A$ —  —  A$ —  Outstanding at the end of the financial year 2,600,000 A$ 0.5580 —  A$ —  Exercisable at the end of the financial year —  A$ —  —  A$ —  2024 Tranche Grant date Expiry date Exercise price Balance at the start of the year - Granted Exercised Expired / lapsed on termination of employment Balance at the end of the year - 3 13/11/2019 04/01/2024 A$ 0.4925 1,200,000 —  —  (1,200,000 ) —  4 13/01/2020 13/01/2025 A$ 0.8812 187,500 —  —  (50,000 ) 137,500 5 09/11/2020 09/11/2024 A$ 1.1320 1,200,000 —  —  —  1,200,000 6 09/11/2020 13/01/2025 A$ 0.8812 600,000 —  —  —  600,000 7 04/01/2021 04/01/2025 A$ 1.6900 187,500 —  —  (50,000 ) 137,500 8 09/09/2021 26/06/2026 A$ 1.3650 100,000 —  —  —  100,000 9 16/11/2021 16/11/2025 A$ 1.6900 750,000 —  —  —  750,000 10 16/11/2021 16/11/2025 A$ 2.2400 500,000 —  —  —  500,000 11 16/11/2021 16/11/2025 A$ 1.5600 800,000 —  —  —  800,000 12 01/02/2022 01/02/2027 A$ 0.9400 800,000 —  —  (800,000 ) —  13 01/02/2022 01/02/2027 A$ 0.9400 425,000 —  —  (100,000 ) 325,000 14 24/05/2022 24/05/2027 A$ 0.7800 100,000 —  —  —  100,000 15 03/03/2023 03/03/2027 A$ 0.1500 3,930,000 —  —  (1,400,000 ) 2,530,000 16 03/05/2023 03/05/2027 A$ 0.1870 4,000,000 —  —  (1,000,000 ) 3,000,000 14,780,000 —  —  (4,600,000 ) 10,180,000 Weighted average exercise price $ 0.6292 $ —  $ —  $ 0.4349 $ 0.7207 At the end of the period the following outstanding options were vested and exerc isab - Options in tranches 3 & 12 expired during the year - Options in tranches 6 were vested and exercisable - Options in tranches 4, 7, 8, & 9 were vested and exercisable to 69%, apart from those in the above table which have expired - Options in tranche 5 were vested and exercisable to 75%, apart from those in the above table which have expired - Options in tranches 10 & 15 were vested and exercisable as to 33%, apart from those in the above table which have expired - Options in tranches 11, 14, & 16 were vested and exercisable as to 50%, apart from those in the above table which have expired - Options in tranches 13 were vested and exercisable as to 35%, apart from those in the above table which have expired The weighted average remaining contractual life of ordinary share options outstanding at 2024 is 2.00 years. Tranche Grant date Expiry date Exercise price Balance at the start of the year - Granted Exercised Expired / lapsed on termination of employment Balance at the end of the year - 17 22/04/2024 22/04/2029 A$ 0.5860 —  1,500,000 —  —  1,500,000 18 17/06/2024 17/06/2029 A$ 0.5130 —  1,100,000 —  (250,000 ) 850,000 19 27/06/2024 27/06/2030 A$ 0.2970 —  250,000 —  —  250,000 —  2,850,000 —  (250,000 ) 2,600,000 Weighted average exercise price $ 0.560 $ 0.576 $ 0.558 At the end of the period the following outstanding options were vested and exercisable: - Options in tranche 17, 18, & 19 were unvested The weighted average remaining contractual life of ADS share options outstanding at 30 June 2024 is years. 2023 Tranche Grant date Expiry date Exercise price Balance at the start of the year - Granted Exercised Expired / lapsed on of Balance at the end of the year - 1 07/08/2017 07/08/2022 A$ 0.6700 15,500 —  —  (15,500 ) —  2 05/02/2018 05/02/2023 A$ 0.7802 240,000 —  —  (240,000 ) —  3 13/11/2019 04/01/2024 A$ 0.4925 1,200,000 —  —  —  1,200,000 4 13/01/2020 13/01/2025 A$ 0.8812 200,000 —  —  (12,500 ) 187,500 5 09/11/2020 09/11/2024 A$ 1.1320 1,200,000 —  —  —  1,200,000 6 09/11/2020 13/01/2025 A$ 0.8812 800,000 —  —  (200,000 ) 600,000 7 04/01/2021 04/01/2025 A$ 1.6900 200,000 —  —  (12,500 ) 187,500 8 09/09/2021 26/06/2026 A$ 1.3650 100,000 —  —  —  100,000 9 16/11/2021 16/11/2025 A$ 1.6900 1,000,000 —  —  (250,000 ) 750,000 10 16/11/2021 16/11/2025 A$ 2.2400 1,500,000 —  —  (1,000,000 ) 500,000 11 16/11/2021 16/11/2025 A$ 1.5600 800,000 —  —  —  800,000 12 01/02/2022 01/02/2027 A$ 0.9400 800,000 —  —  —  800,000 13 01/02/2022 01/02/2027 A$ 0.9400 500,000 —  —  (75,000 ) 425,000 14 24/05/2022 24/05/2027 A$ 0.7800 100,000 —  —  —  100,000 15 03/03/2023 03/03/2027 A$ 0.1500 —  3,930,000 —  —  3,930,000 16 05/03/2023 03/05/2027 A$ 0.1870 —  4,000,000 —  —  4,000,000 8,655,500 7,930,000 —  (1,805,500 ) 14,780,000 Weighted average exercise price $ 1.2826 $ 0.1785 $ —  $ 1.8977 $ 0.6292 At the end of the period the following outstanding options were vested and ex erc - Options in tranches 1 - 2 expired during the year - Options in tranches 3 & 6 were vested and exercisable - Options in tranches 4, 5, 7 & 9 were vested and exercisable to 75%, apart from those in the above table which have expired - Options in tranche 8 were vested and exercisable to 50%, apart from those in the above table which have expired - Options in tranches 10 & 16 were vested and exercisable as to 33%, apart from those in the above table which have expired - Options in tranches 11, 12, 13 & 14 were vested and exercisable as to 25%, apart from those in the above table which have expired - Options in tranche 15 were unvested - Options in tranche 16 were 33% vested The weighted average remaining contractual life of options outstanding at 30 June 2023 is years.
Summary of valuation for each tranche of options	Grant date Expiry date Share price Grant Date Exercise price Volatility (%) Dividend yield (%) Risk Rate Fair value per option 13/11/2019 04/01/2024 A A 74.50% —  1.95% A$ 0.1800 13/01/2020 13/01/2025 A A 74.50% —  1.95% A$ 0.3400 09/11/2020 09/11/2024 A A 90.00% —  0.10% A$ 0.4130 09/11/2020 13/01/2025 A A 90.00% —  0.10% A$ 0.5030 04/01/2021 04/01/2025 A A 90.00% —  0.19% A$ 0.6000 09/09/2021 26/06/2026 A A 76.00% —  1.50% A$ 0.8800 16/11/2021 16/11/2025 A A 76.00% —  1.50% A$ 0.8500 16/11/2021 16/11/2025 A A 76.00% —  1.50% A$ 0.7500 16/11/2021 16/11/2025 A A 76.00% —  1.50% A$ 0.9700 01/02/2022 01/02/2027 A A 79.00% —  1.50% A$ 0.5900 01/02/2022 01/02/2027 A A 44.00% —  2.95% A$ 0.6300 24/05/2022 24/05/2027 A A 80.00% —  3.64% A$ 0.1014 03/03/2023 03/03/2027 A A 80.00% —  3.64% A$ 0.1014 03/05/2023 03/05/2027 A A 80.00% —  3.22% A$ 0.1111 22/04/2024 22/04/2029 A A 95.00% —  3.96% A$ 0.4300 17/06/2024 17/06/2029 A A 95.00% —  3.84% A$ 0.2300 27/06/2024 27/06/2030 A A 95.00% —  4.17% A$ 0.2700

Material accounting policies -

Material accounting policies - Additional Information (Detail)		3 Months Ended		12 Months Ended
	Sep. 04, 2024 USD ($)	Sep. 30, 2024 AUD ($)	Sep. 30, 2024 USD ($)	Jun. 30, 2024 AUD ($)	Jun. 30, 2024 USD ($)	Jun. 30, 2023 AUD ($)	Jun. 30, 2023 USD ($)	Jun. 30, 2022 AUD ($)	Jun. 30, 2023 USD ($)	May 01, 2022 USD ($)	Jun. 30, 2021 AUD ($)
Disclosure of summary of significant accounting policies [line items]
Consolidated loss after income tax				$ 26,778,000		$ 20,465,000		$ 25,014,000
Net current asset position				19,700,000
Net cash outflows from operating activities				9,600,000
Consolidated cash in hand and at bank				1,657,000		5,241,000		7,361,000			$ 27,587,000
Proceeds from issuing shares				$ 2,914,000		$ 12,972,000		$ 3,726,000
Increase of aggregate offering price	$ 50,000,000
At The Market Equity Program [Member]
Disclosure of summary of significant accounting policies [line items]
Aggregate offering										$ 35,000,000
Proceeds from issuing shares					$ 1,656,016		$ 4,203,221
American Depository Shares [member] | At The Market Equity Program [Member]
Disclosure of summary of significant accounting policies [line items]
Number of shares represented by one depositary receipt										100
Net amount eligible to be offered for issue									$ 22,600,000
Major ordinary share transactions [member] | At The Market Equity Program [Member]
Disclosure of summary of significant accounting policies [line items]
Proceeds from the issuance of common stock		$ 816,373	$ 3,609,757
Licensing agreement for paxalisib [member]
Disclosure of summary of significant accounting policies [line items]
Remaining useful life,licensing agreement				15 years	15 years
Licensing agreement for EVT801 [member]
Disclosure of summary of significant accounting policies [line items]
Remaining useful life,licensing agreement				12.5 years	12.5 years

Critical Accounting Judgement_2

Critical Accounting Judgements, Estimates and Assumptions - Additional Information (Detail)	12 Months Ended
	Jun. 30, 2024
Disclosure of significant accounting judgments assumptions and estimates [abstract]
Percentage milestone trigger to account cost of asset conferred under license agreement	50%

Restatement of comparatives - S

Restatement of comparatives - Schedule of material restatement of financial position (Detail) - AUD ($) $ in Thousands	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2022
Disclosure of Detailed Information about Material Restatement of Balance Sheet [Line Items]
Intangible assets other than goodwill	$ 15,400	$ 17,269	$ 19,139
Current contingent consideration	(3,253)	(750)	(759)
Non-Current contingent consideration			(8,209)
Contingent Consideration	(7,005)	(6,871)	(8,968)
Accumulated losses			(68,617)
Total equity			18,275
Previously stated [member]
Disclosure of Detailed Information about Material Restatement of Balance Sheet [Line Items]
Intangible assets other than goodwill			20,050
Current contingent consideration			(759)
Non-Current contingent consideration			(8,756)
Contingent Consideration			(9,515)
Accumulated losses			(68,253)
Total equity			18,638
Increase (decrease) due to corrections of prior period errors [member]
Disclosure of Detailed Information about Material Restatement of Balance Sheet [Line Items]
Intangible assets other than goodwill			(911)
Non-Current contingent consideration			547
Contingent Consideration			547
Accumulated losses			(364)
Total equity			(363)
EVT801 Licensing Agreement [Member]
Disclosure of Detailed Information about Material Restatement of Balance Sheet [Line Items]
Intangible assets other than goodwill	$ 7,327	$ 8,112	8,897
Gross carrying amount [member] | EVT801 Licensing Agreement [Member]
Disclosure of Detailed Information about Material Restatement of Balance Sheet [Line Items]
Intangible assets other than goodwill			26,221
Gross carrying amount [member] | EVT801 Licensing Agreement [Member] | Previously stated [member]
Disclosure of Detailed Information about Material Restatement of Balance Sheet [Line Items]
Intangible assets other than goodwill			27,266
Gross carrying amount [member] | EVT801 Licensing Agreement [Member] | Increase (decrease) due to corrections of prior period errors [member]
Disclosure of Detailed Information about Material Restatement of Balance Sheet [Line Items]
Intangible assets other than goodwill			(1,045)
Accumulated amortisation [member] | EVT801 Licensing Agreement [Member]
Disclosure of Detailed Information about Material Restatement of Balance Sheet [Line Items]
Intangible assets other than goodwill			(7,082)
Accumulated amortisation [member] | EVT801 Licensing Agreement [Member] | Previously stated [member]
Disclosure of Detailed Information about Material Restatement of Balance Sheet [Line Items]
Intangible assets other than goodwill			(7,216)
Accumulated amortisation [member] | EVT801 Licensing Agreement [Member] | Increase (decrease) due to corrections of prior period errors [member]
Disclosure of Detailed Information about Material Restatement of Balance Sheet [Line Items]
Intangible assets other than goodwill			$ 134

Restatement of comparatives -_2

Restatement of comparatives - Schedule of material restatement of profit or loss and other comprehensive income (Detail) - AUD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2022
Disclosure of Detailed Information about Material Restatement of Profit or Loss and Other Comprehensive Income [Line Items]
Research and development expense (Amortisation)	$ (17,380)	$ (15,564)	$ (20,169)
General and administrative expense (foreign exchange impact)			(5,113)
Commercialisation expense	0	0	(127)
Loss before income tax benefit	(27,049)	(20,736)	(25,382)
Income tax benefit	271	271	368
Loss after income tax benefit	$ (26,778)	$ (20,465)	$ (25,014)
Impact on basic and diluted earnings per share increase/ (decrease) in earning per share
Basic loss for the year attributable to equity holders			$ (0.1888)
Diluted loss for the year attributable to equity holders			$ (0.1888)
Previously stated [member]
Disclosure of Detailed Information about Material Restatement of Profit or Loss and Other Comprehensive Income [Line Items]
Research and development expense (Amortisation)			$ (20,252)
General and administrative expense (foreign exchange impact)			(4,511)
Loss on revaluation of contingent consideration			(152)
Commercialisation expense			(127)
Loss before income tax benefit			(25,016)
Income tax benefit			368
Loss after income tax benefit			$ (24,648)
Impact on basic and diluted earnings per share increase/ (decrease) in earning per share
Basic loss for the year attributable to equity holders			$ (0.1861)
Diluted loss for the year attributable to equity holders			$ (0.1861)
Increase (decrease) due to corrections of prior period errors [Member]
Disclosure of Detailed Information about Material Restatement of Profit or Loss and Other Comprehensive Income [Line Items]
Research and development expense (Amortisation)			$ 83
General and administrative expense (foreign exchange impact)			(602)
Loss on revaluation of contingent consideration			152
Loss before income tax benefit			(366)
Loss after income tax benefit			$ (366)
Impact on basic and diluted earnings per share increase/ (decrease) in earning per share
Basic loss for the year attributable to equity holders			$ (0.0027)
Diluted loss for the year attributable to equity holders			$ (0.0027)

Restatement of comparatives - A

Restatement of comparatives - Additional Information (Detail)	Jun. 30, 2024
Restatement of comparatives [Abstract]
Incremental borrowing rate	6%

Reclassification of comparati_3

Reclassification of comparatives - Disclosure in tabular form of reclassification of comparatives (Detail) - AUD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2024	Jun. 30, 2023
Disclosure In Tabular Form Of Reclassification Of Comparatives [Line Items]
Other assets		$ 591	$ 1,632
Borrowings		634	1,796
Current employee benefits		365	690
Non-current employee benefits		$ 35	$ 59
Restated [member]
Disclosure In Tabular Form Of Reclassification Of Comparatives [Line Items]
Other assets	$ 156
Current employee benefits	166
Non-current employee benefits	319
Loss on remeasurement of contingent consideration	152
General and administrative expense	(4,961)
Reclassification [Member]
Disclosure In Tabular Form Of Reclassification Of Comparatives [Line Items]
Other assets	1,841
Borrowings	(1,841)
Current employee benefits	203
Non-current employee benefits	(202)
Loss on remeasurement of contingent consideration	(152)
General and administrative expense	(152)
Reclassified [member]
Disclosure In Tabular Form Of Reclassification Of Comparatives [Line Items]
Other assets	1,997
Borrowings	(1,841)
Current employee benefits	369
Non-current employee benefits	117
General and administrative expense	$ (5,113)

Revenue - Additional Informatio

Revenue - Additional Information (Detail) - Licensing Agreement [Member] $ in Millions, $ in Millions	1 Months Ended		12 Months Ended
	Mar. 31, 2024 USD ($)	Mar. 31, 2021 USD ($)	Jun. 30, 2024 AUD ($)	Jun. 30, 2021 USD ($)	Jun. 30, 2024 USD ($)
Oasmia [Member]
Statement [line items]
Upfront payment received				$ 4
Simcere Pharmaceutical Group Limited [Member]
Statement [line items]
Upfront payment received		$ 11
Upfront payment received in cash		7
Upfront payment received in shares		$ 4
Premium on investment percentage		20%
Oasmia And Simcere Pharmaceutical Group [Member]
Statement [line items]
Revenue recognized of consideration received from customers during the period			$ 2.3
Sovargen Co Ltd [Member]
Statement [line items]
Upfront payment received	$ 1.5
Commercial Milestone [Member] | Oasmia [Member]
Statement [line items]
Contingent milestone payment receivable				$ 42
Commercial Milestone [Member] | Simcere Pharmaceutical Group Limited [Member]
Statement [line items]
Contingent milestone payment receivable		$ 281
Commercial Milestone [Member] | Sovargen Co Ltd [Member]
Statement [line items]
Contingent milestone payment receivable					$ 19

Revenue - Summary of licensing

Revenue - Summary of licensing revenue (Detail) - AUD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2022
Disclosure of products and services [line items]
Revenue from contracts with customers	$ 2,308	$ 0	$ 0
Licensing revenue [Member]
Disclosure of products and services [line items]
Revenue from contracts with customers	2,301	0	0
Sale of paxalisib [Member]
Disclosure of products and services [line items]
Revenue from contracts with customers	$ 7	$ 0	$ 0

Revenue - Summary of disaggrega

Revenue - Summary of disaggregation of revenue from contracts with customers (Detail) - AUD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2022
Disclosure of disaggregation of revenue from contracts with customers [line items]
Revenue from contracts with customers	$ 2,308	$ 0	$ 0
Licensing revenue [Member]
Disclosure of disaggregation of revenue from contracts with customers [line items]
Revenue from contracts with customers	2,301	0	0
Licensing revenue [Member] | Timing of revenue recognition [Member]
Disclosure of disaggregation of revenue from contracts with customers [line items]
Revenue from contracts with customers	2,301	0	0
Sale of paxalisib [Member]
Disclosure of disaggregation of revenue from contracts with customers [line items]
Revenue from contracts with customers	7	0	0
Sale of paxalisib [Member] | Timing of revenue recognition [Member]
Disclosure of disaggregation of revenue from contracts with customers [line items]
Revenue from contracts with customers	7	0	0
KR [Member]
Disclosure of disaggregation of revenue from contracts with customers [line items]
Revenue from contracts with customers	$ 2,308	$ 0	$ 0

Operating segments - Additional

Operating segments - Additional Information (Detail)	12 Months Ended
	Jun. 30, 2024 Segments
Disclosure of operating segments [abstract]
Number of operating segments	0

Other income - Summary of other

Other income - Summary of other income (Detail) - AUD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2022
Material income and expense [abstract]
Research and development rebate	$ 173
Subsidies and grants			$ 10
Bad debt recovery			15
Other sundry income		$ 1
Other income	$ 173	$ 1	$ 25

Expenses - Summary of expenses

Expenses - Summary of expenses (Detail) - AUD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2022
Loss before income tax includes the following specific
Scientific Advisory Board costs		$ 31
Employee benefits expense- salaries & wages and staff benefits	$ 2,161	2,250	$ 1,665
Employee benefits expense- superannuation	36	29	25
Employee benefits expense- share based payments	485	702	365
Total research & development (excluding amortisation)	15,511	13,695	18,300
Amortisation	1,869	1,869	1,869
Total research & development	17,380	15,564	20,169
Net foreign exchange (gain) / loss	(20)	46	(2,154)
Minimum lease payments	124	152	73
Defined contribution superannuation expense	88	131	138
Employee benefits expense G&A
- salaries & wages and staff benefits	486	1,467	1,674
- superannuation	52	102	129
- share based payments	48	457	1,310
Total employee benefits expense G&A	586	2,026	3,113
EVT-801 program costs [member]
Loss before income tax includes the following specific
Research and development	5,277	5,060	2,520
Cantrixil program costs [member]
Loss before income tax includes the following specific
Research and development	1	5	12
Paxalisib program costs [member]
Loss before income tax includes the following specific
Research and development	7,551	5,618	13,713
Paxalisib licensing agreement [member]
Loss before income tax includes the following specific
Amortisation	1,084	1,084	1,084
Evotec Licensing Agreement [member]
Loss before income tax includes the following specific
Amortisation	$ 785	$ 785	$ 785

Income taxes - Summary of Incom

Income taxes - Summary of Income taxes (Detail) - AUD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2022
Numerical reconciliation of income tax benefit and tax at the statutory rate
Loss before income tax benefit	$ (27,049)	$ (20,736)	$ (25,382)
Tax at the statutory tax rate of 25%	(6,762)	(5,184)	(6,345)
Tax effect amounts which are not deductible/(taxable) in calculating taxable income:
Research and development claim	0	0	0
Amortisation of intangibles	467	467	467
Employee option plan	133	289	419
Gain/loss on revaluation of contingent consideration	(22)	(847)	38
Prior year tax losses not recognised now recouped	(6,184)	(5,275)	(5,421)
Adjustment recognised for prior periods	0	0	16
Adjustment to deferred tax balances as a result of change in statutory tax rate	0	0	(113)
Tax losses and timing differences not recognised	5,913	5,004	5,150
Income tax benefit	(271)	(271)	(368)
Australia [member]
Tax losses not recognised
Unused tax losses for which no deferred tax asset has been recognised	139,430	120,412	96,519
Potential tax benefit	34,858	30,103	24,130
US [member]
Tax losses not recognised
Unused tax losses for which no deferred tax asset has been recognised	7,836	4,305	2,380
Potential tax benefit	$ 1,646	$ 904	$ 500

Income taxes - Summary of Inc_2

Income taxes - Summary of Income taxes (Parenthetical) (Detail)	12 Months Ended
	Jun. 30, 2024
Disclosure Of Income Tax Benefit [line items]
Statutory tax rate	25%
Australia [member]
Disclosure Of Income Tax Benefit [line items]
Statutory tax rate	25%
US [member]
Disclosure Of Income Tax Benefit [line items]
Statutory tax rate	21%

Current assets - cash and cas_3

Current assets - cash and cash equivalents - Summary of cash and cash equivalents (Detail) - AUD ($) $ in Thousands	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2021
Cash and cash equivalents [abstract]
Cash at bank and on hand	$ 1,657	$ 5,241
Cash and cash equivalents	$ 1,657	$ 5,241	$ 7,361	$ 27,587

Trade and other receivables - S

Trade and other receivables - Summary of current assets - trade and other receivables (Detail) - AUD ($) $ in Thousands	Jun. 30, 2024	Jun. 30, 2023
Disclosure of financial assets [line items]
Current assets		$ 1
GBM Agile deposit	$ 3,756	3,753
Trade and other receivables	3,897	3,899
BAS receivables [member]
Disclosure of financial assets [line items]
Other receivables	133	104
Deposits held [member]
Disclosure of financial assets [line items]
Other receivables	$ 8	$ 41

Trade and other receivables -_3

Trade and other receivables - non-current - Summary of non-current assets - trade and other receivables noncurrent (Detail) - AUD ($) $ in Thousands	Jun. 30, 2024	Jun. 30, 2023
Disclosure of detailed information about trade and other receivables noncurrent [line items]
Trade and other receivables - non-current	$ 40	$ 43
Corporate credit card deposit [member]
Disclosure of detailed information about trade and other receivables noncurrent [line items]
Trade and other receivables - non-current	$ 40	$ 43

Other assets - Summary of curre

Other assets - Summary of current assets - other (Detail) - AUD ($) $ in Thousands	Jun. 30, 2024	Jun. 30, 2023
Statement of financial position [abstract]
Prepayments	$ 591	$ 1,632

Intangibles - Summary of non-cu

Intangibles - Summary of non-current assets - intangibles (Detail) - AUD ($) $ in Thousands	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2022
Disclosure of detailed information about intangible assets [line items]
Intangibles	$ 15,400	$ 17,269	$ 19,139
GDC licensing agreement [member]
Disclosure of detailed information about intangible assets [line items]
Intangibles	8,073	9,157
GDC licensing agreement [member] | Gross carrying amount [member]
Disclosure of detailed information about intangible assets [line items]
Intangibles	16,408	16,408
GDC licensing agreement [member] | Accumulated amortisation [member]
Disclosure of detailed information about intangible assets [line items]
Intangibles	(8,335)	(7,251)
Licensing Agreement [Member]
Disclosure of detailed information about intangible assets [line items]
Intangibles	7,327	8,112
Licensing Agreement [Member] | Gross carrying amount [member]
Disclosure of detailed information about intangible assets [line items]
Intangibles	9,813	9,813
Licensing Agreement [Member] | Accumulated amortisation [member]
Disclosure of detailed information about intangible assets [line items]
Intangibles	$ (2,486)	$ (1,701)

Intangibles - Summary of reconc

Intangibles - Summary of reconciliations of intangibles (Detail) - AUD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Disclosure of detailed information about intangible assets [line items]
Beginning balance	$ 17,269	$ 19,139
Amortisation expense	(1,869)	(1,870)
Ending balance	15,400	17,269
Paxalisib licensing agreement [member]
Disclosure of detailed information about intangible assets [line items]
Beginning balance	9,157	10,242
Amortisation expense	(1,084)	(1,085)
Ending balance	8,073	9,157
EVT801 licensing agreement [Member]
Disclosure of detailed information about intangible assets [line items]
Beginning balance	8,112	8,897
Amortisation expense	(785)	(785)
Ending balance	$ 7,327	$ 8,112

Trade and other payables - Summ

Trade and other payables - Summary of current liabilities - trade and other payables (Detail) - AUD ($) $ in Thousands	Jun. 30, 2024	Jun. 30, 2023
Trade and other payables [abstract]
Trade payables	$ 4,548	$ 857
Accrued payables	10,519	3,472
Total trade and other payables	$ 15,067	$ 4,329

Borrowings - Schedule of borrow

Borrowings - Schedule of borrowings (Detail) - AUD ($) $ in Thousands	Jun. 30, 2024	Jun. 30, 2023
Disclosure of detailed information about borrowings [line items]
Current liabilities	$ 634	$ 1,796
Insurance premium funding [Member]
Disclosure of detailed information about borrowings [line items]
Current liabilities	$ 634	$ 1,796

Borrowings - Additional Informa

Borrowings - Additional Information (Detail)					12 Months Ended
	Jun. 19, 2024 AUD ($) $ / shares shares	Dec. 20, 2023 AUD ($)	Dec. 20, 2023 USD ($) shares	Oct. 23, 2023 AUD ($)	Jun. 30, 2024 AUD ($) $ / shares	Jun. 30, 2023 AUD ($)	Jun. 30, 2022 AUD ($)	Feb. 01, 2024 shares	Nov. 30, 2023 shares	Oct. 23, 2023 USD ($)
Disclosure of detailed information about borrowings [line items]
Repayments of borrowings, classified as financing activities			$ 253,014		$ 371,000	$ 0	$ 0
Number of shares issued			591,697
Par value per share | $ / shares	$ 0.0643				$ 0
Fair value movement in liability | $	$ 25,174
American Depositary Shares [Member]
Disclosure of detailed information about borrowings [line items]
Number of shares issued									2,620,000
Ordinary shares [member]
Disclosure of detailed information about borrowings [line items]
Number of shares issued								18,244,450
Unsecured Convertible Promissory Note [Member]
Disclosure of detailed information about borrowings [line items]
Notional amount			$ 250,000	$ 776,670						$ 500,000
Borrowings, interest rate				10%						10%
Percentage of borrowings that are called up for equity instrument				50%
Interest expense on borrowings | $			$ 3,014
Repayments of borrowings, classified as financing activities | $		$ 371,802
Percentage of remaining borrowings that are called up for equity instrument		50%	50%
Unsecured Convertible Promissory Note [Member] | American Depositary Shares [Member]
Disclosure of detailed information about borrowings [line items]
Number of shares issued	591,697
Unsecured Convertible Promissory Note [Member] | Ordinary shares [member]
Disclosure of detailed information about borrowings [line items]
Number of shares issued	5,916,970

Employee benefits - Summary of

Employee benefits - Summary of provision (Detail) - AUD ($) $ in Thousands	Jun. 30, 2024	Jun. 30, 2023
Disclosure of defined benefit plans [abstract]
Employee benefits	$ 0	$ 201
Annual leave	365	489
Employee benefits	365	690
Long service leave	35	59
Provisions for employee benefits	$ 400	$ 749

Contingent consideration - Summ

Contingent consideration - Summary of liabilities - contingent consideration (Detail) - AUD ($) $ in Thousands	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2022
Disclosure of contingent liabilities [line items]
Contingent consideration, current	$ 3,253	$ 750	$ 759
Contingent consideration, non-current	3,752	6,121
Contingent Consideration	7,005	6,871	$ 8,968
Contingent consideration - Paxalisib [Member]
Disclosure of contingent liabilities [line items]
Contingent consideration, current	0	750
Contingent consideration, non-current	1,266	654
Contingent consideration - EVT801 [Member]
Disclosure of contingent liabilities [line items]
Contingent consideration, current	3,253	0
Contingent consideration, non-current	$ 2,486	$ 5,467

Contingent consideration - Su_2

Contingent consideration - Summary of reconciliation of contingent consideration (Detail) - AUD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2022
Disclosure In Tabular Form Of Changes In Contingent Consideration During The Period [Line Items]
Contingent Consideration	$ 6,871	$ 8,968
Interest accretion	339	594
Effect of exchange rates on contingent consideration	(86)	697
Gain on remeasurement of contingent consideration	(119)	(3,388)	$ 0
Contingent Consideration	$ 7,005	$ 6,871	$ 8,968

Contingent consideration - Addi

Contingent consideration - Additional Information (Detail)	12 Months Ended
	Jun. 30, 2024 AUD ($) Milestone	Jun. 30, 2024 EUR (€) Milestone	Jun. 30, 2023 AUD ($)	Jun. 30, 2023 EUR (€)
Disclosure of contingent liabilities [line items]
Milestone payments not booked	$ 496,287,928	€ 300,500,000	$ 492,703,722	€ 300,500,000
Paxalisib [Member]
Disclosure of contingent liabilities [line items]
Number of contingent milestone payments | Milestone	4	4
Percentage of milestone payment due and payable	0%	0%	60%	60%
Milestone Two [member] | Paxalisib [Member]
Disclosure of contingent liabilities [line items]
Contingent consideration | $	$ 1,250,000
Milestone Five [member] | Paxalisib [Member]
Disclosure of contingent liabilities [line items]
Milestone payment discount rate	9%	9%	20%	20%
Probability of milestone payments	100%	100%	57%	57%
Contingent consideration – EVT801 [Member]
Disclosure of contingent liabilities [line items]
Percentage of discount rate on milestone payments	9%	9%	7%	7%
Contingent consideration – EVT801 [Member] | Milestone Three [Member]
Disclosure of contingent liabilities [line items]
Probability of milestone payments	100%	100%	100%	100%
Contingent consideration – EVT801 [Member] | Milestone Four [member]
Disclosure of contingent liabilities [line items]
Probability of milestone payments	80%	80%	80%	80%
Contingent consideration – EVT801 [Member] | Milestone Five [member]
Disclosure of contingent liabilities [line items]
Probability of milestone payments	63%	63%	63%	63%

Deferred tax - Summary of non-c

Deferred tax - Summary of non-current liabilities - deferred tax (Detail) - AUD ($) $ in Thousands	Jun. 30, 2024	Jun. 30, 2023
Deferred tax assets and liabilities [abstract]
Deferred tax liability associated with Licensing Agreement - Non-current liabilities	$ 2,018	$ 2,289

Other financial liabilities - S

Other financial liabilities - Summary of other financial liabilities (Detail) - AUD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2022
Other Financial Liabilities Current [Abstract]
Prefunded and ordinary warrants at initial recognition	$ 8,599
Prefunded warrants exercised	(864)	$ 0	$ 0
Gain on remeasurement of financial liabilities	(1,257)	0	$ 0
Prefunded and ordinary warrants at period end	$ 6,478	$ 8,599

Other financial liabilities - A

Other financial liabilities - Additional Information (Detail)	Nov. 30, 2023 AUD ($) shares	Jun. 30, 2024 AUD ($)	May 17, 2024 shares $ / shares	Dec. 20, 2023 shares	Nov. 30, 2023 $ / shares
Disclosure of Changes in Other Financial Liabilities Current [Line Items]
Number of shares issued | shares				591,697
Value of Securities Exercisable	$ 0
Exercise price | $ / shares					$ 0.583
Securities expiry date	Jun. 05, 2029
Fair value warrants issued		$ 5,445,887
Rate of consideration for purchasing warrants		5%
Amount for determining exercise price of warrants		$ 6,000,000
Securities Purchase Agreement [Member]
Disclosure of Changes in Other Financial Liabilities Current [Line Items]
Fair value warrants issued	$ 132,763
Transaction cost incurred for issue of warrants	$ 382,463
Prefunded Warrants [Member]
Disclosure of Changes in Other Financial Liabilities Current [Line Items]
Number of other equity instruments exercisable | shares	1,824,445
Ordinary Warrants [Member]
Disclosure of Changes in Other Financial Liabilities Current [Line Items]
Number of other equity instruments exercisable | shares	4,444,445
Ordinary Warrants [Member] | Securities Purchase Agreement [Member]
Disclosure of Changes in Other Financial Liabilities Current [Line Items]
Financial liabilities, at fair value	$ 3,020,316
American Depositary Shares [Member]
Disclosure of Changes in Other Financial Liabilities Current [Line Items]
Number of shares issued | shares	2,620,000
American Depositary Shares [Member] | Securities Purchase Agreement [Member]
Disclosure of Changes in Other Financial Liabilities Current [Line Items]
Number of other equity instruments exercisable | shares			1,100,000
Exercise price | $ / shares			$ 0.27

Equity - contributed equity - S

Equity - contributed equity - Summary of movements in ordinary share capital (Detail) - AUD ($)

1 Months Ended

12 Months Ended

Jun. 24, 2024

Jun. 19, 2024

Jun. 16, 2024

May 10, 2024

May 07, 2024

May 03, 2024

May 02, 2024

Feb. 26, 2024

Feb. 25, 2024

Feb. 22, 2024

Feb. 21, 2024

Feb. 18, 2024

Feb. 15, 2024

Feb. 14, 2024

Feb. 13, 2024

Dec. 05, 2023

Nov. 29, 2023

Aug. 03, 2023

Jul. 07, 2023

Jul. 06, 2023

Mar. 03, 2023

Feb. 28, 2023

Jan. 16, 2023

Jan. 11, 2023

Oct. 28, 2022

Oct. 07, 2022

Sep. 14, 2022

Sep. 13, 2022

Sep. 12, 2022

Aug. 12, 2022

Aug. 11, 2022

Aug. 10, 2022

Aug. 09, 2022

Aug. 08, 2022

Jul. 07, 2022

Jun. 20, 2022

Jun. 15, 2022

Jun. 14, 2022

Jun. 09, 2022

Jun. 06, 2022

Jun. 02, 2022

May 24, 2022

May 05, 2022

Dec. 15, 2021

Mar. 31, 2024

Jun. 30, 2024

Jun. 30, 2023

Jun. 30, 2022

Contributed equity [member]

Disclosure of classes of share capital [line items]

Beginning Balance

228,029,114

138,755,376

132,012,209

Ending Balance

332,850,784

228,029,114

138,755,376

Beginning Balance

$ 97,452,246

$ 84,480,249

$ 80,290,062

Issue of shares

4,182,000

13,373,000

4,202,000

Ending balance

$ 101,637,758

$ 97,452,246

$ 84,480,249

Conversion of options [member]

Disclosure of classes of share capital [line items]

Issue price

$ 0.668

Conversion of options [member] | Contributed equity [member] | 15 December 2021 [Member]

Disclosure of classes of share capital [line items]

Increase (decrease) in shares outstanding

25,000

Issue of shares

$ 16,700

Conversion of Triaxial Convertible Note [Member]

Disclosure of classes of share capital [line items]

Issue price

$ 0.25

Conversion of Triaxial Convertible Note [Member] | Contributed equity [member] | 5 May 2022 [Member]

Disclosure of classes of share capital [line items]

Increase (decrease) in shares outstanding

1,855,357

Issue of shares

$ 464,000

ATM issue of shares No. 1 [Member]

Disclosure of classes of share capital [line items]

Issue price

$ 0.826

ATM issue of shares No. 1 [Member] | Contributed equity [member] | 24 May 2022 [Member]

Disclosure of classes of share capital [line items]

Increase (decrease) in shares outstanding

10,000

Issue of shares

$ 8,256

ATM issue of shares No. 2 [Member]

Disclosure of classes of share capital [line items]

Issue price

$ 0.802

ATM issue of shares No. 2 [Member] | Contributed equity [member] | 2 June 2022 [Member]

Disclosure of classes of share capital [line items]

Increase (decrease) in shares outstanding

10,000

Issue of shares

$ 8,025

ATM issue of shares No. 3 [Member]

Disclosure of classes of share capital [line items]

Issue price

$ 0.837

ATM issue of shares No. 3 [Member] | Contributed equity [member] | 6 June 2022 [Member]

Disclosure of classes of share capital [line items]

Increase (decrease) in shares outstanding

88,710

Issue of shares

$ 74,258

ATM issue of shares No. 4 [Member]

Disclosure of classes of share capital [line items]

Issue price

$ 0.84

ATM issue of shares No. 4 [Member] | Contributed equity [member] | 9 June 2022 [Member]

Disclosure of classes of share capital [line items]

Increase (decrease) in shares outstanding

603,500

Issue of shares

$ 507,035

ATM issue of shares No. 5 [Member]

Disclosure of classes of share capital [line items]

Issue price

$ 0.824

ATM issue of shares No. 5 [Member] | Contributed equity [member] | 14 June 2022 [Member]

Disclosure of classes of share capital [line items]

Increase (decrease) in shares outstanding

75,940

Issue of shares

$ 62,583

ATM issue of shares No. 6 [Member]

Disclosure of classes of share capital [line items]

Issue price

$ 0.83

ATM issue of shares No. 6 [Member] | Contributed equity [member] | 15 June 2022 [Member]

Disclosure of classes of share capital [line items]

Increase (decrease) in shares outstanding

2,000

Issue of shares

$ 1,661

ATM issue of shares No. 7 [Member]

Disclosure of classes of share capital [line items]

Issue price

$ 0.869

ATM issue of shares No. 7 [Member] | Contributed equity [member] | 20 June 2022 [Member]

Disclosure of classes of share capital [line items]

Increase (decrease) in shares outstanding

4,072,660

Issue of shares

$ 3,540,403

ATM issue of shares No. 8 [Member]

Disclosure of classes of share capital [line items]

Issue price

$ 0.7102

ATM issue of shares No. 8 [Member] | Contributed equity [member] | 7 July 2022 [Member]

Disclosure of classes of share capital [line items]

Increase (decrease) in shares outstanding

573,370

Issue of shares

$ 407,201

ATM issue of shares No. 9 [Member]

Disclosure of classes of share capital [line items]

Issue price

$ 0.3316

ATM issue of shares No. 9 [Member] | Contributed equity [member] | 8 August 2022 [Member]

Disclosure of classes of share capital [line items]

Increase (decrease) in shares outstanding

8,561,490

Issue of shares

$ 2,839,346

ATM issue of shares No. 10 [Member]

Disclosure of classes of share capital [line items]

Issue price

$ 0.2723

ATM issue of shares No. 10 [Member] | Contributed equity [member] | 9 August 2022 [Member]

Disclosure of classes of share capital [line items]

Increase (decrease) in shares outstanding

10,000

Issue of shares

$ 2,723

ATM issue of shares No. 11 [Member]

Disclosure of classes of share capital [line items]

Issue price

$ 0.2465

ATM issue of shares No. 11 [Member] | Contributed equity [member] | 10 August 2022 [Member]

Disclosure of classes of share capital [line items]

Increase (decrease) in shares outstanding

158,020

Issue of shares

$ 38,949

ATM issue of shares No. 12 [Member]

Disclosure of classes of share capital [line items]

Issue price

$ 0.2413

ATM issue of shares No. 12 [Member] | Contributed equity [member] | 11 August 2022 [Member]

Disclosure of classes of share capital [line items]

Increase (decrease) in shares outstanding

330,960

Issue of shares

$ 79,868

ATM issue of shares No. 13 [Member]

Disclosure of classes of share capital [line items]

Issue price

$ 0.2469

ATM issue of shares No. 13 [Member] | Contributed equity [member] | 12 August 2022 [Member]

Disclosure of classes of share capital [line items]

Increase (decrease) in shares outstanding

1,247,440

Issue of shares

$ 308,050

ATM issue of shares No. 14 [Member]

Disclosure of classes of share capital [line items]

Issue price

$ 0.2211

ATM issue of shares No. 14 [Member] | Contributed equity [member] | 12 September 2022 [Member]

Disclosure of classes of share capital [line items]

Increase (decrease) in shares outstanding

651,030

Issue of shares

$ 143,964

ATM issue of shares No. 15 [Member]

Disclosure of classes of share capital [line items]

Issue price

$ 0.2187

ATM issue of shares No. 15 [Member] | Contributed equity [member] | 13 September 2022 [Member]

Disclosure of classes of share capital [line items]

Increase (decrease) in shares outstanding

28,350

Issue of shares

$ 6,200

Scientific Advisory Board [member]

Disclosure of classes of share capital [line items]

Issue price

$ 0.21

Scientific Advisory Board [member] | Contributed equity [member] | 14 September 2022 [Member]

Disclosure of classes of share capital [line items]

Increase (decrease) in shares outstanding

60,000

Issue of shares

$ 12,600

ATM issue of shares No. 16 [Member]

Disclosure of classes of share capital [line items]

Issue price

$ 0.1789

ATM issue of shares No. 16 [Member] | Contributed equity [member] | 7 October 2022 [Member]

Disclosure of classes of share capital [line items]

Increase (decrease) in shares outstanding

736,760

Issue of shares

$ 131,797

ATM issue of shares No. 17 [Member]

Disclosure of classes of share capital [line items]

Issue price

$ 0.1865

ATM issue of shares No. 17 [Member] | Contributed equity [member] | 28 October 2022 [Member]

Disclosure of classes of share capital [line items]

Increase (decrease) in shares outstanding

12,296,180

Issue of shares

$ 2,293,288

ATM issue of shares No. 18 [Member]

Disclosure of classes of share capital [line items]

Issue price

$ 0.138

ATM issue of shares No. 18 [Member] | Contributed equity [member] | 11 January 2023 [Member]

Disclosure of classes of share capital [line items]

Increase (decrease) in shares outstanding

20,000

Issue of shares

$ 2,761

Professional and sophisticated investors placement – 1st tranche [Member]

Disclosure of classes of share capital [line items]

Issue price

$ 0.11

Professional and sophisticated investors placement – 1st tranche [Member] | Contributed equity [member] | 16 January 2023 [Member]

Disclosure of classes of share capital [line items]

Increase (decrease) in shares outstanding

25,387,018

Issue of shares

$ 2,792,572

Professional and sophisticated investors placement – 2nd tranche [Member]

Disclosure of classes of share capital [line items]

Issue price

$ 0.11

Professional and sophisticated investors placement – 2nd tranche [Member] | Contributed equity [member] | 28 February 2023 [Member]

Disclosure of classes of share capital [line items]

Increase (decrease) in shares outstanding

15,522,075

Issue of shares

$ 1,707,428

Share Placement Plan [Member]

Disclosure of classes of share capital [line items]

Issue price

$ 0.11

Share Placement Plan [Member] | Contributed equity [member] | 3 March 2023 [Member]

Disclosure of classes of share capital [line items]

Increase (decrease) in shares outstanding

23,691,045

Issue of shares

$ 2,606,000

ATM issue of shares No. 19 [Member]

Disclosure of classes of share capital [line items]

Issue price

$ 0.19

ATM issue of shares No. 19 [Member] | Contributed equity [member] | 6 July 2023 [Member]

Disclosure of classes of share capital [line items]

Increase (decrease) in shares outstanding

8,148,140

Issue of shares

$ 1,512,523

ATM issue of shares No. 20 [Member]

Disclosure of classes of share capital [line items]

Issue price

$ 0.16

ATM issue of shares No. 20 [Member] | Contributed equity [member] | 7 July 2023 [Member]

Disclosure of classes of share capital [line items]

Increase (decrease) in shares outstanding

157,120

Issue of shares

$ 25,877

ATM issue of shares No. 21 [Member]

Disclosure of classes of share capital [line items]

Issue price

$ 0.17

ATM issue of shares No. 21 [Member] | Contributed equity [member] | 03 August 2023 [Member]

Disclosure of classes of share capital [line items]

Increase (decrease) in shares outstanding

15,000

Issue of shares

$ 2,519

ATM issue of shares No. 22 [Member]

Disclosure of classes of share capital [line items]

Issue price

$ 0.1

ATM issue of shares No. 22 [Member] | Contributed equity [member] | 29 November 2023 [Member]

Disclosure of classes of share capital [line items]

Increase (decrease) in shares outstanding

1,066,070

Issue of shares

$ 107,268

Registered Direct Offering Issue [Member]

Disclosure of classes of share capital [line items]

Issue price

$ 0

Registered Direct Offering Issue [Member] | Contributed equity [member] | 05 December 2023 [Member]

Disclosure of classes of share capital [line items]

Increase (decrease) in shares outstanding

26,200,000

Issue of shares

$ 0

ATM issue of shares No. 23 [Member]

Disclosure of classes of share capital [line items]

Issue price

$ 0.0466

ATM issue of shares No. 23 [Member] | Contributed equity [member] | 13 February 2024 [Member]

Disclosure of classes of share capital [line items]

Increase (decrease) in shares outstanding

25,910

Issue of shares

$ 1,207

ATM issue of shares No. 24 [Member]

Disclosure of classes of share capital [line items]

Issue price

$ 0.0464

ATM issue of shares No. 24 [Member] | Contributed equity [member] | 14 February 2024 [Member]

Disclosure of classes of share capital [line items]

Increase (decrease) in shares outstanding

319,650

Issue of shares

$ 14,834

ATM issue of shares No. 25 [Member]

Disclosure of classes of share capital [line items]

Issue price

$ 0.0468

ATM issue of shares No. 25 [Member] | Contributed equity [member] | 15 February 2024 [Member]

Disclosure of classes of share capital [line items]

Increase (decrease) in shares outstanding

2,195,980

Issue of shares

$ 102,825

ATM issue of shares No. 26 [Member]

Disclosure of classes of share capital [line items]

Issue price

$ 0.0614

ATM issue of shares No. 26 [Member] | Contributed equity [member] | 16 February 2024 [Member]

Disclosure of classes of share capital [line items]

Increase (decrease) in shares outstanding

205,260

Issue of shares

$ 12,597

Armistice warrants [Member]

Disclosure of classes of share capital [line items]

Issue price

$ 0.045

Armistice warrants [Member] | Contributed equity [member] | 21 February 2024 [Member]

Disclosure of classes of share capital [line items]

Increase (decrease) in shares outstanding

18,244,450

Issue of shares

$ 892,655

ATM issue of shares No. 27 [Member]

Disclosure of classes of share capital [line items]

Issue price

$ 0.0595

ATM issue of shares No. 27 [Member] | Contributed equity [member] | 21 February 2024 [Member]

Disclosure of classes of share capital [line items]

Increase (decrease) in shares outstanding

8,626,580

Issue of shares

$ 513,584

ATM issue of shares No. 28 [Member]

Disclosure of classes of share capital [line items]

Issue price

$ 0.0461

ATM issue of shares No. 28 [Member] | Contributed equity [member] | 22 February 2024 [Member]

Disclosure of classes of share capital [line items]

Increase (decrease) in shares outstanding

316,540

Issue of shares

$ 14,584

ATM issue of shares No. 29 [Member]

Disclosure of classes of share capital [line items]

Issue price

$ 0.0464

ATM issue of shares No. 29 [Member] | Contributed equity [member] | 23 February 2024 [Member]

Disclosure of classes of share capital [line items]

Increase (decrease) in shares outstanding

304,860

Issue of shares

$ 14,147

ATM issue of shares No. 30 [Member]

Disclosure of classes of share capital [line items]

Issue price

$ 0.046

ATM issue of shares No. 30 [Member] | Contributed equity [member] | 26 February 2024 [Member]

Disclosure of classes of share capital [line items]

Increase (decrease) in shares outstanding

250,000

Issue of shares

$ 11,502

ATM issue of shares No. 31 [Member]

Disclosure of classes of share capital [line items]

Issue price

$ 0.0478

ATM issue of shares No. 31 [Member] | Contributed equity [member] | 01 May 2024 [Member]

Disclosure of classes of share capital [line items]

Increase (decrease) in shares outstanding

2,112,560

Issue of shares

$ 100,961

ATM issue of shares No. 32 [Member]

Disclosure of classes of share capital [line items]

Issue price

$ 0.0457

ATM issue of shares No. 32 [Member] | Contributed equity [member] | 02 May 2024 [Member]

Disclosure of classes of share capital [line items]

Increase (decrease) in shares outstanding

375,410

Issue of shares

$ 17,147

ATM issue of shares No. 33 [Member]

Disclosure of classes of share capital [line items]

Issue price

$ 0.0469

ATM issue of shares No. 33 [Member] | Contributed equity [member] | 03 May 2024 [Member]

Disclosure of classes of share capital [line items]

Increase (decrease) in shares outstanding

288,900

Issue of shares

$ 13,544

ATM issue of shares No. 34 [Member]

Disclosure of classes of share capital [line items]

Issue price

$ 0.0456

ATM issue of shares No. 34 [Member] | Contributed equity [member] | 07 May 2024 [Member]

Disclosure of classes of share capital [line items]

Increase (decrease) in shares outstanding

790,100

Issue of shares

$ 36,024

ATM issue of shares No. 35 [Member]

Disclosure of classes of share capital [line items]

Issue price

$ 0.0455

ATM issue of shares No. 35 [Member] | Contributed equity [member] | 10 May 2024 [Member]

Disclosure of classes of share capital [line items]

Increase (decrease) in shares outstanding

20,000

Issue of shares

$ 910

ATM issue of shares No. 36 [Member]

Disclosure of classes of share capital [line items]

Issue price

$ 0.045

ATM issue of shares No. 36 [Member] | Contributed equity [member] | 16 May 2024 [Member]

Disclosure of classes of share capital [line items]

Increase (decrease) in shares outstanding

242,170

Issue of shares

$ 10,891

Repayment of promissory note [Member]

Disclosure of classes of share capital [line items]

Issue price

$ 0.0643

Repayment of promissory note [Member] | Contributed equity [member] | 19 June 2024 [Member]

Disclosure of classes of share capital [line items]

Increase (decrease) in shares outstanding

5,916,970

Issue of shares

$ 380,223

Equity line of credit Issued [Member]

Disclosure of classes of share capital [line items]

Issue price

$ 0.0268

Equity line of credit Issued [Member] | Contributed equity [member] | 24 June 2024 [Member]

Disclosure of classes of share capital [line items]

Increase (decrease) in shares outstanding

29,000,000

Issue of shares

$ 776,264

Share issue transaction costs [member] | Contributed equity [member]

Disclosure of classes of share capital [line items]

Issue of shares

$ (376,573)

$ (400,750)

$ (492,735)

Equity - contributed equity -_2

Equity - contributed equity - Summary of equity - contributed equity (Detail) - AUD ($) $ in Thousands	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2022
Disclosure of classes of share capital [abstract]
Ordinary shares - fully paid, shares	332,850,784	228,029,114	138,755,376
Ordinary shares - fully paid	$ 101,638	$ 97,452	$ 84,480

Equity - contributed equity - A

Equity - contributed equity - Additional Information (Detail)		1 Months Ended		12 Months Ended
	May 17, 2024 AUD ($) shares $ / shares	Feb. 29, 2024 shares $ / shares	Feb. 29, 2024 shares $ / shares	Jun. 30, 2024 AUD ($) $ / shares shares	Jun. 30, 2024 AUD ($) $ / shares $ / shares shares	Jun. 30, 2023 USD ($)	Jun. 30, 2024 USD ($) $ / shares shares	Jun. 19, 2024 $ / shares	May 17, 2024 $ / shares	Apr. 19, 2024 USD ($)	Feb. 01, 2024 shares	Dec. 20, 2023 shares	Nov. 30, 2023 $ / shares shares	Jun. 30, 2023 AUD ($)	Jun. 30, 2022 AUD ($)
Weighted average exercise price of other equity instruments exercisable in share-based payment arrangement | $ / shares													$ 0.583
Fair value of warrants | $							$ 1,981,756
Number of shares issued												591,697
Issued capital | $				$ 101,638,000	$ 101,638,000									$ 97,452,000	$ 84,480,000
Fully paid ordinary shares par value | $ / shares				$ 0	$ 0			$ 0.0643
Securities Purchase Agreement [Member]
Fair value of warrants derivative liability | $	$ 232,488
Purchase Agreement With Aluni Capital LP [Member]
Common stock value authroized for issuance as per agreement | $										$ 15,000,000
Purchase Agreement With Aluni Capital LP [Member] | ADR [Member]
Issue of shares | $				$ 776,264
Warrant reserve [member]
Proceeds from issuing other equity instruments				3,020,315		$ 1,981,756
Proceeds From Issuing Other Equity Instruments Before Transaction Cost | $				$ 382,463
Institutional Investor [Member]
Number of shares issued				26,200,000	26,200,000		26,200,000
Issued capital | $				$ 0	$ 0
Prefunded Warrants [Member]
Number of warrants issued				1,824,445
Warrants issue price per share | $ / shares					$ 0.44
Weighted average exercise price of other equity instruments exercisable in share-based payment arrangement | $ / shares							$ 0.01
Warrants exercised		1,824,445	1,824,445
Weighted average exercise price, exercised | (per share)		$ 27,901	$ 18,244
Ordinary Warrants [Member]
Number of warrants issued				4,444,445
Weighted average exercise price of other equity instruments exercisable in share-based payment arrangement | $ / shares							$ 0.583
American Depositary Shares [Member]
Number of shares issued													2,620,000
American Depositary Shares [Member] | Securities Purchase Agreement [Member]
Weighted average exercise price of other equity instruments exercisable in share-based payment arrangement | $ / shares									$ 0.27
Decrease exercise price of warrant | $ / shares	$ 0.27
Number of other equity instruments exercisable in share-based payment arrangement	1,100,000
American Depositary Shares [Member] | Institutional Investor [Member]
Shares Issued Price Per Share 1 | $ / shares					$ 0.45
Number of shares issued				2,620,000	2,620,000		2,620,000
Ordinary shares [member]
Number of shares issued											18,244,450

Equity - reserves - Additional

Equity - reserves - Additional Information (Detail) $ in Millions	12 Months Ended
	Jun. 30, 2024 AUD ($)
Disclosure of reserves within equity [abstract]
Share based payment reserve for Employee Share Option plan	$ 0.5
Share based payment reserve for Employee Share Option plan Expired	$ 0.7

Equity - reserves - Summary of

Equity - reserves - Summary of tabular form of other reserves (Detail) - AUD ($) $ in Thousands	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2022
Disclosure of reserves within equity [abstract]
Foreign currency reserve	$ (750)	$ (742)	$ (852)
Share-based payments reserve for Employee Share Option Plan	4,225	4,423	3,264
Other reserves	$ 3,475	$ 3,681	$ 2,412

Equity - dividends - Additional

Equity - dividends - Additional Information (Detail)	12 Months Ended
	Jun. 30, 2024 AUD ($)
Statement of changes in equity [abstract]
Dividends paid	$ 0

Financial instruments - Summary

Financial instruments - Summary of foreign currency denominated financial assets and financial liabilities (Detail) - AUD ($) $ in Thousands	Jun. 30, 2024	Jun. 30, 2023
Disclosure Of Financial Asset Liabilities [Line Items]
Trade and other receivables - current	$ 3,897	$ 3,899
Trade and other payables - current	15,067	4,329
USD [Member]
Disclosure Of Financial Asset Liabilities [Line Items]
Cash and cash equivalents - current	1,421	2,326
Trade and other receivables - current	1,908	0
Trade and other payables - current	942	1,135
Other financial liabilities	6,478	0
Net financial asset liabilities	10,749	3,461
EURO [Member]
Disclosure Of Financial Asset Liabilities [Line Items]
Cash and cash equivalents - current	0	0
Trade and other receivables - current	0	0
Trade and other payables - current	7,320	2,710
Other financial liabilities	0	0
Net financial asset liabilities	7,320	2,710
GBP [Member]
Disclosure Of Financial Asset Liabilities [Line Items]
Cash and cash equivalents - current	0	0
Trade and other receivables - current	0	0
Trade and other payables - current	18	0
Other financial liabilities	0	0
Net financial asset liabilities	18	0
SGD [Member]
Disclosure Of Financial Asset Liabilities [Line Items]
Cash and cash equivalents - current	0	0
Trade and other receivables - current	0	0
Trade and other payables - current	0	1
Other financial liabilities	0	0
Net financial asset liabilities	$ 0	$ 1

Financial instruments - Additio

Financial instruments - Additional Information (Detail) - AUD ($)	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2021
Disclosure of detailed information about financial instruments [line items]
Net assets denominated in foreign currencies	$ 21,585,000	$ 28,084,000
Net Liabilities denominated in foreign currencies	31,602,000	16,034,000
Cash and cash equivalents	1,657,000	5,241,000	$ 7,361,000	$ 27,587,000
Foreign currency risk [member]
Disclosure of detailed information about financial instruments [line items]
Net assets denominated in foreign currencies		$ 2,200,000
Net Liabilities denominated in foreign currencies	$ 11,400,000
Foreign currency risk [member] | US dollars [member]
Disclosure of detailed information about financial instruments [line items]
Hypothetical percentage change in risk	10%	10%
Interest rate risk [member]
Disclosure of detailed information about financial instruments [line items]
Hypothetical percentage change in risk	1%	1%
Favourable/adverse effect on profit before tax and equity	$ 16,575	$ 52,411

Financial instruments - Summa_2

Financial instruments - Summary of foreign currency risk sensitivity (Detail) - AUD ($) $ in Thousands	Jun. 30, 2024	Jun. 30, 2023
Foreign currency risk [member] | US dollars [member]
Disclosure of detailed information about financial instruments [line items]
% change	10%	10%
Increase in market risk [member] | US dollars [member]
Disclosure of detailed information about financial instruments [line items]
% change		10%
Increase in market risk [member] | Euros [member]
Disclosure of detailed information about financial instruments [line items]
% change		10%
Increase in market risk [member] | Foreign currency risk [member]
Disclosure of detailed information about financial instruments [line items]
% change	10%
Increase in market risk [member] | Foreign currency risk [member] | US dollars [member]
Disclosure of detailed information about financial instruments [line items]
% change	10%
Increase in market risk [member] | Foreign currency risk [member] | Euros [member]
Disclosure of detailed information about financial instruments [line items]
% change	10%
Effect of increase in market risk on profit (loss) before tax [member] | Foreign currency risk [member]
Disclosure of detailed information about financial instruments [line items]
Effect on profit before tax/equity	$ 140	$ (223)
Effect of increase in market risk on profit (loss) before tax [member] | Foreign currency risk [member] | US dollars [member]
Disclosure of detailed information about financial instruments [line items]
Effect on profit before tax/equity	142	(494)
Effect of increase in market risk on profit (loss) before tax [member] | Foreign currency risk [member] | Euros [member]
Disclosure of detailed information about financial instruments [line items]
Effect on profit before tax/equity	0	271
Effect of increase in market risk on profit (loss) before tax [member] | Foreign currency risk [member] | GBP [Member]
Disclosure of detailed information about financial instruments [line items]
Effect on profit before tax/equity	(2)
Effect of increase in market risk on equity [member] | Foreign currency risk [member]
Disclosure of detailed information about financial instruments [line items]
Effect on profit before tax/equity	140	(223)
Effect of increase in market risk on equity [member] | Foreign currency risk [member] | US dollars [member]
Disclosure of detailed information about financial instruments [line items]
Effect on profit before tax/equity	142	(494)
Effect of increase in market risk on equity [member] | Foreign currency risk [member] | Euros [member]
Disclosure of detailed information about financial instruments [line items]
Effect on profit before tax/equity	0	$ 271
Effect of increase in market risk on equity [member] | Foreign currency risk [member] | GBP [Member]
Disclosure of detailed information about financial instruments [line items]
Effect on profit before tax/equity	$ (2)
Decrease in market risk [member] | US dollars [member]
Disclosure of detailed information about financial instruments [line items]
% change		(10.00%)
Decrease in market risk [member] | Euros [member]
Disclosure of detailed information about financial instruments [line items]
% change		(10.00%)
Decrease in market risk [member] | Foreign currency risk [member]
Disclosure of detailed information about financial instruments [line items]
% change	(10.00%)
Decrease in market risk [member] | Foreign currency risk [member] | US dollars [member]
Disclosure of detailed information about financial instruments [line items]
% change	(10.00%)
Decrease in market risk [member] | Foreign currency risk [member] | Euros [member]
Disclosure of detailed information about financial instruments [line items]
% change	(10.00%)
Effect of decrease in market risk on profit (loss) before tax [member]
Disclosure of detailed information about financial instruments [line items]
Effect on profit before tax/equity		$ 223
Effect of decrease in market risk on profit (loss) before tax [member] | US dollars [member]
Disclosure of detailed information about financial instruments [line items]
Effect on profit before tax/equity		494
Effect of decrease in market risk on profit (loss) before tax [member] | Euros [member]
Disclosure of detailed information about financial instruments [line items]
Effect on profit before tax/equity		(271)
Effect of decrease in market risk on profit (loss) before tax [member] | Foreign currency risk [member]
Disclosure of detailed information about financial instruments [line items]
Effect on profit before tax/equity	$ (140)
Effect of decrease in market risk on profit (loss) before tax [member] | Foreign currency risk [member] | US dollars [member]
Disclosure of detailed information about financial instruments [line items]
Effect on profit before tax/equity	(142)
Effect of decrease in market risk on profit (loss) before tax [member] | Foreign currency risk [member] | Euros [member]
Disclosure of detailed information about financial instruments [line items]
Effect on profit before tax/equity	0
Effect of decrease in market risk on profit (loss) before tax [member] | Foreign currency risk [member] | GBP [Member]
Disclosure of detailed information about financial instruments [line items]
Effect on profit before tax/equity	2
Effect of decrease in market risk on equity [member]
Disclosure of detailed information about financial instruments [line items]
Effect on profit before tax/equity		223
Effect of decrease in market risk on equity [member] | US dollars [member]
Disclosure of detailed information about financial instruments [line items]
Effect on profit before tax/equity		494
Effect of decrease in market risk on equity [member] | Euros [member]
Disclosure of detailed information about financial instruments [line items]
Effect on profit before tax/equity		$ (271)
Effect of decrease in market risk on equity [member] | Foreign currency risk [member]
Disclosure of detailed information about financial instruments [line items]
Effect on profit before tax/equity	(140)
Effect of decrease in market risk on equity [member] | Foreign currency risk [member] | US dollars [member]
Disclosure of detailed information about financial instruments [line items]
Effect on profit before tax/equity	(142)
Effect of decrease in market risk on equity [member] | Foreign currency risk [member] | Euros [member]
Disclosure of detailed information about financial instruments [line items]
Effect on profit before tax/equity	0
Effect of decrease in market risk on equity [member] | Foreign currency risk [member] | GBP [Member]
Disclosure of detailed information about financial instruments [line items]
Effect on profit before tax/equity	$ 2

Financial instruments - Summa_3

Financial instruments - Summary of variable interest rate balances (Detail) - AUD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Disclosure of financial instruments by type of interest rate [line items]
Cash and cash equivalents	$ 1,657	$ 5,241
Interest rate risk [member] | Variable interest rate [member]
Disclosure of financial instruments by type of interest rate [line items]
Cash and cash equivalents	1,657	5,241
Net exposure to cash flow interest rate risk	$ 1,657	$ 5,241
Interest rate risk [member] | Variable interest rate [member] | Weighted average [member] | Cash at bank and in hand [member]
Disclosure of financial instruments by type of interest rate [line items]
Interest rate	0.39%	0.40%

Financial instruments - Summa_4

Financial instruments - Summary of remaining contractual maturities of financial instrument liabilities (Detail) - AUD ($) $ in Thousands	Jun. 30, 2024	Jun. 30, 2023
Disclosure of maturity analysis for non-derivative financial liabilities [line items]
Trade payables	$ 4,548	$ 857
Accrued payables	10,519	3,472
Contingent consideration	7,938	8,152
Total non-derivatives		12,481
Trade payables carrying amount	4,548	857
Accrued payables carrying amount	10,519	3,472
Contingent consideration carrying amount	7,005	6,871
Total undiscounted financial liabilities carrying amount		11,200
Derivatives
Other financial liabilities	6,478
Total undiscounted financial liabilities	29,483
Other financial liabilities carrying amount	6,478
Total undiscounted financial liabilities carrying amount	28,550
1 year or less [member]
Disclosure of maturity analysis for non-derivative financial liabilities [line items]
Trade payables	4,548	857
Accrued payables	10,519	3,472
Contingent consideration	3,389	750
Total non-derivatives		5,079
Derivatives
Total undiscounted financial liabilities	18,456
Between 1 and 2 years [member]
Disclosure of maturity analysis for non-derivative financial liabilities [line items]
Contingent consideration		4,303
Total non-derivatives		4,303
Between 2 and 5 years [member]
Disclosure of maturity analysis for non-derivative financial liabilities [line items]
Contingent consideration	4,549	3,099
Total non-derivatives		$ 3,099
Derivatives
Other financial liabilities	6,478
Total undiscounted financial liabilities	$ 11,027

Fair value measurement - Summar

Fair value measurement - Summary of assets and liabilities, measured or disclosed at fair value (Detail) - AUD ($) $ in Thousands	Jun. 30, 2024	Jun. 30, 2023
Disclosure of fair value measurement of assets [line items]
Contingent Consideration	$ 3,752	$ 6,121
Total liabilities	31,602	16,034
At fair value [member]
Disclosure of fair value measurement of assets [line items]
Contingent Consideration	7,005	6,871
Warrant liability	6,478
Total liabilities	13,483	6,871
At fair value [member] | Level 3 [member]
Disclosure of fair value measurement of assets [line items]
Contingent Consideration	7,005	6,871
Warrant liability	6,478
Total liabilities	$ 13,483	$ 6,871

Fair value measurement - Summ_2

Fair value measurement - Summary of movements in level 3 assets and liabilities (Detail) - At fair value [member] - AUD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Disclosure of detailed information about movements in level 3 assets and liabilities [Line Items]
Balance Beginning	$ 6,871	$ 8,968
Gain (loss) recognized in profit or loss	(1,123)	(2,097)
Issuance of warrants	8,599
Exercise of warrants	(864)
Balance Ending	13,483	6,871
Level 3 [member]
Disclosure of detailed information about movements in level 3 assets and liabilities [Line Items]
Balance Beginning	6,871	8,968
Gain (loss) recognized in profit or loss	(1,123)	(2,097)
Issuance of warrants	8,599
Exercise of warrants	(864)
Balance Ending	$ 13,483	$ 6,871

Fair value measurement - Additi

Fair value measurement - Additional Information (Detail)	12 Months Ended
	Jun. 30, 2024
Bottom of range [member]
Disclosure of fair value measurement of assets [line items]
Milestone payment discount rate	0%
Top of range [member]
Disclosure of fair value measurement of assets [line items]
Milestone payment discount rate	100%

Key management personnel disc_3

Key management personnel disclosures - Summary of compensation made to directors and other members of key management personnel (Detail) - AUD ($)	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2022
Related party transactions [abstract]
Short-term employee benefits	$ 1,962,563	$ 3,148,514	$ 2,589,088
Post-employment benefits	72,784	149,626	115,950
Share-based payments	353,437	1,045,860	1,559,930
Key management personnel compensation	$ 2,388,784	$ 4,344,000	$ 4,264,968

Related party transactions - Ad

Related party transactions - Additional Information (Detail)	Jun. 30, 2024 AUD ($)
Disclosure of transactions between related parties [line items]
Trade receivables from related parties	$ 0
Trade payables to related parties	0
Loan to related parties	0
Loan from related parties	$ 0

Parent entity information - Sta

Parent entity information - Statement of profit or loss and other comprehensive income (Detail) - AUD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2022
Disclosure of parent entity information [line items]
Loss after income tax	$ (26,778)	$ (20,465)	$ (25,014)
Total comprehensive loss	(26,786)	(20,355)	$ (24,979)
Parent [member]
Disclosure of parent entity information [line items]
Loss after income tax	(24,008)	(20,863)
Total comprehensive loss	$ (24,008)	$ (20,863)

Parent entity information - S_2

Parent entity information - Statement of financial position (Detail) - AUD ($) $ in Thousands	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2022
Disclosure of parent entity information [line items]
Total current assets	$ 6,145	$ 10,772
Total assets	21,585	28,084
Total current liabilities	25,797	7,565
Total liabilities	31,602	16,034
Equity:
Contributed equity	101,638	97,452	$ 84,480
Reserves	3,475	3,681	$ 2,412
Accumulated losses	(115,130)	(89,083)
Parent [member]
Disclosure of parent entity information [line items]
Total current assets	3,048	4,645
Total assets	18,488	21,915
Total current liabilities	25,529	7,003
Total liabilities	31,335	15,472
Equity:
Contributed equity	101,638	97,452
Reserves	4,225	4,423
Accumulated losses	(118,710)	(95,432)
Total equity	$ (12,847)	$ 6,443

Interests in subsidiaries - Sum

Interests in subsidiaries - Summary of interest in subsidiaries (Detail)	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Kazia Laboratories Pty Ltd [member]
Disclosure of subsidiaries [line items]
Principal place of business	Australia
Country of incorporation	Australia
Ownership interest	100%	100%
Kazia Research Pty Ltd [member]
Disclosure of subsidiaries [line items]
Principal place of business	Australia
Country of incorporation	Australia
Ownership interest	100%	100%
Kazia Therapeutics Inc [member]
Disclosure of subsidiaries [line items]
Principal place of business	United States of America
Country of incorporation	United States of America
Ownership interest	100%	100%
Glioblast Pty Ltd [member]
Disclosure of subsidiaries [line items]
Principal place of business	Australia
Country of incorporation	Australia
Ownership interest	100%	100%

Earnings per share - Summary of

Earnings per share - Summary of earnings per share (Detail) - AUD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2022
Earnings per share [abstract]
Loss after income tax attributable to the owners of Kazia Therapeutics Limited	$ (26,778)	$ (20,465)	$ (25,014)
Loss after income tax attributable to the owners of Kazia Therapeutics Limited	$ (26,778)	$ (20,465)	$ (25,014)
Weighted average number of ordinary shares used in calculating basic and diluted earnings per share	263,676,313	184,284,350	132,467,686
Basic earnings per share	$ (0.1016)	$ (0.1123)	$ (0.1888)
Diluted earnings per share	$ (0.1016)	$ (0.1123)	$ (0.1888)

Earnings per share - Additional

Earnings per share - Additional Information (Detail) - shares	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2022
Unissued Shares Under Options [Member]
Earnings per share [line items]
Number of options that have been excluded from the calculations as they were antidilutive	36,180,000	14,780,000	8,655,500

Share-based payments - Addition

Share-based payments - Additional Information (Detail) $ in Thousands	12 Months Ended
	Jun. 30, 2024 AUD ($) shares	Jun. 30, 2023 AUD ($)	Jun. 30, 2022 AUD ($)
Disclosure of terms and conditions of share-based payment arrangement [line items]
Employee remuneration expense	$ 532,597	$ 1,159,125	$ 1,674,581
Weighted average remaining contractual life of outstanding share options	4 years 11 months 1 day	2 years 11 months 28 days
Number of options issued to employees	2,850,000	7,930,000
Ordinary shares [member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Weighted average remaining contractual life of outstanding share options	2 years
Number of options issued to employees		7,930,000
Tranche 13 [member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Percentage of options vested and exercisable	35%
Tranche 14 [member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Percentage of options going to vest	33%
Tranche 16 [member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Percentage of options vested not vested and exercisable	33%	33%
Number of options issued to employees		4,000,000
Tranche 8 [member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Percentage of options vested and exercisable		50%
Tranches 4, 5, 7 and 9 [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Percentage of options vested and exercisable		75%
Tranches 10 and 16 [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Percentage of options vested and exercisable		33%
Tranches 11, 12, 13 and 14 [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Percentage of options vested and exercisable		25%
Tranches 12 and 13 [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Percentage of options going to vest	25%
Tranches 4, 7, 8 and 9 [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Percentage of options vested and exercisable	69%
Tranche 5 [member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Percentage of options vested and exercisable	75%
Tranche 10 and 15 [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Percentage of options vested and exercisable	33%
Tranche 11, 14 and 16 [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Percentage of options vested and exercisable	50%

Share-based payments - Summary

Share-based payments - Summary of share-based payments (Detail)	12 Months Ended
	Jun. 30, 2024 shares $ / shares	Jun. 30, 2023 $ / shares
Disclosure of terms and conditions of share-based payment arrangement [line items]
Balance at the start of the year, share options	14,780,000	8,655,500
Granted, share options	2,850,000	7,930,000
Expired / lapsed on termination of employment	(4,600,000)	(1,805,500)
Balance at the end of the year, share options	10,180,000	14,780,000
Balance at the start of the year, Weighted average exercise price	$ 0.6292	$ 1.2826
Granted, Weighted average exercise price	0	0.1785
Exercised, Weighted average exercise price	0	0
Expired, Weighted average exercise price	0.4349	1.8977
Balance at the end of the year, Weighted average exercise price	$ 0.7207	$ 0.6292
Ordinary shares [member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Balance at the start of the year, share options	14,780,000	8,655,500
Granted, share options		7,930,000
Forfeited, share options	(3,400,000)	(1,550,000)
Expired / lapsed on termination of employment	(1,200,000)	(255,500)
Balance at the end of the year, share options	10,180,000	14,780,000
Exercisable at the end of the financial year, share option	7,290,000	6,483,333
Balance at the start of the year, Weighted average exercise price	$ 0.63	$ 1.28
Granted, Weighted average exercise price		0.18
Forfeited, Weighted average exercise price	0.42	1.9
Expired, Weighted average exercise price	0.49	1.9
Balance at the end of the year, Weighted average exercise price	0.72	0.63
Exercisable at the end of the financial year, Weighted average exercise price	$ 0.84	$ 0.96
American Depository Shares [member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Balance at the start of the year, share options	0	0
Granted, share options	2,850,000	0
Forfeited, share options	(250,000)
Expired / lapsed on termination of employment	(250,000)
Balance at the end of the year, share options	2,600,000	0
Exercisable at the end of the financial year, share option	0	0
Balance at the start of the year, Weighted average exercise price	$ 0	$ 0
Granted, Weighted average exercise price	0.56	0
Forfeited, Weighted average exercise price	0.576
Expired, Weighted average exercise price	0.576
Balance at the end of the year, Weighted average exercise price	0.558	0
Exercisable at the end of the financial year, Weighted average exercise price	$ 0	$ 0
Tranche 1 [member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date		07/08/2017
Expiry date		Aug. 07, 2022
Exercise price		$ 0.67
Balance at the start of the year, share options		15,500
Expired / lapsed on termination of employment		(15,500)
Tranche 2 [member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date		05/02/2018
Expiry date		Feb. 05, 2023
Exercise price		$ 0.7802
Balance at the start of the year, share options		240,000
Expired / lapsed on termination of employment		(240,000)
Tranche 3 [member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	13/11/2019	13/11/2019
Expiry date	Jan. 04, 2024	Jan. 04, 2024
Exercise price	$ 0.4925	$ 0.4925
Balance at the start of the year, share options	1,200,000	1,200,000
Expired / lapsed on termination of employment	(1,200,000)
Balance at the end of the year, share options		1,200,000
Tranche 4 [member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	13/01/2020	13/01/2020
Expiry date	Jan. 13, 2025	Jan. 13, 2025
Exercise price	$ 0.8812	$ 0.8812
Balance at the start of the year, share options	187,500	200,000
Expired / lapsed on termination of employment	(50,000)	(12,500)
Balance at the end of the year, share options	137,500	187,500
Tranche 5 [member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	09/11/2020	09/11/2020
Expiry date	Nov. 09, 2024	Nov. 09, 2024
Exercise price	$ 1.132	$ 1.132
Balance at the start of the year, share options	1,200,000	1,200,000
Balance at the end of the year, share options	1,200,000	1,200,000
Tranche 6 [member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	09/11/2020	09/11/2020
Expiry date	Jan. 13, 2025	Jan. 13, 2025
Exercise price	$ 0.8812	$ 0.8812
Balance at the start of the year, share options	600,000	800,000
Expired / lapsed on termination of employment		(200,000)
Balance at the end of the year, share options	600,000	600,000
Tranche 7 [member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	04/01/2021	04/01/2021
Expiry date	Jan. 04, 2025	Jan. 04, 2025
Exercise price	$ 1.69	$ 1.69
Balance at the start of the year, share options	187,500	200,000
Expired / lapsed on termination of employment	(50,000)	(12,500)
Balance at the end of the year, share options	137,500	187,500
Tranche 8 [member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	09/09/2021	09/09/2021
Expiry date	Jun. 26, 2026	Jun. 26, 2026
Exercise price	$ 1.365	$ 1.365
Balance at the start of the year, share options	100,000	100,000
Balance at the end of the year, share options	100,000	100,000
Tranche 9 [member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	16/11/2021	16/11/2021
Expiry date	Nov. 16, 2025	Nov. 16, 2025
Exercise price	$ 1.69	$ 1.69
Balance at the start of the year, share options	750,000	1,000,000
Expired / lapsed on termination of employment		(250,000)
Balance at the end of the year, share options	750,000	750,000
Tranche 10 [member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	16/11/2021	16/11/2021
Expiry date	Nov. 16, 2025	Nov. 16, 2025
Exercise price	$ 2.24	$ 2.24
Balance at the start of the year, share options	500,000	1,500,000
Expired / lapsed on termination of employment		(1,000,000)
Balance at the end of the year, share options	500,000	500,000
Tranche 11 [member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	16/11/2021	16/11/2021
Expiry date	Nov. 16, 2025	Nov. 16, 2025
Exercise price	$ 1.56	$ 1.56
Balance at the start of the year, share options	800,000	800,000
Balance at the end of the year, share options	800,000	800,000
Tranche 12 [member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	01/02/2022	01/02/2022
Expiry date	Feb. 01, 2027	Feb. 01, 2027
Exercise price	$ 0.94	$ 0.94
Balance at the start of the year, share options	800,000	800,000
Expired / lapsed on termination of employment	(800,000)
Balance at the end of the year, share options		800,000
Tranche 13 [member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	01/02/2022	01/02/2022
Expiry date	Feb. 01, 2027	Feb. 01, 2027
Exercise price	$ 0.94	$ 0.94
Balance at the start of the year, share options	425,000	500,000
Expired / lapsed on termination of employment	(100,000)	(75,000)
Balance at the end of the year, share options	325,000	425,000
Tranche 14 [member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	24/05/2022	24/05/2022
Expiry date	May 24, 2027	May 24, 2027
Exercise price	$ 0.78	$ 0.78
Balance at the start of the year, share options	100,000	100,000
Balance at the end of the year, share options	100,000	100,000
Tranche 15 [member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	03/03/2023	03/03/2023
Expiry date	Mar. 03, 2027	Mar. 03, 2027
Exercise price	$ 0.15	$ 0.15
Balance at the start of the year, share options	3,930,000
Granted, share options		3,930,000
Expired / lapsed on termination of employment	(1,400,000)
Balance at the end of the year, share options	2,530,000	3,930,000
Tranche 16 [member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	03/05/2023	05/03/2023
Expiry date	May 03, 2027	May 03, 2027
Exercise price	$ 0.187	$ 0.187
Balance at the start of the year, share options	4,000,000
Granted, share options		4,000,000
Expired / lapsed on termination of employment	(1,000,000)
Balance at the end of the year, share options	3,000,000	4,000,000
Tranche 17 [member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	01/02/2022
Expiry date	Feb. 01, 2027
Exercise price	$ 0.78
Tranche 17 [member] | American Depository Shares [member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	22/04/2024
Expiry date	Apr. 22, 2029
Exercise price	$ 0.586
Granted, share options	1,500,000
Balance at the end of the year, share options	1,500,000
Tranche 18 [member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	17/06/2024
Expiry date	Jun. 17, 2029
Exercise price	$ 0.5757
Tranche 18 [member] | American Depository Shares [member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	17/06/2024
Expiry date	Jun. 17, 2029
Exercise price	$ 0.513
Granted, share options	1,100,000
Expired / lapsed on termination of employment	(250,000)
Balance at the end of the year, share options	850,000
Tranche 19 [member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	24/05/2022
Expiry date	May 24, 2027
Exercise price	$ 0.15
Tranche 19 [member] | American Depository Shares [member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	27/06/2024
Expiry date	Jun. 27, 2030
Exercise price	$ 0.297
Granted, share options	250,000
Balance at the end of the year, share options	250,000

Share-based payments - Summar_2

Share-based payments - Summary of valuation for each tranche of options (Detail) - AUD ($)	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Tranche 3 [member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	13/11/2019	13/11/2019
Expiry date	Jan. 04, 2024	Jan. 04, 2024
Share price at Grant Date	$ 0.41
Exercise price	$ 0.4925	$ 0.4925
Volatility (%)	74.50%
Dividend yield (%)	0%
Risk free Rate	1.95%
Fair value per option	$ 0.18
Tranche 4 [member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	13/01/2020	13/01/2020
Expiry date	Jan. 13, 2025	Jan. 13, 2025
Share price at Grant Date	$ 0.62
Exercise price	$ 0.8812	$ 0.8812
Volatility (%)	74.50%
Dividend yield (%)	0%
Risk free Rate	1.95%
Fair value per option	$ 0.34
Tranche 5 [member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	09/11/2020	09/11/2020
Expiry date	Nov. 09, 2024	Nov. 09, 2024
Share price at Grant Date	$ 0.89
Exercise price	$ 1.132	$ 1.132
Volatility (%)	90%
Dividend yield (%)	0%
Risk free Rate	0.10%
Fair value per option	$ 0.413
Tranche 6 [member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	09/11/2020	09/11/2020
Expiry date	Jan. 13, 2025	Jan. 13, 2025
Share price at Grant Date	$ 0.89
Exercise price	$ 0.8812	$ 0.8812
Volatility (%)	90%
Dividend yield (%)	0%
Risk free Rate	0.10%
Fair value per option	$ 0.503
Tranche 7 [member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	04/01/2021	04/01/2021
Expiry date	Jan. 04, 2025	Jan. 04, 2025
Share price at Grant Date	$ 1.185
Exercise price	$ 1.69	$ 1.69
Volatility (%)	90%
Dividend yield (%)	0%
Risk free Rate	0.19%
Fair value per option	$ 0.6
Tranche 9 [member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	16/11/2021	16/11/2021
Expiry date	Nov. 16, 2025	Nov. 16, 2025
Share price at Grant Date	$ 1.57
Exercise price	$ 1.69	$ 1.69
Volatility (%)	76%
Dividend yield (%)	0%
Risk free Rate	1.50%
Fair value per option	$ 0.85
Tranche 10 [member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	16/11/2021	16/11/2021
Expiry date	Nov. 16, 2025	Nov. 16, 2025
Share price at Grant Date	$ 1.57
Exercise price	$ 2.24	$ 2.24
Volatility (%)	76%
Dividend yield (%)	0%
Risk free Rate	1.50%
Fair value per option	$ 0.75
Tranche 11 [member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	16/11/2021	16/11/2021
Expiry date	Nov. 16, 2025	Nov. 16, 2025
Share price at Grant Date	$ 1.57
Exercise price	$ 1.56	$ 1.56
Volatility (%)	76%
Dividend yield (%)	0%
Risk free Rate	1.50%
Fair value per option	$ 0.97
Tranche 12 [member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	01/02/2022	01/02/2022
Expiry date	Feb. 01, 2027	Feb. 01, 2027
Share price at Grant Date	$ 0.96
Exercise price	$ 0.94	$ 0.94
Volatility (%)	79%
Dividend yield (%)	0%
Risk free Rate	1.50%
Fair value per option	$ 0.59
Tranche 15 [member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	03/03/2023	03/03/2023
Expiry date	Mar. 03, 2027	Mar. 03, 2027
Share price at Grant Date	$ 0.17
Exercise price	$ 0.15	$ 0.15
Volatility (%)	80%
Dividend yield (%)	0%
Risk free Rate	3.64%
Fair value per option	$ 0.1014
Tranche 16 [member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	03/05/2023	05/03/2023
Expiry date	May 03, 2027	May 03, 2027
Share price at Grant Date	$ 0.19
Exercise price	$ 0.187	$ 0.187
Volatility (%)	80%
Dividend yield (%)	0%
Risk free Rate	3.22%
Fair value per option	$ 0.1111
Tranche 17 [member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	01/02/2022
Expiry date	Feb. 01, 2027
Share price at Grant Date	$ 0.8
Exercise price	$ 0.78
Volatility (%)	44%
Dividend yield (%)	0%
Risk free Rate	2.95%
Fair value per option	$ 0.63
Tranche 18 [member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	17/06/2024
Expiry date	Jun. 17, 2029
Share price at Grant Date	$ 0.3484
Exercise price	$ 0.5757
Volatility (%)	95%
Dividend yield (%)	0%
Risk free Rate	3.84%
Fair value per option	$ 0.23
Tranche 19 [member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	24/05/2022
Expiry date	May 24, 2027
Share price at Grant Date	$ 0.17
Exercise price	$ 0.15
Volatility (%)	80%
Dividend yield (%)	0%
Risk free Rate	3.64%
Fair value per option	$ 0.1014
Tranche 20 [member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	27/06/2024
Expiry date	Jun. 27, 2030
Share price at Grant Date	$ 0.3461
Exercise price	$ 0.3311
Volatility (%)	95%
Dividend yield (%)	0%
Risk free Rate	4.17%
Fair value per option	$ 0.27
Tranche 22 [member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	22/04/2024
Expiry date	Apr. 22, 2029
Share price at Grant Date	$ 0.586
Exercise price	$ 0.586
Volatility (%)	95%
Dividend yield (%)	0%
Risk free Rate	3.96%
Fair value per option	$ 0.43
Tranche 24 [member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date	09/09/2021
Expiry date	Jun. 26, 2026
Share price at Grant Date	$ 1.42
Exercise price	$ 1.37
Volatility (%)	76%
Dividend yield (%)	0%
Risk free Rate	1.50%
Fair value per option	$ 0.88

Subsequent events - Additional

Subsequent events - Additional Information (Detail) $ in Thousands		3 Months Ended	12 Months Ended
	Jul. 10, 2024 Month	Sep. 30, 2024 AUD ($)	Jun. 30, 2024 AUD ($)	Jun. 30, 2023 AUD ($)	Jun. 30, 2022 AUD ($)	Oct. 28, 2024
Cash flows from (used in) financing activities [abstract]
Proceeds from issue of shares			$ 2,914	$ 12,972	$ 3,726
ADR [member]
Cash flows from (used in) financing activities [abstract]
Number of shares represented by one depositary receipt			10
Major ordinary share transactions [member] | ADR [member]
Cash flows from (used in) financing activities [abstract]
Number of shares represented by one depositary receipt						100
Major ordinary share transactions [member] | ATM Issue of Shares [member]
Cash flows from (used in) financing activities [abstract]
Proceeds from issue of shares		$ 5,348,262
Major ordinary share transactions [member] | Equity Line of Credit [member]
Cash flows from (used in) financing activities [abstract]
Proceeds from issue of ordinary shares		$ 816,373
Phase II/III Clinical Trial Results for Paxalisib in Glioblastoma [member]
Cash flows from (used in) financing activities [abstract]
Improvement in overall survival	3 months 24 days
Percentage increase in improvement compared to standard health care	33%
Number of patients considered for study | Month	313
Median survival in months	14 months 23 days
Standard overall survival in months	13 months 25 days
Secondary analysis median survival in months	15 months 16 days
Secondary analysis standard overall survival in months	11 months 27 days